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Our ability to precisely manipulate size, shape, and composition of nanoscale 
carriers is essential for controlling their in-vivo transport, biodistribution, and drug 
release mechanism. Shape-specific, “smart” nanoparticles that deliver drugs or imaging 
agents to target tissues primarily in response to disease-specific or physiological signals 
could significantly improve therapeutic care of complex diseases. Current methods in 
nanoparticle synthesis do not allow such simultaneous control over particle size, shape, 
and environmentally-triggered drug release, especially at the sub-100 nm range. In this 
dissertation, we discuss the development of high-throughput nanofabrication techniques 
using synthetic and biological macromers (peptides) to produce highly monodisperse 
nanoparticles, as well as enzymatically-triggered nanoparticles, of precise sizes and 
shapes. We evaluated thermal nanoimprint lithography (ThNIL) and step and flash 
imprint lithography (SFIL) as two possible fabrication techniques.  We successfully 
employed ThNIL and SFIL for fabricating nanoparticles and have extensively 
 ix
characterized the SFIL fabrication process, as well as the properties of the imprinted 
biopolymers. Particles as small as 50 nm were fabricated on silicon wafers and harvested 
directly into aqueous buffer using a biocompatible, one-step release technique. These 
methods provide a novel way to fabricate biocompatible nanoparticles with precise size 
and geometry. Furthermore, we developed an enzyme-degradable material system and 
demonstrated successful encapsulation and enzyme-triggered release of antibodies and 
nucleic acids from these imprinted nanoparticles; thus providing a potential means for 
disease-controlled delivery of biomolecules. Finally, we evaluated the bioactivity of the 
encapsulated therapeutics in-vitro.  The development of the SFIL method for fabrication 
of biocompatible nanocarriers has great potential in the drug delivery field for its ability 
to create monodisperse particles of pre-designed geometry and size, and to incorporate 
stimulus-responsive release mechanisms. This research provides the potential to broaden 
the study of how particle size and shape affect the biodistribution of drugs within the 
body. 
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Introduction: Specific Aims and Overview 
 
1.1 INTRODUCTION 
Nanoparticle-based delivery of therapeutics has been extensively studied in a 
variety of diseases and is considered to be an ideal platform for targeted intravenous and 
intracellular delivery of bioactive agents. Current concepts in the synthesis of drug 
nanocarriers primarily involve the use of polymers or lipids to fabricate self-assembled or 
emulsion-based particles that are mostly spherical, polydisperse, and release drugs 
through diffusion or hydrolytic degradation. Although significant progress has been made 
in polymeric or liposomal drug delivery systems, there remain critical limitations in 
synthesizing nanocarriers with highly controllable architectures that can, at the same 
time, impart environmentally-triggered release mechanisms. Our ability to precisely 
manipulate size, shape, composition, and drug release mechanism of nanoparticles is 
essential for controlling their in-vivo transport, biodistribution, and therapeutic efficacy 
[1-3].   
While particles below 500 nm in size can be injected intravenously, only those 
below 200 nm are efficiently internalized by somatic cells. Recent reports also suggest 
that delivery into the lymphatic circulation requires particles that are even smaller in size 
(< 50 nm) [4]. Besides size, mechanism of drug release from particle carriers is another 
important design parameter in nanomedicine. Stimuli-sensitive hydrogels have been 
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widely studied as micro or macroscale “smart” delivery systems to release drugs in 
response to specific environmental stimuli [5-8]. Similar nanoparticles that deliver their 
cargo to target cells primarily in response to disease-specific environmental signals could 
significantly improve therapeutic care of complex diseases. For example, most 
chemotherapeutic drugs that are toxic to normal cells would have significantly less 
morbidity and mortality if they could be released primarily in response to a tumor-
specific, pathological signal. The design of carriers at the nanometer length scale that 
incorporate such triggered-release mechanisms has remained elusive because of the lack 
of flexible fabrication methods that can incorporate responsive bio-molecules within the 
nanoparticle matrix.   
Size, material chemistry, and particle surface characteristics have so far been the 
primary variables used to fabricate nanocarriers. However, recent reports suggest that 
particle shape could play a significant role in the in-vivo performance of delivery 
vehicles [1, 9]. Specifically, shape and shape-related form factors, like aspect ratio or 
edges, affect particle transport characteristics, influence cell-particle interactions, and 
alter drug release kinetics [1, 3]. Furthermore, theoretical modeling has shown that size 
and shape can significantly affect how particles interact with tumor capillaries during 
transport [10, 11].  Until recently, particle shape has been an unexplored area of research 
in drug delivery due to our inability to reliably synthesize nano or microparticle carriers 
with precise and pre-designed geometry.  
Nano-sized, injectable drug carriers having precise geometry and 
environmentally-responsive release mechanisms could provide targeted, disease-specific 
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delivery of molecules as well as tunable in-vivo release characteristics.   In order to create 
such multi-functional, shape-specific drug delivery carriers, recent research has focused 
on top-down manufacturing approaches such as soft-lithography, micromolding and 
nanoimprinting to generate devices with more controllable properties [12-14].  Top-down 
fabrication of nanocarriers for drug delivery can allow for fabrication of highly 
monodisperse particles of precise size and shape, thus allowing for better control of 
transport, biodistribution and release kinetics.  
We have previously reported that polyethylene glycol (PEG)-based materials can 
be used to create three dimensional, container-like nanostructures suitable for drug 
delivery using nanoimprint lithography [15]. Recently, DeSimone and colleagues 
elegantly demonstrated the ability to form nano-sized particles on silicon wafers using a 
top-down particle nanoreplication (PRINT) method [14, 16, 17]. Synthesis of shape-
specific particles as small as 160 nm was demonstrated using this process. However, 
methods to generate particles with precise size and shape that also incorporate 
environmentally-triggered drug release are yet to be reported, especially at the sub-100 
nm range. In addition, a major limitation in current nanofabricated delivery devices is the 
process of particle harvesting. For example, the PRINT particles are harvested from the 
wafer either using physical scraping with surgical blades [14] or by shear force using a 
glass slide, [17] both of which could damage the particles and may not be suitable for 
large scale manufacturing.  
Recent advances in nanoscale fabrication methods could provide unique solutions 
to manufacture stimuli-sensitive nanocarriers for drug delivery in a high-throughput 
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manner. However, it is evident that successful translation of any top-down 
nanofabrication technologies to drug delivery applications would require development of 
techniques that are mild and compatible with a variety of biological molecules. 
Furthermore, any such technique must allow easy harvesting of nanoparticles and the 
ability to incorporate unique functionalities, such as disease-triggered drug release.  
The research presented here provides a novel application of imprint lithography 
techniques to fabricate biocompatible, as well as stimuli-responsive, easily-harvestable, 
nanoparticles (as small as 50 nm) of precise sizes, shapes and compositions. This project 
provides a significant advance in the creation of monodisperse, injectable nanocarriers of 
specific geometry and can provide a characterized environment for the study of the effect 
of size and shape in in-vivo release properties of nanoparticles.  The overall goal of this 
work is to develop nano-fabrication techniques to create monodisperse, biocompatible, 
nanocarriers as well as demonstrate triggered-release of therapeutics. Nano-sized, 
injectable drug carriers having precise geometry and environmentally-responsive release 
mechanisms could provide targeted, disease-specific delivery of molecules as well as 
tunable in-vivo release characteristics. The long term goal is to achieve site-specific, 
controlled, on-demand systemic drug delivery leading to lower side-effects, increased 
bioavailability, and improved therapeutic effectiveness, as well as simultaneous non-
invasive monitoring of the therapeutics and the delivery device.  
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1.2 SPECIFIC AIMS 
1.2.1 Aim 1: To synthesize a peptide-based material system for creating photo-
crosslinked PEG-peptide hydrogels suitable for enzyme-triggered 
degradation and drug release. 
We hypothesized that the use of a specific peptide sequence within acrylated 
polyethylene glycol polymers would allow the cross-linked hydrogel to dissolve and 
cause an enzyme-triggered release of drug in the presence of a tissue/cell-specific 
enzyme. Such a design would allow for incorporation of other degradable peptide 
sequences specific for other tissue targets, and could thus provide a platform technology 
for disease-controlled delivery of biomolecules. In this particular design we explored 
Gly-Phe-Leu-Gly-Lys (GFLGK), a Cathepsin sensitive peptide as the degradable 
component of the photo-crosslinkable hydrogel material system. Two photo-crosslinkable 
configurations were evaluated: acrylate-poly(ethylene glycol)-GFLGK-poly(ethylene 
glycol)-acrylate (ACRL-PEG-GFLGK-PEG-ACRL) and poly(ethylene glycol)-
diacrylate-GFLGK-diacrylate (PEGDA-GFLGK-DA). ACRL-PEG-GFLGK-PEG-ACRL 
was successfully synthesized and imprinted. Release studies revealed an enzyme-
triggered release of DNA in the presence of Cathepsin B as expected. To create a tighter 
network, PEGDA-GFLGK-DA and a lower molecular weight PEGDA were utilized. 
PEGDA-GFLGK-DA hydrogels were successfully synthesized and imprinted. In order to 
estimate the pore size of the cross-linked peptide-PEG hydrogels for future release 
studies, swelling studies were performed using PEGDA. 
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1.2.2 Aim 2: To develop a nanoimprint lithography technique with a gentle 
harvesting method to fabricate and release drug delivery nanoparticles of 
specific size and shape (< 500 nm). 
We hypothesized that utilizing semiconductor nanoimprint lithography techniques 
to pattern biocompatible polymers would enable us to fabricate monodisperse, injectable 
drug nanocarriers (50 - 400 nm) of precise shape and size suitable for intracellular drug 
delivery applications. With the development of such a method, we believe there is broad 
applicability to aid in further study of how nanoparticle shape and size affect delivery of 
drugs to tissues and cells within the body. Two methods were evaluated and optimized 
for imprinting of biocompatible polymers: Thermal Nanoimprint Lithography (ThNIL) 
and Step and Flash Imprint Lithography (SFIL).  We demonstrated the use of ThNIL and 
SFIL, coupled with biocompatible materials, to fabricate monodisperse nanoparticles of 
pre-designed sizes and geometries as small as 50 nm.  Particles of varying shape (square, 
circular, pentagonal, and triangular), size (50 - 400 nm), and composition Poly(methyl 
methacrylate) (PMMA), Poly(lactide-co-glycolide) (PLGA), PEG) were fabricated using 
these techniques.  Furthermore, we have demonstrated full wafer imprinting and 
successful isolation and release of the particles from the wafer using a mild harvesting 
method. The SFIL method, with its low temperature and force applications, as well as 
wafer-scale imprinting capability, was more suitable for large scale fabrication and was 
chosen for further optimization.  
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1.2.3 Aim 3: To demonstrate enzymatic degradation and in-vitro stimuli-
responsive drug release of nanoimprinted nanocarriers fabricated by 
combining the material system in Aim 1 and the nanoimprinting technique 
developed in Aim 2. 
We hypothesized that after nanoimprinting, the stimuli-responsive material 
developed in Aim 1 would retain its ability to: a) degrade in the presence of the tumor-
specific enzyme Cathepsin B, and b) would show an enzyme-responsive release of model 
drug only upon addition of the tumor-specific enzyme Cathepsin B. Upon imprinting 
with the PEGDA-GFLGK-DA developed in Aim 1 and exposure to Cathepsin B, we 
demonstrated enzymatic degradation of the photo-crosslinked material system.  In order 
to show release of both a nucleic acid and a protein, plasmid DNA and a fluorescently-
labeled IgG were each encapsulated in PEGDA-GLFLG-DA and imprinted.  The release 
studies demonstrated successful retention of the model drug in the absence of tumor-
specific enzymes (with a small amount of leakage) and an enzyme-triggered release of 
model drug upon the addition of Cathepsin B. After performing swelling studies on 
macroscale PEGDA polymers in Aim 1, we further explored the change in morphology 
of imprinted PEGDA nanocarriers before and after swelling. 
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1.2.4 Aim 4: To demonstrate bioactivity of model drugs encapsulated in 
nanoimprinted nanocarriers fabricated by combining the material system in 
Aim 1 and the nanoimprinting technique developed in Aim 2. 
Because the SFIL process utilizes low temperature, low pressure, and standard 
UV illumination, we hypothesized that encapsulated model drugs such as proteins and 
nucleic acids would remain bioactive after undergoing the imprinting process. We 
performed bioactivity studies using proteins (streptavidin, trypsin, and luciferase) and 
DNA with either PEGDA or stimuli-responsive PEGDA-GFLGK-DA material systems.  
The streptavidin bioactivity study successfully demonstrated qualitative evidence that the 
streptavidin remains bioactive after imprinting, as well as etching. Both the luciferase and 
trypsin bioactivity studies showed limited quantitative bioactivity. We hypothesize that 
the limited bioactivity is due to the fact that these particles are not able to diffuse from 
the nanocarriers due to the small pore size. The DNA transfection studies have been 
unsuccessful due to a limitation in the ability to concentrate the DNA sufficiently and 
separate it from Cathepsin B. Though qualitative and quantitative bioactivity has been 
demonstrated, we further suggest ways to more accurately measure the bioactivity of 
these proteins and nucleic acids after imprinting. 
 
1.3 OVERVIEW 
The following Chapter Two discusses the background and significance of the 
research study with references to the latest developments in nanoparticle synthesis, 
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nanoimprint lithography, top-down approaches to nanoparticle formation, and studies on 
the effect of size and shape of nanoparticles on drug delivery. Chapter Three describes 
the synthesis and characterization of photo-crosslinked, PEG-peptide material systems 
suitable for use as nanoimprinted, enzyme-responsive nanocarriers. Chapter Four 
discusses the development of nanoimprint lithography techniques for fabrication of 
nanoparticles of specific size and shape. ThNIL and SFIL are evaluated, and a discussion 
of the optimization of the SFIL process for biopolymer imprinting follows. This chapter 
demonstrates the ability of the SFIL technique to create nanoparticles of precise size and 
shape as small as 50 nm. Chapter Five illustrates in-vitro drug release of DNA and 
proteins from a nanoimprinted enzyme-responsive biomaterial, and demonstrates enzyme 
mediated degradation. Chapter Six describes in-vitro bioactivity studies of DNA and 
proteins encapsulated in nanoimprinted biomaterials. The biotin-streptavidin bioactivity 
assay demonstrates qualitative evidence of bioactivity.  Finally, the implications of the 
research are explained in Chapter Seven with conclusions and recommendations for 
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Background and Significance 
 
2.1 OVERVIEW OF DRUG DELIVERY IN CANCER THERAPY 
The American Cancer Society estimates that 1.4 million new cancer cases are 
diagnosed and 550,000 Americans die every year from cancer. Chemotherapy has been 
the main modality of treatment for cancer patients; however, its success rate remains low, 
primarily due to the inability to target and release drugs only within tumor tissues and 
cells.  The goal of cancer therapy is to selectively destroy cancer cells, while leaving 
normal tissues intact. Targeting of the diseased tissues is achieved through passive 
targeting, avoidance of the reticuloendothelial system (RES) and targeting through the 
enhanced permeability and retention (EPR) effect, as well as through active tumor-
specific targeting of tumor tissues and vasculature, as seen in Figure 2.1 [1-5]. The initial 
stage in cancer drug delivery design is to create a system that avoids uptake by the 
phagocytic cells of the RES, thus avoiding clearance from the body and providing for 
longer systemic circulation. Commonly this involves surface modification of the delivery 
system to provide stealth characteristics [1, 2, 4]. Furthermore, one must take into 
account how the system will interact with the biology of the disease.  
Although cancer cells are similar to normal tissue cells in many aspects, there are 
certain structural and behavioral differences that can be utilized for tumor-specific drug 
delivery. Tumor cells tend proliferate rapidly and undergo angiogenesis to create new 
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vasculature that supplies nutrients to the cancerous tissues. This rapid replication leads to 
the creation of leaky vasculature. Furthermore, tumor tissue tends to have poor lymphatic 
drainage. The combination of these factors allows high molecular weight (MW) 
molecules and nanoparticles to passively accumulate at higher concentration than in 
normal tissues, a concept called the enhanced permeability and retention effect (EPR) [1-
7].  Besides passive tumor targeting, systems have been developed to actively target 
cancerous tissue by targeting the tumor cell surface, vasculature, angiogenesis and 
extracellular space. Common tumor-specific targeting methods involve receptor-ligand 
based targeting [1, 3, 4]. Site-specific targeting has the potential to reduce systemic 
toxicity by allowing drugs to accumulate specifically at tumor tissues. 
Successful drug delivery to tumor cells only solves half of the challenge.  For 
many chemotherapeutic agents that cannot permeate the cell membrane, the drug must be 
delivered inside the cell through receptor mediated endocytosis. When a ligand binds to a 
receptor on the tumor cell surface it can trigger uptake of the ligand-drug conjugate, or 
ligand-carrier conjugate, into the endocytic pathway. The drug initiates in the early 
endosome (pH 5.5-6.5 as compared to physiological pH 7.4) and ends up in the lysosome 
(pH 3.0-5.0). Throughout the pathway the drug must be protected from degradation by 
the some 40 proteases present [8, 9].  Furthermore, the drug must have some means of 
escaping the endosome either by diffusion or pH triggered membrane-destabilization 
[10]. 
Currently, chemotherapy and other anti-cancer treatments are targeted to diseased 
cells and tissues in-vivo, however significant amount of toxic drugs diffuse to normal 
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tissues during transport resulting in unwanted side-effects and may cause a patient to 
cease treatment. If cytotoxic agents could be targeted and released in response to a 
disease-specific signal, the agent could be preferentially delivered to a particular diseased 
tissue or cell, which could provide a significant improvement in morbidity and mortality 
and potentially reduce systemic side-effects of toxic drugs.  
 
2.2 CURRENT NANOPARTICLE SYSTEMS IN DRUG DELIVERY 
Nanoparticle-based delivery of therapeutics has been extensively studied in a 
variety of diseases and is considered to be an ideal platform for targeted intravenous and 
intracellular delivery of bioactive agents [11]. The goals of nanoparticulate design are to: 
prevent drug degradation or interaction with the body’s environment, enhance drug 
absorption into tissues, control the biodistribution profile and improve penetration into 
cells [4]. Current concepts in the synthesis of drug nanocarriers primarily involve the use 
of natural or synthetic polymers or lipids to fabricate self-assembled or emulsion-based 
particles that are mostly spherical, polydisperse, and release drugs through diffusion or 
hydrolytic degradation [4]. Table 2.1 provides an extensive overview of current 
nanoparticulate delivery system architectures.  
Although various nanoparticle carrier designs have significantly improved, 
several challenges still remain. In polymeric nanoparticle-based delivery systems, 
bottom-up synthesis processes produce a large polydisperse population of particles whose 
physico-chemcial characteristics, drug release profiles, degradation kinetics and material 
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properties are hard to evaluate and reproduce. Lipid-based carriers tend to be rapidly 
cleared by the RES and suffer from instability and burst release [4]. Liposomes and most 
emulsion or micelle-based particle type carriers have limited encapsulation efficacy and 
rapid leakage of drug leading to loss of expensive drugs; however solid lipid 
nanoparticles have recently shown promise in encapsulating both proteins and water-
soluble drugs [12, 13]. These diffusion/degradation-based delivery systems have 
fundamental limitations of non-linearity, difficulty in predicting in-vivo release kinetics 
and a lack of stimuli responsive release mechanisms resulting in systemic side-effects.  
 
2.3 SIGNIFICANCE OF SMART NANOPARTICLE DRUG DELIVERY SYSTEMS 
Disease-responsive release is a key issue in ‘intelligent’ nanocarrier design. 
Intravenously injectable nanocarriers, that can efficiently deliver drugs or contrast agents 
to target tissues only in response to cellular or disease-specific signals, could significantly 
improve therapeutic and diagnostic care of complex diseases [14, 15].  Despite current 
efforts to target drug nanoparticles and liposomal drug carriers to diseased cells in-vivo, 
significant amounts of toxic drugs diffuse to normal tissues during transport [16-19].  If 
the encapsulated cargo can be released preferentially at a particular diseased tissue or cell 
or inside a specific cellular compartment, it could provide significant improvement in 
patient compliance, especially for highly toxic chemotherapeutic drugs or for molecules 
with short half-life.   
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Stimuli-sensitive hydrogels have been developed in ‘smart’ drug delivery systems 
to sense environmental changes and induce a structural change on their own. PH-
sensitive hydrogels, have been developed to swell in response to a change in pH from 
physiological conditions, and biomolecule-sensitive hydrogels have been used to deliver 
drugs when in contact with glucose or specific antigens [20-40]. There are also hydrogels 
that are sensitive to temperature, light, magnetic field and ultrasound [41-43]. 
Although stimuli-responsive release mechanisms are well established for 
macroscale devices and hydrogels [41-43], reports on nanocarriers incorporating 
environmental- or disease-triggered release of drugs are limited to only pH-responsive 
systems, which still reveal a large distribution in diameter [44-49].  Polymer-based pro-
drugs combine multiple functionalities [50-57]; however, they do not allow for 
simultaneous delivery of multiple agents (drugs, contrast agents etc.).  With current 
concepts, the inherent complexity of a bottom-up synthetic approach makes it difficult to 
achieve multiple functionalities such as targeting, loading multiple agents, and 
incorporating stimuli-sensitive properties in a single nanocarrier.  Although significant 
progress has been made in polymeric or liposomal drug delivery systems, there remain 
critical limitations in synthesizing nanocarriers with highly controllable architecture that 
can, at the same time, impart environmentally-triggered release mechanisms. 
 
 17
2.4 SIGNIFICANCE OF NANOPARTICLE SIZE AND SHAPE IN DRUG DELIVERY 
Particle size has a large impact on the biodistribution, clearance and uptake of 
nanoparticles within the body and dictates the way in which particles can be administered 
[58]. While particles below 500 nm in size can be injected intravenously, only those 
below 200 nm are efficiently internalized by somatic cells. In fact, delivery efficiency of 
therapeutics inside cells as well as intravenous delivery to tissues and organs, especially 
tumors, increases with sub-100 nm particles [59-62]. Particles smaller than 100 nm are 
typically recognized less by the mononuclear phagocytic system (MPS) (synonymous 
with the RES), can circulate longer in the blood stream, and have efficient diffusion into 
the vasculature of diseased tissue [11]. Recent reports also suggest that delivery into the 
lymphatic circulation require particles that are even smaller in size (< 50 nm) [63].  
 As well as size, recent reports suggest that particle shape could play a significant 
role in the in-vivo performance of delivery vehicles [58, 64]. Specifically, shape and 
shape-related form factors, like aspect ratio or edges, affect particle transport 
characteristics, influence cell-particle interactions, and alter drug release kinetics [58, 65]. 
Ferrari and colleagues have shown through theoretical modeling that shape and size of 
nanovectors and spherical and spheroidal nanoparticles can significantly affect how 
particles interact with tumor capillaries during transport [66, 67]. Ferrari and colleagues 
concluded that there is a critical radius necessary for a larger number of nanovectors 
(hollow nanotubes) to reach tumor vessels, and that vectors of different diameters would 
need to be fabricated in order to specifically target drug nanocarriers to specific locations 
within the body [66]. Furthermore, spheroidal particles must circulate through small 
capillaries, thus there is a limit to the aspect ratio of a spheroidal particle such that 
transport through the vasculature is not blocked and blood flow is not altered. Ferrari and 
colleagues further demonstrate, through mathematical modeling, that spheroidal particles 
can have larger volumes than spherical particles with the same probability of adhesion to 
a target tumor cell. They calculate that spheroidal particles with 2 to 1 aspect ratios could 
potentially be able to carry 50 times as much drug as 500 nm spherical particles with the 
same probability of adhesion (same adhesive strength); thus a higher dose of drug could 
be achieved at a target site. This is based on the derived formula: 











mV ropt  
where Vopt  is the optimal volume, γ is the aspect ratio, mr is the surface density of 
receptors, and μS is the shear stress at the capillary walls. The equation was shown to 
approximate independent experimental data by a separate group [67].   
Discher and colleagues demonstrated that self-assembled, filamentous particles 
with very high aspect ratios (less than 100 nm diameter with several microns in length) 
have unique long-circulating properties compared to traditional spherical liposomes [64, 
67]. In order to study the effect of shape on circulation time, filomecelles with varying 
lengths were injected into mice. Filomecelles with lengths greater than 8 μm circulated 
in-vivo for up to one week, while comparable PEGylated vesicles circulated for two days. 
To test the filomecelles as cancer drug delivery vehicles, they were loaded with paclitaxel 
and injected into mice. Discher and colleagues demonstrated that with an eightfold 
increase in length, they were able to achieve an equivalent increase in dose, and they 
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demonstrated a decrease in overall tumor size. This study verifies the model by Ferrari 
and colleagues by showing a larger dose capability with non-spherical particles [67]. 
Until recently, particle shape has been an unexplored area of research in drug 
delivery due to our inability to reliably synthesize nano or microparticle carriers with 
precise and pre-designed geometry. However, several groups have demonstrated the 
ability to create such particles using techniques varying from microfluidics, self-assembly 
and photopolymerization [58]. Figure 2.2 provides a broad overview of the current 
capabilities to create micro and nanoparticles of specific shape. Whitesides and 
colleagues have demonstrated the ability to create monodisperse microparticles utilizing 
microfluidics techniques [68]. Monodisperse liquid droplets were formed using a 
microfluidic device and shaped in a microchannel. Subsequently the drops were solidified 
in situ by photopolymerization or other means to form non-spherical particles. Figure 
2.2D demonstrates a micro-rod fabricated using these methods.  
Dendukuri and colleagues have also demonstrated the ability to make particles of 
non-spherical particles using a similar technique, Figure 2.2A [69]. Subsequently the 
same group fabricated poly(ethylene glycol) diacrylate (PEGDA) particles combining 
microfluidics techniques with photolithography, Figure 2.2E [70]. Sozzani and 
colleagues have used a direct pattern transfer with a silica mold to create poly(styrene) 
(PS) and poly(methyl methacrylate) PMMA microparticles with gyroidal, tubular and 
hollow cylindrical shapes, as shown in Figure 2.2C [71].  Velev and colleagues have 
used self assembly to create poly(styrene) donuts, as shown in Figure 2.2B [72]. All of 
the before-mentioned groups, as well as more, are using new techniques to create 
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particles of various geometries [58,73]; however, the micron-sized dimensions of the 
particles created from these techniques are not suitable for intracellular delivery. 
There are in fact only a few methods that have been developed to fabricate 
particles with varying shape, especially at the nanoscale. Recently, Mitragotri and 
colleagues reported unique solvent-based methods to generate poly(styrene) micro and 
nanoparticles of various shapes with feature sizes as low as 60 nm [74]. Spherical 
nanoparticles were suspended in an aqueous solution of PVA and cast into films. 
Subsequently, various shaped particles were created using a technique that involved: a) 
suspending liquefying spherical particles in heat (120-150oC) or solvent, b) stretching the 
particles into a film, c) re-solidifying particles using solvent extraction or cooling and d) 
dissolving the film. It remains to be studied how these methods are translated to 
biopolymers and whether other features, like stimuli-responsiveness, can be incorporated. 
DeSimone and colleagues have recently demonstrated top-down nanofabrication to create 
nanoparticles of specific size and shape, as shown in Figure 2.2D [75]. 
 
2.5 TOP-DOWN MICROFABRICATION APPROACHES IN DRUG DELIVERY 
In order to provide a unique approach to creating drug delivery particles with a 
pre-designed geometry and/or multiple functionalities, a new field of research has 
focused on top-down manufacturing approaches such as soft-lithography, micromolding 
and imprinting [76-80]. Several groups have successfully used top-down micro-
fabrication techniques to create drug delivery microparticles, as shown in Figure 2.3. 
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Desai and colleagues initially reported bioadhesive microparticles fabricated using bulk 
micromachining and photolithography to create silicon and poly(methyl methacrylate) 
(PMMA) microcontainers, respectively.  The silicon microcontainers were 50 μm with 25 
μm reservoirs, and the PMMA microcontainers were 150 μm with 80 μm reservoirs. The 
PMMA devices underwent surface modification through avidin–biotin chemistry to 
attach targeting ligands (e.g. lectins) and thus targeted the GI tract for oral delivery [81-
83].  
Subsequently the same group demonstrated multi-layer fabrication of SU-8 
epoxy, gelatin, and poly(lactide-co-glycolide) (PLGA) microparticles using a 
micromolding technique [84]. A poly(dimethyl siloxan) (PDMS) mold was used as a 
stamp to create microcontainers that were 150 μm in size with 70 - 80 μm reservoirs. 
Furthermore, a second layer of 10 μm posts were fabricated on top of the initial layer. 
Figure 2.3A-B demonstrates the stamped and released microcontainers fabricated from 
PMMA and SU-8. Figure 2.3C demonstrates the ability to create a tri-layered 
microparticle. The fabrication method for all polymers involved heating to at or above 
65oC, which could pose a problem for encapsulation of proteins.  
Recently, Hansford and colleagues reported fabrication of PLGA and 
poly(ethylene glycol) dimethacrylates (PEGDMA) microparticles using soft lithography 
[85]. For the fabrication of PLGA microparticles, a PDMS stamp was dipped in 
PLGA/acetone solution and inverted onto a silicon wafer with poly(vinyl alcohol) PVA. 
The temperature was increased to 80oC in order to mold the PLGA and the microparticles 
subsequently released in water. To fabricate PEGDMA microparticles, the 
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PEGDMA/water solution was brushed onto the PDMS stamp. The stamp was then 
exposed to UV light to crosslink the PEGDMA. Subsequently the stamp was inverted 
onto a silicon wafer with PVA and released in water. Figure 2.3D-G shows the 
microfabricated particles of varying size and shape before and after release. They report 
fabricating microparticles down to 6 μm; however there is little control over specific 
shape at that size with their current method. 
Considerable innovation has gone into developing micro-fabrication approaches 
to drug delivery; however these systems are too large for systemic and intracellular 
applications and have not yet demonstrated stimuli-responsive mechanisms.  
Microfabricated particles can be used for delivery by ingestion, inhalation, and injection 
into tissue. To be released into circulation, microparticles must be smaller than 10 μm 
[86]. Although much research has been performed on micro-fabrication of microparticles, 
the field of nanofabricated devices capable of intracellular drug delivery and imaging is a 
nascent field. 
 
2.6 NANOIMPRINT LITHOGRAPHY TECHNIQUES 
Several recent advancements in nanomanufacturing methods could provide new 
approaches for top-down, high-throughput, large-scale fabrication of nanocarriers for 
drug delivery applications. One of the most promising nanoimprinting techniques is the 
step and flash imprint lithography (SFIL) method invented by Wilson and colleagues at 
UT Austin.  The SFIL process [87-93], shown in Figure 2.4, is essentially a nanomolding 
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process in which the topography of a template defines the patterns created on a substrate. 
In brief, a transparent quartz template is treated with a release agent to facilitate substrate 
separation. Next, a low viscosity, UV curable, organosilicon monomer is dispensed onto 
a silicon substrate. The gap between the template and substrate is closed, using low 
pressure at room temperature. Following this, the quartz template is irradiated with UV 
light. The transparency of the quartz allows the UV light to pass through and 
photopolymerize the monomer beneath the template. When the template is separated 
from the substrate, the cured monomer on the substrate retains the desired 3D 
nanotopography. Further processing with oxygen plasma cleaning removes residual 
monomer for distinct features. Nanofeatures created using SFIL can be seen in Figure 
2.5.  
SFIL has several advantages over conventional lithography and micromolding 
processes.  First, SFIL is only limited by the resolution of the imprint template created by 
e-beam lithography. Recent work has demonstrated 20 nm lines using the SFIL process 
Figure 2.5B.  Traditional micromolding requires high pressures (> 10 MPa) and 
temperatures (> glass transition temperature of the polymer film), which may distort 
nanofeatures. SFIL uses a low-viscosity (~ 2-3 cps), photocurable, monomer that allows 
high resolution features to be imprinted at room temperature with minimal pressure (< 1 
psi). Furthermore, the reusable transparent quartz template enables sub-10 nm alignment 
of nanofeatures, a task very difficult in other processes. Finally, 3D structures can 
accurately be replicated by the SFIL process, and patterns can be imprinted on top of 
existing topography by using an appropriate planarization material, as shown in Figure 
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2.5C-D. The ability for three-dimensional nanopatterning is particularly useful for 
biomedical applications [94], in particular for fabricating nanocontainers/particles for 
drug delivery [95]. 
Another nanoimprint method for fabricating nanoscale features is thermal 
nanoimprint lithography.  First proposed in 1995 by SY Chou [96, 97], the process 
consists of imprinting with a reusable template and pattern transfer with RIE. However, 
in contrast to SFIL, thermal nanoimprint lithography requires heating a polymer above its 
glass transition temperature and applying considerably more pressure. Upon cooling, the 
polymer hardens into a desired 3D nanotopography. As with SFIL, this method is 
advantageous in that its resolution is limited only by the template fabrication process and 
it is capable of replicating precise 3D features.  
 
2.7 SIGNIFICANCE OF NANOIMPRINT FABRICATION IN DRUG DELIVERY 
Nanofabrication techniques for biomedical applications have the potential to 
create well-defined and characterized drug delivery devices without the limitations of 
current methods.  A top-down approach would ensure precise control of particle size, 
shape, and geometry, and would provide a monodisperse population of carriers, yielding 
better reproducibility and prediction of properties. Furthermore, this approach avoids 
high shear and mechanical forces typical for emulsion-based encapsulation, thus 
improving encapsulation efficiency and possibly improving drug stability. In addition, 
top-down manufacturing would allow for easy fabrication/incorporation of multiple 
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properties such as targeting and triggered release of drug in response to a stimulus. This 
approach could allow for the manufacturing of carriers that deliver toxic or unstable 
therapeutic compounds on demand to targeted organs in the body, while reducing 
systemic side-effects and providing for simultaneous monitoring of therapeutics and 
device.  
Furthermore, the creation of size and shape-specific particles could allow for a 
controllable study of the affects that size and shape have on particle transport 
characteristics, influence cell-particle interactions, and alter drug release kinetics. Finally, 
top-down manufacturing provides a novel, high-throughput, and highly automated 
method for fabricating drug delivery devices.  Since most of the top-down manufacturing 
processes are already well established and applicable in large industrial scales, the overall 
cost of development for such nanofabricated delivery devices could be significantly less 
than any novel bottom-up synthesis approach.   
 
2.8 CURRENT TOP-DOWN NANOFABRICATION-BASED SYSTEMS IN DRUG DELIVERY 
Recently, DeSimone and colleagues reported the ability to form nano-size PEG 
diacrylate (PEGDA) and poly(lactic acid) (PLA) particles using a particle nano-
replication (PRINT) method, similar to nanoimprint lithography [75, 98]. Unlike many 
soft lithography or imprint lithography techniques, DeSimone and colleagues utilized a 
photocurable perfluoropolyether (PFPE) stamp that is non-wetting to both inorganic and 
organic materials. Thus, formation of particles without a residual film between them was 
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accomplished. To fabricate PLA particles, PLA was in-situ polymerized at 110oC to mold 
the polymer solution. PEG particles were formed by imprinting and photopolymerization.  
Figure 2.6A-D demonstrates PEG particles fabricated in trapezoidal, conical, bar and 
arrow shapes with sizes ranging from 200 nm to 3 μm. Furthermore encapsulation of 
avidin-FITC and doxorubicin in PEG particles was demonstrated. Figures 2.6G shows 
fluorescence confocal images of encapsulated doxorubicin in 500 nm particles.  
In any fabrication process involving therapeutics or biologics, harvesting of 
nanoparticles into a usable form is of considerable importance. A major limitation in the 
PRINT fabrication process is the mechanism of particle harvesting. Currently, the PRINT 
particles are harvested from the wafer either using physical scraping with surgical blades 
(as shown in Figure 2.6E) [75] or by shear force using a glass slide (as shown in Figure 
2.6F) [99], both of which could damage the particles and may not be suitable for large 
scale manufacturing. Recently, DeSimone and colleagues have reported preliminary in-
vitro and in-vivo studies using 200 nm PEG triacrylate particles [99]. The particles in the 
study were measured in their dry-state to have a width of 201 ± 10 nm and a height of 
155 ± 10 nm. Using dynamic light-scattering the polydispersity of the particles remained 
at 234 ± 12 nm over the course of 6 hours at 37oC. For in-vivo studies, PRINT particles 
were injected in a bolus dose into the tail of a healthy mouse. The particles were cleared 
rapidly from the blood, but otherwise appeared to be in agreement with liposomes in 
regards to biocompatibility and distribution. 
Although nanoparticle synthesis was demonstrated using the PRINT method, 
stimuli-responsive nanoparticle fabrication has not been demonstrated. Top-down 
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nanofabrication methods to generate particles with precise size and shape that also 
incorporate environmentally-triggered drug release are yet to be reported, especially at 
the sub-100 nm range.  
2.9 BIOCOMPATIBLE POLYMERS FOR TOP-DOWN FABRICATION 
Currently only a few types of polymeric material have be used to make micro and 
nanofabricated drug delivery devices. The knowledge of the types of patternable 
polymers can allow us to choose from them the ones with properties (biocompatibility, 
biodegradability, and mechanical robustness) suitable for specific drug delivery 
applications.  
2.9.1 Poly(methyl methacrylate) (PMMA) 
PMMA has been previously used by Desai and co-workers to micro-fabricate oral 
drug delivery devices [81-83]. It is commonly used in such biomedical applications as 
bone cement and intraocular lenses [100, 101].  PMMA is biocompatible with a 
hydrophilic surface that can easily be modified for incorporation of targeting ligands and 
provides high resolution features in photolithography, e-beam lithography, and 
nanoimprint lithography techniques [96, 97].  Furthermore, it is a high strength material 
with good mechanical stability necessary to retain the shape and integrity of the nano-
containers. Although PMMA is non-biodegradable it has been used to create nanospheres 
that have shown a prolonged half-life in circulation in mice [2, 102]. 
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2.9.2 Poly(ethylene glycol) (PEG) 
PEG is widely regarded as an extremely biocompatible polymer and has 
numerous uses in biomedical applications, including: drug delivery, tissue engineering, 
pro-drug design, tissue sealants, and nanoparticle surface modification. PEG has been 
shown to provide stealth characteristics, increase drug circulation time and to reduce 
nonspecific attachment or uptake by the RES (ie. less recognized by the macrophages of 
the mononuclear phagocyte system (MPS)) [11, 103-105].  PEG-based materials are also 
non-fouling and prevent protein adsorption to material or carrier surfaces [106-108]. In 
drug delivery, PEG-conjugation to nanoparticle surfaces (e.g. liposomes) has been shown 
to protect against particle clearance in blood, thus generating long-circulating carriers 
[109, 110]. Hansford and Colleagues and DeSimone and colleagues have both 
demonstrated successful imprinting and releasing of PEG-based microparticles using 
photopolymerization [75, 85]. 
2.9.3 Poly(lactide-co-glycolide) (PLGA) 
PLGA is one of the most widely used biodegradable polymers in drug delivery, 
with other applications in tissue engineering and surgical sutures. Nanoimprinting-based 
fabrication would provide a novel method to synthesize PLGA-based carriers with 
precise size and shape for degradation controlled release. Desai and Hansford’s groups 
have shown successful creation of PLGA microparticles using top-down approaches [84, 
85]. Furthermore DeSimone and colleagues have successfully imprinted PLGA using the 
PRINT technique [75]. 
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By synergizing the knowledge of top-down fabrication techniques with concepts 
from biomaterials and nanoparticle drug delivery systems surveyed from literature, this 
dissertation discusses development of nanoimprint lithography techniques to create 
monodisperse, injectable nanocarriers of specific sizes, shapes, and functionalities (i.e.,  


















Figure 2.1  Schematic of Passive and Active Targeting of Tumor Tissues and Cells. 
Reprinted by permission from Macmillan Publishers Ltd: [Nature 











Table 2.1  Overview of Current Nanoparticulate Drug Carriers.  Table courtesy of 






Figure 2.2  Non-spherical Micro and Nanoparticles: (A) microparticles created 
using microfluidics [35]*1, (B) donut-shaped PS particles created using 
self-assembly [38]*2, (C) gyroidal particles created using a silica mold 
[37]*3, (D) micro-rods created using microfluidics [34]*4, (E) tear-drop 
shaped PEG microparticles created using microfluidics combined with 
photolithography [36]*5, (F) conical PEG particles created using the 
PRINT process [40].*6 Overall figure reprinted from J Control Release, 
121, J. A. Champion, Y. K. Katare, and S. Mitragotri, 3-9, 2007, with 




*1 Reprinted with permission from (35). Copyright (2005) American Chemical Society. 
*2From [O. D. Velev, A. M. Lenhoff, and E. W. Kaler. A class of microstructured particles 
through colloidal crystallization. Science 287: 2240–2243(2000)]. Reprinted with 
permission from AAAS.  
*3Reprinted by permission from Macmillan Publishers Ltd: [Nature Materials] (37),  
copyright (2006). 
*4Reproduced with permission from S. Q. Xu, Z. H. Nie, M. Seo, P. Lewis, E. Kumacheva, 
H. A. Stone, P. Garstecki, D. B. Weibel, I. Gitlin, and G. M. Whitesides: Generation of 
monodisperse particles by using microfluidics: control over size, shape, and 
composition. 2005. 44. 724-728. Copyright Wiley-VCH Verlag GmbH & Co. KGaA.  
*5 Reprinted by permission from Macmillan Publishers Ltd: [Nature Materials] (36), 
copyright (2006). 
*6 Reprinted by permission from (40). Copyright (2005) American Chemical Society. 
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Figure 2.3  Top-down Microfabricated Drug Delivery Microparticles: (A) PMMA 
microcontainers [44] *1, (B) released SU-8 microcontainers [44] *1, (C) 
profilometer side profile of tri-layered SU-8 microcontainers [44] *1, (D) 
cross-shaped PEG microparticles [45] *2, (E) released cross-shaped PEG 
particles [45] *2, (F) square-shaped PLGA microparticles [45] *2, and G) 





*1 Reproduced with permission from S. L. Tao and T. A. Desai: Microfabrication of 
multilayer, asymmetric, polymeric devices for drug delivery. 2005. 17. 1625-1630. 
Copyright Wiley-VCH Verlag GmbH & Co. KGaA.  
*2 Reprinted from Biomaterials, 27, J. Guan, N. Ferrell, L.J. Lee, and D.J. Hansford, 





Figure 2.4  Schematic of Step and Flash Imprint Lithography (SFIL). Reprinted 
from I. McMackin, P. Schumaker, D. Babbs, J. Choi, W. Collison, S. V. 
Sreenivasan, N. Schumaker, M. Watts, and R. Voisin, Design and 
Performance of a Step and Repeat Imprinting Machine Proc SPIE, 
Emerging Lithographic Technologies VII, 5037,  2003, with permission 























Figure 2.5  Three-dimensional Nano-topographies Created Using SFIL: (A) 50 nm 
dense lines [51]*1 (B) 20 nm spaced lines [51]*1, (C) 60 nm posts [51]*1, 








*1 Reproduced with permission from D. J. Resnick, S.V. Sreenivasan and C. G. Willson: 
Microfabrication Step & flash imprint lithography. 2005. 8. 34-42. Copyright Wiley-
VCH Verlag GmbH & Co. KGaA.  
*2 Reproduced with permission from S. Johnson, D. J. Resnick, D. Mancini, K. Nordquist, 
W. J. Dauksher, K. Gehoski, J. H. Baker, L. Dues, A. Hooper, T. C. Bailey, S. V. 
Sreenivasan, J. G. Ekerdt and C. G. Willson: Fabrication of multi-tiered structures on 
step and flash imprint lithography templates. 2003. 67-68. 221-228. Copyright Wiley-
VCH Verlag GmbH & Co. KGaA.  
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Figure 2.6  PRINT Particle Fabrication: (A) 200 nm trapezoidal PEG particles     
[40]*1, (B) 200 x 800 nm PEG bar particles [40]*1, (C) 500 nm conical 
PEG particles [40]*1, (D) 3 μm arrow PEG particles [40]*1, (E) isolated 
200 nm trapezoidal triacrylate particles harvested mechanically with a 
doctor blade [40]*1, (F) 200 nm PEG particles released using a glass 
slide and acetone [57]*2 (G) fluorescent confocal micrograph of conical 








*1 Reprinted by permission from (40). Copyright (2005) American Chemical Society. 
*2 Reprinted from J Control Release, 121, S. E. Gratton, P. D. Pohlhaus, J. Lee, J. Guo, 
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Photo-crosslinked, PEG-peptide Material Systems for use as 
Nanoimprinted, Enzyme-responsive Nanocarriers 
 
3.1 INTRODUCTION 
For the care of complex disorders, such as cancer, disease-responsive release is a 
key issue in the design of drug delivery carriers. The ability to efficiently deliver drugs or 
contrast agents to target tissues in response to a patient’s therapeutic need could 
significantly improve therapeutic and diagnostic care of such diseases [1, 2].  Due to their 
biocompatibility and flexibility in design, hydrogels have been widely used in the 
biomedical field and in drug delivery. Hydrogels are three-dimensional crosslinked 
hydrophilic polymer networks that can imbibe large amounts of water. Hydrogels can 
protect drugs from the environment and control drug release [3]. Stimuli-sensitive 
hydrogels have been developed in ‘smart’ drug delivery systems to sense environmental 
changes and induce a structural change on their own [3-9]. For diseases that require a 
bolus dose of drug at a target location, such as for cancer therapy, enzymatically 
degradable hydrogel membranes could be advantageous. The use of enzyme-responsive 
membranes could allow degradation to be localized to tissues where the enzyme is 
present, while little or no diffusion of the drug would occur in the absence of the enzyme. 
The key issue would be to fabricate the membrane such that there is little or no diffusion 
of the drug through it in the absence of enzyme-triggered degradation. 
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A series of enzymatically degradable hydrogels have been extensively reported by 
West and coworkers and also by Hubbell and colleagues [10-12]. These hydrogels were 
developed to mimic the extracellular matrix and were specifically designed with a peptide 
linkage that dissolved in the presence of tissue-specific enzymes (e.g., collagenase, 
elastase or matrix metalloproteinases (MMPs) ). Hubbell and colleagues reported highly 
specific enzyme-controlled release of recombinant human bone morphogenetic protein 
(rhBMP) from peptide-functionalized, enzymatically degradable poly(ethylene glycol) 
(PEG) hydrogels [11]. They demonstrated that PEG-peptide hydrogels (10% w/v) did not 
allow a significant release of entrapped rhBMP; however, with the addition of enzyme, a 
rapid burst release of rhBMP occurred (Figure 3.1A). West and coworkers demonstrated 
concentration dependent enzyme-controlled release using a PEG-peptide-PEG hydrogel 
(20% w/v) and various concentrations of peptide-specific enzymes (collagenase or 
elastase) [12]. They reported no hydrogel degradation in the absence of enzyme and were 
able to achieve rapid degradation upon optimization of enzyme concentration (Figure 
3.1B). The key relevance of these studies is the possibility that similar peptide-
functionalized, enzyme-degradable hydrogels could be used to control drug release from 
nano-fabricated devices.  
The overall goal of this chapter is to develop a stimuli-responsive peptide-
functionalized PEG material system that has: (a) little or no diffusion of the drug through 
it in the absence of enzyme-triggered degradation, and (b) the ability to be 
nanoimprinted. In this research we have developed an enzyme-responsive PEG hydrogel, 
using a Cathepsin sensitive peptide, Gly-Leu-Phe-Gly-Lys (GFLGK), as the degradable 
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component of a photo-crosslinkable material system. GFLG is a tetra-peptide sequence 
that has been widely used as a spacer in tumor-targeted polymer-drug conjugates [13-19].  
This peptide cross linker can degrade in the presence of several lysosomal thiol proteases, 
especially cysteine proteases such as cathepsins B, H, L, and C [14, 18, 20-26].  Of the 11 
cysteine cathepsins in the human genome, cathepsins B, L, and H are by far the most 
abundant [27-29].  GFLG is particularly sensitive to Cathepsin B [20, 22, 30], which is 
over-expressed in lung, ovarian and colorectal tumor cells and is present extracellularly 
in tumor tissues [26, 31-38]. Cathepsin B levels in tumor cells and tissues of patients with 
specific cancers are significantly elevated (2 to 50 times over-expression) and have been 
directly related to their prognosis [31, 32, 35, 39-44].  In addition, based on information 
from the ExPASy (Expert Protein Analysis System) proteomics server of the Swiss 
Institute of Bioinformatics (SIB), the other major human enzymes that can degrade 
GFLG include digestive enzymes such as chymotrypsin, trypsin, or pepsin. For 
intravenous, parenteral or intranasal delivery, those enzymes are not encountered and the 
sequence should be highly specific for cysteine cathepsins.  
Because previous studies using GFLG as a spacer in drug-polymer conjugates 
have shown enzymatic degradability, we hypothesized that using GFLGK as an enzyme-
degradable linker in a PEG-based material system would cause an enzyme-triggered 
release of drug in the presence of Cathepsin B. Two photo-crosslinkable configurations 
were evaluated: Acrylate-poly(ethylene glycol)-GFLGK-poly(ethylene glycol)-acrylate 
(ACRL-PEG-GFLGK-PEG-ACRL) and poly(ethylene glycol)-diacrylate-GFLGK-
diacrylate (PEGDA-GFLGK-DA), as shown in Figure 3.2A-B.  Both material systems 
 54
were successfully synthesized and imprinted. Release studies revealed an enzyme-
triggered  release of DNA in the presence of Cathepsin B as expected. 
A primary design criterion of the material system is that it should allow drug 
release upon enzymatic degradation and that there should be minimal diffusion of drugs 
through the membrane beforehand. To create a tighter network, PEGDA-GFLGK-DA 
and a lower molecular weight PEG were utilized. In order to estimate the mesh size of the 
cross-linked peptide-PEG hydrogels for future release studies, swelling studies were 
performed on PEGDA. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Polymers and Reagents 
The peptide sequence Gly-Phe-Leu-Gly-Lys (GFLGK) (MW 527) was 
synthesized at ICMB Protein Facility at UT Austin and GFLGK (MW 520.6) was 
purchased from Bachem.  Triethylamine, dimethylacetamide, acryloyl chloride, and n-
heptane were purchased from Sigma-Aldrich. Acrylate-PEG-N-Hydroxy-succinamide 
(ACRL-PEG-NHS, MW 3400) and poly(ethylene glycol) diacrylate (PEGDA, MW 
3400) were purchased from Nektar Therapeutics. Poly(ethylene glycol) diacrylate 
(PEGDA, MW 700) was purchased from Sigma Aldrich and poly(ethylene glycol) 
diacrylate (PEGDA, MW 1000) was purchased from Polysciences. Sodium bicarbonate 
and phosphate buffered saline (PBS, pH 7.4) were purchased from Sigma Aldrich. The 
ultraviolet (UV) photoinitiator, 2-hydroxy-1-[4-(hydroxyethoxy) phenyl]-2-methyl-1 
 55
propanone (I2959) was purchased from Ciba Geigy. Plasmid DNA, pgWiz β-
galactosidase (8500 bps) was purchased from Aldevron. The Picogreen assay was 
purchased from Invitrogen. Cathepsin B from bovine spleen was purchased from Sigma 
Aldrich. Relmat (Molecular Imprints) was supplied by the NNIN and MRC at the 
University of Texas Pickle Research Center. Four inch p-type <100> silicon test wafers 
single-side polished were ordered from Silicon Quest International. 
3.2.2 Conjugation of ACRL-PEG-NHS and GFLGK 
The peptide sequence, GFLGK (MW 527), was reacted ACRL-PEG-NHS.  The 
primary (alpha) amine of Glycine (G) and the primary amine of Lysine (K) at either end 
of the peptide molecule react with the N-Hydroxy-succinamide (NHS) groups of two 
hetero-bifunctional PEG chains, i.e. each peptide molecule cross-links two PEG 
molecules [45-46]. This creates a 2:1 molar reaction (ACRL-PEG-NHS:GFLGK) to form 
ACRL-PEG-GFLGK-PEG-ACRL (a homo-bifunctional PEG diacrylate), as illustrated in 
Figure 3.3. Specifically, the peptide was dissolved to a final concentration of 1 mg/mL in 
50 mM sodium bicarbonate buffer, pH 8.2.  Separately, the ACRL-PEG-NHS was also 
dissolved in 50 mM sodium bicarbonate buffer, pH 8.2. The PEG solution (300 μL) was 
then added one drop at a time into the peptide solution and reacted at room temperature 
for 2-3 hours [45-46]. Next the unconjugated ACRL-PEG-NHS and free peptides were 
removed by dialysis (Spectrum* Spectra/Por* 5000 MWCO dialysis tubing, Fischer 
Scientific) in deionized water. The solution was dialyzed for 4 hours at room temperature 
and then overnight at 4°C with periodic changing of buffer followed by lyophilization of 
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the sample.  Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
mass spectrometry (Perspectives Biosystems Voyager) and H1 NMR were used to verify 
conjugation and removal of unconjugated material.   
3.2.3 Photopolymerization of PEG-GFLGK-PEG and PEGDA  
The lyophilized ACRY-PEG-GFLGK-PEG-ACRL was dissolved in dH2O to 
form a (100% w/v) solution. PEGDA (MW 3400) was dissolved in dH2O to form various 
weight percentages ranging from 25% to 100% (w/v). The ultraviolet (UV) 
photoinitiator, I2959, was first dissolved in dH2O to a concentration of 0.7% (w/v) to 
ensure complete solubility. Subsequently the photoinitiator was added to the polymer 
solution at concentrations of 0.07 wt %, to generate free radicals to in order to induce 
chain polymerization. A thin film of the polymerized hydrogel was formed by dispensing 
specific volumes of the polymer solution onto substrates and placing them under a UV 
lamp (365 nm, intensity ~ 4 mW/cm2, Blak-Ray Lamp, Ted Pella Inc.) for 10 to 20 
minutes depending on the volume of solution dispensed.  The photopolymerization 
process used is similar to that described by the Hubbell and Anseth groups [45-48].   
3.2.4 Acrylation of GFLGK 
3.2.4.1 Acrylation of GFLGK in Dimethylacetamide 
The peptide sequence GFLGK was acrylated at the primary (alpha) amine of 
Glycine (G) and the primary amine of Lysine (K) at either end of the peptide sequence 
using acryloyl chloride as described previously by Hubbell, West, and Healy [49, 50]. 
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Figure 3.4 shows a schematic of the reaction. 30 mg of peptide was dissolved in 1.2 mL 
of dimethylacetamide (DMAc) with equimolar triethylamine, and a 2-fold molar excess 
of acryloyl chloride was added drop wise while stirring. The reaction temperature was 
kept at 0-5°C. After adding all of the acryloyl chloride, the solution continued to stir for 4 
h at 0-5°C and 20 h at room temperature. Subsequently the solution was rotovapped 
under vacuum in a water bath at 40ºC, and rotated at 103 rpm at a 45º angle, for 1-2 
hours. The resulting concentrate was dialyzed (Spectrum* Spectra/Por* 500 MWCO 
Float-A-Lyzer dialysis tube, Spectrum Labs) for 48 hours in dH2O and lyophilized over 
night. Acrylation of the free amine groups in the peptide sequence was analyzed with a 
1H NMR spectrometer; and the spectra recorded in D2O at room temperature.   
3.2.4.2 Acrylation of GFLGK in dH2O 
Acrylation of the peptide sequence GFLGK was based on the previously 
described method using water as a solvent. 25 mg of GFLGK powder was dissolved into 
2 mL of de-ionized water. A ten-fold molar excess of triethylamine and acryloyl chloride 
was added drop-wise to the dissolved peptide solution while stirring. The reaction was 
kept under nitrogen for 4 hours at 0-5oC while stirring and then 20 hours at room 
temperature.  Following this, the solution was filtered, dialyzed and lyophilized as 
previously described. Successful acrylation was analyzed using proton NMR.  
3.2.5 Direct photopolymerization of PEGDA-GFLGK-DA  
PEGDA and GFLGK-DA were dissolved in dH2O in a 1:1 molar ratio to form 
varying concentration (% (w/v)) PEGDA-GFLGK-DA solutions. The ultraviolet (UV) 
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photoinitiator, I2959, was first dissolved in dH2O to a concentration of 0.7% (w/v) to 
ensure complete solubility. Subsequently the photoinitiator was added to the polymer 
solution at concentrations of 0.05 wt % or 0.07 wt %, to generate free radicals in order to 
induce chain polymerization. 
3.2.6 Evaluation of Enzyme-Responsive Release 
3.2.6.1 Evaluation of PEG-GFLGK-PEG Release  
The enzyme specific release kinetics of encapsulated plasmid DNA, pgWiz β-
galactosidase (8500 bps), from a photo-crosslinked PEG-GFLGK-PEG homo-
bifunctional network (100% w/v) was evaluated in vitro. The experiment was performed 
in duplicate with 40 μL hydrogels in 0.01 M PBS solution (pH 7.4) with 0.18% plasmid 
DNA (w/w of polymer). The DNA loaded hydrogels were rinsed, placed in 2mL tubes in 
PBS buffer (1 mL), and placed on a shaker in an incubator at 37oC for the duration of the 
study. At various time intervals (2 hrs, 4 hrs, 6 hrs, 8 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs), 
buffer samples were collected. At each time point 100 μL of buffer was removed and 100 
μL of fresh buffer was replaced.  At the 72 hour time point, the entire PBS buffer solution 
was removed from the samples.  Then a 1 mL solution of Cathepsin B (10 U/mL in PBS 
pH 5) was added to each sample, in agreement with previous studies performed with 
Cathepsin B [51, 52]. The samples were returned to the incubator and at various time 
intervals buffer samples were collected. Each time 100 μL of enzyme solution was 
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removed, and 100 μL of fresh enzyme solution was replaced. The amount of plasmid 
DNA released into buffer was measured for each time point using the NanoDrop.  
3.2.6.2 Evaluation of PEGDA-GFLGK-DA Release 
The enzyme specific release kinetics of encapsulated plasmid DNA, pgWiz β-
galactosidase (8500 bps), from a PEGDA-GFLGK-DA hydrogel (100% w/v) (PEGDA 
MW 1000) was evaluated in vitro. The experiment was performed in duplicate with 20 
μL hydrogels in 0.01 M PBS solution (pH 7.4) with 0.18% plasmid DNA (w/w of 
polymer). The DNA loaded hydrogels were placed in 2 mL tubes in PBS buffer (1 mL), 
and were then placed on a shaker in an incubator at 37oC for the duration of the study. At 
various time intervals (2 hrs, 4 hrs, 6 hrs, 8 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs), buffer 
samples were collected. At each time point 100 μL of buffer was removed and 100 μL of 
fresh buffer was replaced.  At the 72 hr time point, the entire PBS buffer solution was 
removed from the samples.  Then a 1mL solution of Cathepsin B (10 U/mL in PBS pH 5) 
was added to each sample. The samples were returned to the incubator and at various 
time intervals buffer samples were collected. Each time 100 μL of enzyme solution was 
removed, and 100 μL of fresh enzyme solution was replaced. The amount of plasmid 
DNA released into the buffer was measured using a Picogreen Assay, an ultra-sensitive 
fluorescent nucleic acid stain used for quantification of double stranded DNA, and a 
fluorescence plate reader (DTX 880, Beckman Coulter). 
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3.2.7 PEGDA and PEGDA-GFLGK-DA Hydrogel Swelling Studies 
3.2.7.1 PEGDA Hydrogel Swelling Experiment 
PEGDA (MW 700) was dissolved in dH2O to form various weight percentages 
ranging from 25%, 33%, 50%, 60% and 75% w/v. The ultraviolet (UV) photoinitiator, 
I2959, was first dissolved in dH2O to a concentration of 0.7% (w/v) to ensure complete 
solubility. Subsequently, the photoinitiator was added to the polymer solution at 
concentrations of 0.05 wt %. The experiment was performed with n=8 for each PEGDA 
concentration. A volume of 100 μL polymer solution was pipetted into a mold (a cuvette 
cap) and exposed to 365 nm UV light (Blak-Ray, nominal intensity ~ 4 mW/cm2) for 20 
minutes.  The relaxed state of the hydrogels immediately after cross-linking was 
measured in air (Wa,r) and in heptane (Wn,r). The hydrogels were then rinsed in 500 mL 
beakers of dH2O to remove the unreacted polymer and then vacuum dried for 5 days. 
Following this, the weight of the hydrogels  in the dried state was measured in air (Wa,d) 
followed by heptane (Wn,d). The hydrogels were then allowed to swell in 50 mL tubes for 
48 hours in PBS at 37oC. After swelling, the hydrogels in the swollen state were 
measured in air (Wa,s) and in heptane (Wn,s). For the heptane measurements, the hanging-
basket method was used.  Heptane was placed into a 250 mL beaker, with the hanging 
basket fully submerged in the heptane. Subsequently, each hydrogel was placed in the 
basket (submerged in the heptane) and a weight measurement was taken. 
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3.2.7.2 PEGDA-GFLGK-DA Hydrogel Swelling Experiment 
PEGDA-GFLGK-DA (MW 700) was dissolved in dH2O in a 1:1 molar ratio to 
60% w/v. The ultraviolet (UV) photoinitiator, I2959, was first dissolved in dH2O to a 
concentration of 0.7 wt% to ensure complete solubility. Subsequently the photoinitiator 
was added to the polymer solution at concentrations of 0.05 wt %. The experiment was 
performed in duplicate. A volume of 100 μL polymer solution was pipetted into a mold 
(a cuvette cap) and exposed to 365 nm UV light (Blak-Ray, nominal intensity ~ 4 
mW/cm2) for 20 minutes.  The relaxed state of the hydrogels immediately after cross-
linking was measured in air (Wa,r) and in heptane (Wn,r). Differing from the previous 
PEGDA swelling study, the hydrogels were then rinsed and lyophilized, following a 
protocol from Anseth [53]. The weight of the hydrogels in the dried state was measured 
in air (Wa,d) followed by heptane (Wn,d). The hydrogels were then allowed to swell in 50 
mL tubes for 48 hours in PBS at 37oC. After swelling, the hydrogels in the swollen state 
were measured in air (Wa,s) and in heptane (Wn,s). For the heptane measurements, the 
hanging-basket method was used. Because we cannot use standard theory with the 
PEGDA-GFLGK polymer we simply measured the mass swelling ratio using equation 
below, to calculate the volumetric swelling ratio and compare it to the values obtained for 
PEGDA. 
 
3.2.7.3 Calculation of PEGDA and PEGDA-GFLG-DA Hydrogel Properties 
Average molecular weight between crosslinks (Mc), mesh size (ξ), as well as 
other PEG hydrogel properties were calculated using the Peppas and Merrill and Bar-
Howell theories. The equation used to determine Mc is the Peppas and Merrill modified 
Flory-Rehner theory for molecular weight of the polymer chain between two adjacent 



























































Where Mn is the number average molecular weight of the uncrosslinked polymer (ie – 
molecular weight of the macromer), V1 is the molar volume of water (18 cm3/mol), ν2,r is 
the polymer volume fraction in the relaxed state, ν2,s is the polymer volume fraction in the 
equilibrium swollen gel, ν is the specific volume of the polymer (0.893 cm3/g), and χ is 
the polymer-solvent interaction parameter. A value of 0.426 was assumed for PEG [54]. 









where νp is the volume of the polymer and νgel,r is the volume of the relaxed gel. The 




















   (4) 
where Wa,r is the sample weight in air after crosslinking and Wn,r  is the sample weight in 
heptane (nonsolvent) after crosslinking, ρn is the density of the nonsolvent (0.684 g/cm3 
for heptane), Wa,d  is the sample weight in air after vacuum drying and Wn,d is the sample 
weight in heptane after vacuum drying. Using the two equations above, the polymer 
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where νgel,s is the volume of the swollen gel and Q is the volume swelling ratio. The 












where Wa,s is the sample weight in air after swelling and Wn,s  is the sample weight in 
heptane (nonsolvent) after swelling. Using the equations (3) and (7), the polymer volume 












=   (8) 
The mesh size was determined as described by Canal and Peppas [55]. To 
calculate mesh size in Angstroms of the swollen polymer, the following equations were 
used: 
 ( ) 2/12/12/12 NlCr no =  (9) 
 ( ) 2/123/1,2 os rv −=ξ   (10) 
where ro is the root mean squared end-to-end distance of the polymer chain in the 
unperturbed state, l is the length of the bond along the polymer backbone, Cn is the Flory 
characteristic ratio, N is the number of links/chains between crosslinks and ξ is the mesh 
size. Typical values for l and Cn for PEG are (1.47 Å - 1.5 Å) and 4.0, respectively [54, 
56, 57]. In this case 1.5 Å was used for the value of l, and was taken as the weighted 
average of one carbon-carbon bond and two carbon-oxygen bonds. Substituting equation 
(9) into equation (10) we get: 
   (11)  2/12/13/1,2 NlCv ns
−=ξ
In order to simplify further, we estimate that: 
 
Mr
McN 2=   (12) 
where Mr is the molecular weight of the repeating units from which the polymer chain is 
composed (ie – the monomer). The value of Mr for PEG is 44 g/mol. Substituting 
















= −ξ  (13)   
Equation (13) was used to calculate the mesh size in Angstroms of the swollen PEGDA 
polymers for the varying concentrations. This will provide a basic estimate on what 
cross-linking densities must be used to fabricate membranes for a particular drug size and 
will provide the theoretical limitation of stimuli-responsive release from such a design. 
To calculate an estimate of parameters for the PEGDA-GFGLK-DA hydrogels, the mass 
swelling ratio (Qm) was calculated using the equation: 
 
Wd
WsQm =  (14) 
where Ws is the swollen weight of the hydrogel and Wd is the dry weight of the gel. 
From here we can estimate the value of the volumetric swelling ratio using equation (15) 
[58-60]: 
 




)ρ  (15) 
where ρp is the density of the polymer and ρs is the density of the solvent (~ 1 g/mL for 
dH2O). The volumetric swelling ratio the density of the polymer was calculated by 
estimating the molar volume for the PEGDA-GFLGK and dividing by the molecular 
weight of the segment [59]. A molar volume for PEGDA MW 700 (784 cm3/mol) and a 
molar volume of a penta-peptide incorporating Tyr-Gly-Gly-Phe-Leu (409.3 cm3/mol) 
were used [61]. The values from this study provide a basic estimate on what cross-linking 
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densities must be used to fabricate membranes for a particular drug size and will provide 
the theoretical limitation of stimuli-responsive release from such a design. 
3.2.8 Evaluation of PEGDA, PEG-GFLGK-PEG and PEG-GFLGK-DA 
Imprintability 
As described previously, the ACRL-PEG-GFLGK-PEG-ACRL was dissolved in 
dH2O to form a (100% w/v) solution. PEGDA (MW 3400) was dissolved in dH2O to 
form a 100% w/v concentration. The ultraviolet (UV) photoinitiator, I2959, was first 
dissolved in dH2O to a concentration of 0.7% (w/v) to ensure complete solubility. 
Subsequently, the photoinitiator was added to the polymer solution at concentrations of 
0.07 wt %, to generate free radicals in order to induce chain polymerization (ref). To 
verify the imprintability of the PEGDA solutions, the IMPRIO 100 SFIL system 
(Molecular Imprints) was used. Prior to imprinting, a Relmat release layer was applied to 
a quartz template with a 25 x 25 mm mesa containing nanoline patterns (supplied by 
NNIN and the MRC at the University of Texas Pickle Research Center). The Relmat was 
dispensed using a dropper. Two to three drops of Relmat were dropped onto the mesa of 
the quartz template and subsequently blown dry with Nitrogen.  Subsequently, a silicon 
wafer was manually loaded into the IMPRIO 100.  The automated dispensing unit was 
inactivated and a volume of 0.5 to 2.5 μL of ACRL-PEG-GFLGK-PEG-ACRL and 
PEGDA concentrations was manually pipetted onto to the silicon wafer, prior to each 
imprint. The solutions were imprinted with a force of 2 N, a 30 second exposure time, 
and a pre-delay of 120 seconds. After optimization of the imprinting process described in 
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3.3.1 Verification of ACRL-PEG-NHS and GFLGK Conjugation 
As shown in Figure 3.5A (measured before dialyzing through the 5000 MWCO 
membrane), the presence of a ~ 7300 Da peak indicates successful conjugation of one 
peptide to two PEG molecules, representing a conjugated PEG-GFLGK-PEG. The peak 
at 3707 may represent either a not fully conjugated PEG-GFLGK or possibly a dimer of 
the PEG-GFLGK-PEG. H NMR spectroscopy further supported the conjugation. The 
NMR data, Figure 3.5B-D, shows spectra of ACRL-PEG-NHS, GFLGK, and the 
conjugated form, respectively. In Figure 3.5D, the acrylate groups are seen at 5.9 – 6.4 
ppm and the aromatic phenyl group on Phe of the peptide is seen at 7.15 – 7.3 ppm. To 
determine the degree of conjugation, the ratio of protons was calculated by comparing the 
area under the aromatic phenyl group on Phe (5 protons) to the area under the acrylate 
group (3 protons). The results show a 1 to 1.5 molar ratio of GFLGK to PEG, suggesting 
that there is ACRL-PEG-GLFGK and ACRL-PEG-GLFGK-PEG-ACRL; however, the 
cleanliness of the overall NMR spectra suggests that there is mostly one species. After 
dialyzing and lyophilizing the yield was approximately 80%. 
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3.3.2 Verification of Acrylation of GFLGK 
H NMR data for both methods of acrylating GFLGK using DMAc and dH2O as 
solvent, show successful acrylation of the peptide sequence. Figure 3.6A-D shows the 
1H NMR data of acryloyl chloride, triethylamine, GFLGK, and the acrylated peptide 
using the first acrylation method with DMAc as a solvent. Successful acrylation was 
achieved using this method as can be seen by the addition of the acrylate peaks at 5.7 - 
6.2 ppm in Figure 3.6D. However, due to impurities within the sample, it was difficult to 
estimate the actual degree of acrylation. The yield for this method was approximately 
20%. Figure 3.7A-B shows acrylated peptide using the second method with water as a 
solvent. Successful acrylation was achieved using both the acrylation methods as can be 
seen by the addition of the acrylate peaks at 5.7 - 6.2 ppm in Figure 3.6D and Figure 
3.7B.  To determine the degree of acrylation, the ratio of protons were calculated by 
comparing the area under the isopropyl group (6 protons) and the area under the acrylate 
curve (3 protons). The NMR spectra for the second acrylation method showed a 1 to 2 
molar ratio of GFLGK to acrylate, demonstrating successful di-acrylation of the peptide. 
The yield for this process is approximately 89%1.  
3.3.3 Evaluation of PEGDA, PEG-GFLGK-PEG and PEGDA-GLFKG-DA 
Enzyme-Responsive Release 
As shown in Figure 3.8A, there was an initial release of 10 to 20% of the DNA 
from PEG-GFLGK-PEG hydrogel, followed by saturation and then an enzyme-triggered 
 
1 NMR analysis for Figure 2.7 and yield value courtesy Mary Caldorera-Moore. 
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release of DNA upon addition of Cathepsin B; however, we believe this may be due to 
the hydrophilic nature of the DNA. It may have adsorbed to the surface of the hydrogel or 
not fully encapsulated within the gel. When Cathepsin B was introduced to the PEGDA-
GFLGK-DA hydrogel, Figure 3.8B, we see a rapid release of DNA. The results for the 
PEGDA-GFLGK also show a smaller ratio of initial DNA release compared to overall 
release. As expected, the results demonstrate that specific enzyme-induced burst release 
does occur.  
3.3.4 PEGDA and PEGDA-GFLGK swelling properties 
Results of the mesh size (ξ), the molecular weight between crosslinks (Mc), the 
polymer volume fraction in the swollen state (v2,s), and the mass swelling ratio can be 
found in Table 3.1. The results indicate that mesh size, molecular weight between 
crosslinks and the mass swelling ratio decrease as the PEGDA concentration decreases. 
Table 3.1 shows that the Mc varies from 18.09 ± 1.59 Å (75% w/v) to 179.10 ± 13.53 Å 
(25% w/v) with mesh sizes of 2.86 ± 0.3 Å to 12.92 ± 1.56 Å, respectively. Polymer 
volume fraction in the swollen state increased with a decrease in PEGDA concentration. 
Because the volumetric swelling ratio is inversely proportional to v2,s, the results indicate 
that that the volumetric swelling ratio increases as the PEGDA concentration decreases. 
The v2,s ranged from 0.86 ± 0.05 Å (75% w/v) to 0.29 ± 0.03 Å (25% w/v) with 
volumetric swelling ratios calculated as 1.16 ± 0.06 Å and 3.44 ± 0.32 Å, respectively. 
The mass swelling ratio of the PEGDA-GFLGK (60% w/v) was 3.59 ± 0.59 Å, with an 
estimated volumetric swelling ratio of 3.51 ± 0.58 Å. 
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3.3.5 Evaluation of PEGDA, PEG-GFLGK-PEG and PEGDA-GLFKG-DA 
Imprintability 
Figure 3.9A-B demonstrates that PEGDA (MW 3400) was successfully able to 
create well-defined patterns and nano-lines (800 nm with 200 nm spacing) with the 
imprinting process. Figure 3.9C-D demonstrates successful imprinting of PEG-GFLGK-
PEG. The imprinted nano-lines were 600 nm in width with 100 nm spacing (Figure 
3.9C), and 300 nm in width with 50 nm spacing (Figure 3.9D). There were some issues 
with the PEG-GFLGK-PEG adhering to the template/not adhering to the wafer; therefore 
only two to three imprints could be performed at a time. PEG-GFLGK-DA was also 
successfully imprinted and had fewer issues with adhering to the template. 
 
3.4 DISCUSSION 
The overall goal of these experiments was to create a stimuli-responsive peptide-
functionalized PEG material system that demonstrated: (a) minimal diffusion of the drug 
through it in the absence of enzyme-triggered degradation, and (b) the ability to be 
nanoimprinted.  We developed two configurations. The first configuration involved a 
photo-crosslinkable, homo-bifunctional PEG diacrylate, ACRL-PEG-GFGLK-PEG-
ACRL, polymer using a 2 to 1 molar ratio of PEGDA (MW 3400) to ACRL-PEG-NHS. 
The second configuration involved a photo-crosslinkable PEGDA-GFLGK-DA hydrogel 
using an equimolar mixture of PEGDA (MW 700) and a diacrylated, enzymatically 
degradable peptide, GFLGK-DA. Both configurations create a matrix crosslinked with a 
degradable peptide spacer, GFLGK, designed for degradation by Cathepsin B, shown in 
Figure 3.2. The results from NMR and MALDI show successful incorporation of 
GFLGK with PEGDA and ACRL-PEG-NHS using previously established techniques for 
the conjugation [46, 48] and acrylation [49, 50], respectively.  The second acrylation 
method using water has shown to be much easier to perform and provides a better 
acrylation efficiency and yield than the previous acrylation method.  
A primary design criterion of the material system is that it should demonstrate 
drug release upon enzymatic degradation and that there should be minimal diffusion of 
drugs beforehand. The pore size (ξ) and molecular weight between crosslinks (Mc) of 
these hydrogels dictate whether a certain drug can be entrapped without significant 
diffusive leaching prior to an environmental trigger. For little to no diffusion to occur, the 
cross-linking density of the membrane must be such that the pore sizes are smaller than 
the drug molecule sizes; thus it is possible to a priori model which particular therapeutic 
or diagnostic agents are suitable for stimuli-responsive, triggered release from particles of 
a specific composition.  Assuming a spherical configuration for protein or DNA 
molecules, the expected hydrodynamic size (Stokes diameter) of a typical drug can be 






where k is the Boltzman constant, T is the temperature in Kelvin, µ is the viscosity of the 
solution, DA is the diffusion coefficient of the peptide or model drug and d is the 
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    (18) 
for DNA. 
Pore size measurements for bulk PEGDA (MW 3400) hydrogels of various 
concentrations have been reported by Bryant and Anseth [62]. Anseth et al. 
experimentally determined the pore size of photo-crosslinked PEGDA (MW 3400) 
polymers at 10%, 20%, 30% and 40% w/v concentrations [62]. Their results indicate that 
the average pore sizes are approximately 14, 6, 5 and 4 nm, respectively. Our lab has 
experimentally determined the pore size of PEGDA 100% (w/v) (MW 3400) to be 1.5 nm 
(data not shown). Experimentally obtained values show that the hydrodynamic diameter 
of the model protein BSA (MW 67 kDa) is ~ 4 nm [63], while that of circular plasmid 
DNA is approximately 100 nm [64]. This indicates that at concentrations of 40% (w/v) or 
higher, the pore sizes are less than the calculated hydrodynamic size of BSA; meanwhile 
for plasmid DNA delivery, polymer concentrations of 20% (w/v) or above will be 
suitable.   
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Therefore, the PEG-GFLGK-PEG design (using PEGDA MW 3400) should 
efficiently prevent diffusion of both protein and DNA drugs in the absence of Cathepsin 
B. Our release study results indicate that ~ 20% of DNA is initially released using the 
PEG-GFLGK-PEG polymer configuration, followed by saturation and then an enzyme-
triggered release of DNA upon addition of Cathepsin B. We believe some of the initial 
release and saturation may be due to the hydrophilic nature of plasmid DNA. It may have 
adsorbed to the surface of the hydrogel and or not fully encapsulated within the gel. 
Unfortunately, the company that manufactured the NHS-PEG-ACRL stopped producing 
the product, so no further studies could proceed with using a smaller molecular weight 
PEGDA in efforts to create a tighter polymer network.  
In order to potentially reduce the initial DNA release we created the PEGDA-
GFLGK-DA hydrogels. To create a tighter polymer network, a photo-crosslinkable 
PEGDA-GFLGK-DA polymer using an equimolar mixture of PEGDA (MW 700) and a 
diacrylated, enzymatically degradable peptide, GFLGK-DA were evaluated. In order to 
estimate the pore size of the PEGDA-GFLGK-DA polymer membranes, hydrogel 
swelling studies were performed on PEGDA (MW 700) hydrogels. Specific assumptions 
were used in the calculations, specifically for the polymer-solvent interaction factor (χ). 
We assumed a value of 0.426, based on a study by Merrill, et al. This value was shown to 
be nearly independent of polymer volume fraction for values of 0.04 to 0.2 with swelling 
performed in water [54]. Since we are using PBS and have larger polymer volume 
fractions, this value of χ may not be valid and would need to be measured for a more 
 74
accurate study. Needless to say, this is the value commonly reported in literature and 
should provide a good estimate of Mc and mesh size [65, 66].  
The results of the swelling study demonstrated mesh sizes that range from 2.86 to 
12.92 Å, for a 25% (w/v) to 75% (w/v) PEGDA hydrogel, respectively.  While the 
PEGDA concentration increases, this affects the number of crosslinks, and leads to an 
increased entanglement and thus a decreased swelling ratio. Furthermore, the estimated 
volumetric swelling ratio of the 60% (w/v) PEGDA-GFLGK-DA resembled that of the 
25% (w/v) PEGDA hydrogel. This suggests that the PEGDA-GFLGK-DA polymer 
membrane may be less entangled and may display similar properties to a 25% (w/v) 
PEGDA hydrogel. Depending on the concentration of the PEGDA (MW 700), we 
hypothesize that protein and nucleic acid-based drugs with hydrodynamic radii larger 
than two nanometers should be successfully retained and slowly released from such 
particles, even with a 25% (w/v) concentration. Thus protein, peptide and nucleic acid-
based drugs, hydrophobic drug particles as well as nanoparticle-based contrast agents 
could be successfully retained within such hydrogels and released primarily upon 
environmentally-triggered matrix degradation. Using the PEGDA-GLFGK-DA polymer 
configuration did result in a smaller ratio of initial DNA release compared to overall 
release (~ 8%) than was present in the first hydrogel design. We also demonstrate a steep 
burst release of DNA. This is comparable to the ~ 10% initial release of rhBMP from the 
enzyme-responsive hydrogel demonstrated by Hubbell and colleagues, as seen in Figure 
3.1B. 
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In conclusion, the PEG-GFGLK-PEG and PEGDA-GFLGK-DA configurations 
demonstrated an enzyme-triggered release of DNA upon addition of Cathepsin B and 
were both successfully imprinted. Characterization of degradation and release kinetics 
would be required for future study; however, the goal of this research was to demonstrate 
enzyme-responsive release with minimal initial diffusion of drug from the hydrogel 
material system, as well as to show the potential for use with nanoimprinting. The key 
relevance of these studies is the possibility that these material designs, as well as other 
similar peptide-functionalized, enzyme-degradable hydrogels could be nanoimprinted, 
and used to control drug release from nanoimprinted carriers. The ability to create nano-
sized, injectable drug carriers fabricated with precise geometry and environmentally-
responsive release mechanisms could provide targeted, disease-specific delivery of 








                                                                    
 
 
                                                                                                                                                                              
Figure 3.1   Enzymatically Degradable Hydrogel Release and Degradation: (A) 
Hubbell and colleagues demonstrated rapid burst release of BMP-2 
upon addition of MMP-2 [11]*1, and (B) West and colleagues 
demonstrated enzyme-dependent degradation of PEG-peptide-PEG 





*1 Reproduced with permission from M. P. Lutolf, F. E. Weber, H. G. Schmoekel, J. C. 
Schense, T. Kohler, R. Müller, and J. A. Hubbell: Repair of bone defects using 
synthetic mimetics of collagenous extracellular matrices. 2003. 21. 513-518. Copyright 
Wiley-VCH Verlag GmbH & Co. KGaA.  
*2 Reproduced with permission from B. K. Mann, A. S. Gobin, A.T. Tsai, R. H. 
Schmedlen, and J. L. West: Smooth muscle cell growth in photopolymerized hydrogels 
with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for 









Figure 3.2   Enzyme-Responsive Polymer Chemistry, Photopolymerization and 
Degradation Mechanism: (A) Method 1: photo-crosslinked ACRL-






Figure 3.3   Schematic of ACRL-PEG-NHS and GFLGK Conjugation. 
  
  















Figure 3.5  MALDI and NMR Images of Conjugated ACRL-PEG-GFLGK-PEG-
ACRL: (A) MALDI image showing the conjugated ACRL-PEG-
GFLGK-PEG-ACRL and a possible dimer or ACRL-PEG-GFLGK, (B) 
NMR image showing NHS-PEG-ACRL, (C) NMR image showing 










Figure 3.6 NMR images of Acrylated GFLGK using Dimethylacetamide as a 












Figure 3.7  NMR images of Acrylated GFLGK using dH2O as a solvent: (A) 
GFLGK and (B) successfully di-acrylated GFLGK. Reprinted from J 
Control Release, 125, L. C. Glangchai, M. Caldorera-Moore, L. Shi, and K. 








Figure 3.8  Enzyme-Responsive Plasmid DNA Release from: (A) 100% (w/v) PEG-
GFLGK-PEG hydrogel   (PEGDA MW 3400), and (B) 100% (w/v) 
PEGDA-GFLGK-DA hydrogel (PEGDA MW 1000), showing enzyme-






Table 3.1  Swelling Properties of PEGDA and PEGDA-GLFGK-DA: (A) PEGDA 
(MW 700) with concentrations varying from 75% to 25% (w/v) (n=8), 





ζ           
(Angstrom) (SD) Mc (SD) v2s (SD) Qv  (SD)
75 2.86 0.30 18.09 1.59 0.86 0.05 1.16 0.05 
60 3.15 0.48 21.47 2.69 0.84 0.07 1.19 0.07 
50 5.07 0.55 47.23 3.90 0.65 0.05 1.53 0.05 
33 8.75 1.36 106.42 11.30 0.43 0.05 2.34 0.05 






Qm (SD) Qv (SD) 














Figure 3.9  SFIL Imprinted PEGDA and PEG-GFLGK-PEG: (A) Nanofeatures in 
100% (w/v) PEGDA (MW 3400) (scale bar = 4μm), (B) 800 nm 
nanolines with 200 nm spacing in 100% (w/v) PEGDA (MW 3400) 
(scale bar = 400nm), (C) 600 nm lines in 100% (w/v) PEG-GFLGK-
PEG with 100 nm spacing (scale bar = 400nm), (D) 300 nm nanolines 
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Nanoimprint Lithography Techniques for Fabrication of Injectable, 
Intracellular Drug Delivery Nanoparticles of Specific Size and Shape 
 
4.1 INTRODUCTION   
Nanoparticle-based delivery of therapeutics has been extensively studied in a 
variety of diseases and is considered to be an ideal platform for targeted intravenous and 
intracellular delivery of bioactive agents. Current concepts in the synthesis of drug 
nanocarriers primarily involve the use of polymers or lipids to fabricate self-assembled or 
emulsion-based particles that are mostly spherical, polydisperse, and release drugs 
through diffusion or hydrolytic degradation. Although significant progress has been made 
in polymeric or liposomal drug delivery systems, there remain critical limitations in 
synthesizing nanocarriers with highly controllable architectures that can, at the same 
time, incorporate multiple functionalities. Our ability to precisely manipulate size, shape, 
composition, and drug release mechanism of nanoparticles is essential for controlling 
their in-vivo transport, biodistribution, and therapeutic efficacy [1-3].   
Recent reports suggest that particle shape could play a significant role in the in-
vivo performance of delivery vehicles [4, 5]. Specifically, shape and shape-related form 
factors, like aspect ratio or edges, affect particle transport characteristics, influence cell-
particle interactions, and alter drug release kinetics [4, 6]. Ferrari and colleagues have 
shown through theoretical modeling that shape and size of nanovectors and spherical and 
spheroidal nanoparticles can significantly affect how particles interact with tumor 
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capillaries during transport [7, 8]. Discher and colleagues demonstrated that self-
assembled, filamentous particles with very high aspect ratios (less than 100 nm diameter 
with several microns in length) have unique long-circulating properties compared to 
traditional spherical liposomes [5]. Until recently, particle shape has been an unexplored 
area of research in drug delivery due to our inability to reliably synthesize nano or 
microparticle carriers with precise and pre-designed geometry.  
Several groups have demonstrated the ability to create such shape-specific and 
monodisperse microparticles using techniques varying from microfluidics, self-assembly, 
photopolymerization, micromolding and lithography [4, 9-13]; however, there are in fact 
only a few methods that have been developed to fabricate particles with varying shape 
and size, especially at the nanoscale. Recently, Mitragotri and colleagues reported a 
unique solvent-based method to generate polystyrene micro and nanoparticles of various 
shapes with feature sizes as low as 60 nm [14].  The technique involved stretching 
particles into a film, heating (120 – 150oC) or placing the film in solvent, and dissolving 
the film; however, it remains to be studied how these methods are translated to 
biopolymers.  
Currently, the concept of a shape-specific, injectable nanocarrier capable of 
systemic, intracellular delivery of therapeutics has not fully been explored, especially at 
the sub-100 nm size.  While particles below 500 nm in size can be injected intravenously, 
only those below 200 nm are efficiently internalized by somatic cells. Reports also 
suggest that delivery into the lymphatic circulation requires particles that are even smaller 
in size (< 50 nm) [15].  Significant technological challenges exist in fabricating such 
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small nanocarriers with a pre-designed geometry and the potential for tunable in-vivo 
properties; therefore, new nano-scale fabrication techniques are necessary to create such 
drug delivery devices. Recent advancements in nano-scale fabrication using nanoimprint 
lithography techniques could provide new approaches for top-down, high-throughput, 
large scale fabrication of size and shape-specific nanoparticles for drug delivery 
applications.  
DeSimone and colleagues have recently demonstrated top-down nanofabrication 
to create nanoparticles of specific size and shape, as small as 160 nm using the particle 
nano-replication (PRINT) method [16-18]. They reported the ability to form nano-size 
PEG diacrylate (PEGDA) and poly(lactic acid) (PLA) particles using a photocurable 
perfluoropolyether (PFPE) stamp that is non-wetting to both inorganic and organic 
materials. Thus formation of particles without a residual film between them was 
accomplished. To fabricate PLA particles, PLA was in-situ polymerized at 110oC to mold 
the polymer solution. PEG particles were formed by imprinting and photopolymerization.  
PEG particles were fabricated in a variety of shapes (trapezoidal, conical, bar and arrow 
shapes) with sizes ranging from 200 nm to 3 μm. Furthermore, encapsulation of avidin-
FITC and doxorubicin in 500 nm PEG particles was demonstrated.  
Recently, DeSimone and colleagues demonstrated an improvement in 
monodispersity when compared to current liposomes [18]. This suggests that top-down 
fabrication does indeed produce monodisperse nanoparticles using biopolymers. The use 
of a top-down approach could ensure precise control of particle size and geometry, 
creating a monodisperse population of particles, therefore yielding better reproducibility 
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and prediction of properties than current self-assembly and emulsion-based nanoparticle 
systems. A top-down approach could further allow for incorporation of multiple 
functionalities, such as targeting, loading multiple agents, and stimuli-responsiveness. 
In any fabrication process involving therapeutics or biologics, harvesting of 
nanoparticles into a usable form is of considerable importance. A major limitation in the 
PRINT fabrication process is the mechanism of particle harvesting. Currently, the PRINT 
particles are harvested from the wafer either using physical scraping with surgical blades 
or by shear force using a glass slide [16-18], both of which could damage the particles 
and may not be suitable for large scale manufacturing. Although the PRINT fabrication 
method has demonstrated fabrication of 160 nm conical particles, the process is not 
immediately scalable and utilizes methods of particle release that could damage the 
particles. It is evident that successful translation of any top-down nanofabrication 
technologies to drug delivery applications would require development of techniques that 
are mild and compatible with a variety of biological molecules. Furthermore, any such 
technique must allow easy harvesting of nanoparticles and ability to incorporate unique 
functionalities, such as disease-triggered drug release. 
This research provides a more in depth overview of nanoimprint lithography 
techniques, thermal nanoimprint lithography (ThNIL), and step and flash imprint 
lithography (SFIL), and discusses the optimization of the process characteristics and 
materials for imprinting biocompatible polymers and materials.  We hypothesized that 
utilizing semiconductor nanoimprint lithography techniques to pattern biocompatible 
polymers would enable us to fabricate monodisperse, injectable drug nanocarriers of 
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precise shape and size suitable for intracellular drug delivery applications. In this 
research we demonstrate the use of ThNIL and SFIL, coupled with biocompatible 
polymer and crosslinked networks to imprint monodisperse injectable nanoparticle of 
pre-designed sizes and geometries as small as 50 nm.  Particles of varying shape (square, 
circular, pentagonal, and triangular), size (50 - 400 nm), and composition (PMMA, 
PLGA, PEG) were fabricated using these techniques.  We have demonstrated full wafer 
imprinting and successful isolation and release of the particles from the wafer using a 
mild harvesting method. The SFIL method, with its low temperature and force 
applications, as well as wafer-scale imprinting capability, was more suitable for large 
scale fabrication and was chosen for further optimization.   
4.1.1 Overview of Step and Flash Imprint Lithography (SFIL) and Thermal 
Imprint Lithography (ThNIL) 
Several recent advancements in nanomanufacturing methods could provide new 
approaches for top-down, high-throughput, large-scale fabrication of nanocarriers for 
drug delivery applications. One of the most promising nanoimprinting techniques is the 
step and flash imprint lithography (SFIL) method invented by Wilson and colleagues at 
UT Austin.  The SFIL process [19-25], shown in Figure 4.1, is essentially a nanomolding 
process in which the topography of a template defines the patterns created on a substrate. 
In brief, a transparent quartz template is treated with a release agent to facilitate substrate 
separation. Next, a low viscosity, UV curable, organosilicon monomer is dispensed onto 
a silicon substrate. The gap between the template and substrate is closed, using low 
 99
pressure at room temperature. Following this, the quartz template is irradiated with UV 
light. The transparency of the quartz allows the UV light to pass through and 
photopolymerize the monomer beneath the template. When the template is separated 
from the substrate, the cured monomer on the substrate retains the desired 3D 
nanotopography. As shown in Figure 4.2, this is a step and repeat process. Therefore the 
wafer is stepped and the process is performed again in the next field. Once the entire 
wafer has been patterned, further processing with oxygen plasma cleaning removes 
residual monomer for distinct features.  
SFIL has several advantages over conventional lithography and micromolding 
processes.  Unlike conventional lithography, imprint lithography does not use energetic 
beams, therefore it is not diffraction limited.  SFIL is only limited by the resolution of the 
imprint template created by e-beam lithography. Recent work has demonstrated 20 nm 
lines using the SFIL process.  Traditional micromolding requires high pressures (> 10 
MPa) and temperatures (> glass transition temperature of the polymer film), which may 
distort nanofeatures. SFIL uses a low-viscosity (~ 2-3 cps), photocurable, monomer that 
allows high resolution features to be imprinted at room temperature with minimal 
pressure (< 1 psi). Furthermore, the reusable transparent quartz template enables sub-10 
nm alignment of nanofeatures, a task very difficult in other processes. Finally, 3D 
structures can accurately be replicated by the SFIL process, and patterns can be imprinted 
on top of existing topography by using an appropriate planarization material. The 
availability of pre-existing equipment (IMPRIO 100) in cleanroom facilities and ease of 
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high-fidelity replication of features, suggests the potential capability of high-throughput 
and low cost manufacturing of nanoparticles for drug delivery.  
Another nanoimprint method with potential for fabricating nanocarriers is thermal 
nanoimprint lithography. First proposed in 1995 by SY Chou [26, 27], the process 
consists of imprinting with a reusable Silicon template and pattern transfer with RIE. 
However, in contrast to SFIL, thermal nanoimprint lithography requires heating a 
polymer above its glass transition temperature and applying considerably more pressure. 
Upon cooling, the polymer hardens into a desired 3D nanotopography.  This method has 
shown the ability to create sub-20 nm features. As with SFIL, this method is 
advantageous in that its resolution is limited only by the template fabrication process and 
it is capable of replicating precise 3D features. The SFIL and ThNIL techniques have the 
potential to create well-defined and characterized drug delivery particles without the 
limitations of self-assembly, or emulsion techniques.   
4.1.1.1 SFIL: IMPRIO 100 
The IMPRIO 100, shown in Figure 4.3A, is fabricated by Molecular Imprints and 
is used to perform step and flash imprint lithography. The tool is a precise mechanical 
system that incorporates a motorized z-head, a fluid dispensing system and a mercury arc 
lamp, shown in Figure 4.3C-F. The IMPRIO has a wafer loading station and template 
loading station on the front of the tool as seen in Figure 4.3B. Within the wafer loading 
station there is a semi-automated wafer handler that can load wafers (ranging from 2” to 
8”) onto a wafer chuck inside the tool (Figure 4.3D). The IMPRIO 100 has dual dispense 
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tips connected to monomer storage vials for the use of two different monomers (Figure 
4.3E-F), and has software as well as hardware to create a drop pattern recipe to imprint 
with these monomers. The fluid dispense system uses a piezo electric ink jet head to 
dispense droplets smaller than 5 nL (Figure 4.3E) [28], with the dispense volume 
directly proportional to the length of the voltage pulse applied. A typical dispense uses 
multiple drops of 200 pL.  
Figure 4.4 shows a schematic of how the motorized z-head and wafer chuck are 
situated within the tool. A wafer is loaded onto the wafer chuck, which sits on a vacuum 
preloaded XY air bearing stage. The template is loaded in the template chuck beneath the 
z-head and held by vacuum. Following this the template is aligned and leveled to the 
stage with an upward air gauge; the wafer is subsequently leveled to the stage with a 
downward air gauge [20]. When the user is ready to imprint the motorized z-head lowers 
the template towards the wafer, and a flexure ring allows the wafer to match the 
orientation of the template. Following this a mercury arc lamp provides UV light at 365 
nm, which is then collimated by a lens and reflected by a mirror onto the backside onto 
the template/wafer interface [25]. Throughout the imprinting process Helium gas is 
supplied around the wafer chuck to displace oxygen so that the monomer can be fully 
photopolymerized. 
4.1.1.2 SFIL: IMPRIO 100 Optimization Parameters 
Key factors to obtaining uniform, low residual layer, imprints involve 
minimization of particles in the environment, flatness of the wafer, a non-wetting release 
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layer on the template, a suitable fluid for dispensing and an optimized imprinting recipe. 
The Graphical User Interface (GUI), displayed on the computer screen (Figure 4.3A) 
allows an operator to create recipes, optimize the imprinting and troubleshoot any 
problems. Within the recipe, the dispensing parameters, imprint force, pre-exposure delay 
(prior to UV exposure), and UV exposure setting can be set. The imprint force typically 
used is 2-3 N, but can be varied to optimize the recipe. Changing the pre-exposure delay 
changes the length of time that the fluid spreads while under the set force, and the UV 
exposure time dictates the time that the fluid will be exposed to the UV light source. The 
optimal release force of the substrate from the template is typically ~ 10 N. 
Dispensing parameters are optimized by changing the drop box size, drop offset, 
volume per drop and overall volume per imprint in the Drop Layout Panel, as seen in 
Figure 4.5. The drop box size sets the boundary for where the drops will be placed and 
the drop offset moves the location of the drops. The volume per drop and location of each 
drop can be changed as well to provide a more uniform imprint. The overall volume of 
the liquid, as well as the pattern density of the template, helps determine the residual 
layer of an imprint. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Polymers and Reagents 
Chromium was purchased from Williams Advanced Materials. Four inch p-type 
<100> silicon test wafers single-side polished were ordered from Silicon Quest 
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International. Four inch p-type <100> silicon test wafers (both single-side polished and 
double-side polished) were purchased from University Wafers. Four inch p-type <100>, 
double-side polished, prime silicon wafers with and without an epitaxial layer of silicon 
on one side were purchased from Montco Silicon Technologies. ZEP 520A and Zedn50 
(ZEON Corp.) were provided by the NNIN and MRC at The University of Texas Pickle 
Research Center.  Quartz templates were purchased from the Canadian National Research 
Center and from the NNIN and MRC at The University of Texas Pickle Research Center.  
Isopropyl Alcohol (IPA), Acetone, N-Methyl Pyrrolidone (NMP) and other cleanroom 
processing chemical provided by the NNIN and MRC at The University of Texas Pickle 
Research Center. Poly(ethylene glycol) diacrylate (PEGDA, MW 3400) was purchased 
from Nektar Therapeutics. Poly(ethylene glycol) diacrylate (PEGDA, MW 700) was 
purchased from Sigma Aldrich and poly(ethylene glycol) diacrylate (PEGDA, MW 1000) 
was purchased from Polysciences. The ultraviolet (UV) photoinitiator, 2-hydroxy-1-[4-
(hydroxyethoxy) phenyl]-2-methyl-1 propanone (I2959) was purchased from Ciba Geigy. 
Polymethyl methacrylate (PMMA, MW 950k and 450k) in Anisole was purchased from 
MicroChem. Poly(lactide co-glycolide) (PLGA) Resomers 502H (MW 11,000), 503H 
(MW 25,000) and 502A (MW 12,000) were purchased from Boehringer Ingelheim. A 
glass viscometer tube (size 100) (viscosity range: 1 – 30 cSt) was ordered from Fisher 
Scientific. BARC DUV-30J (Brewer Sciences) was supplied by NNIN and the MRC at 
the University of Texas Pickle Research Center. Tridecafluoro-1,1,2,2-Tetra-Hydrooctyl 
Dimethylchloro-silane was purchased from Gelest Inc, and toluene was purchased from 
Sigma. Relmat (Molecular Imprints) was supplied by the NNIN and MRC at the 
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University of Texas Pickle Research Center. Poly(vinyl alcohol) (PVA, MW 31000) 
(Fluka) and Dicloromethane (DCM) were purchased from Sigma.  
4.2.2 Template Fabrication Process 
4.2.2.1 Thermal Imprint Lithography Template 
In order to make monodisperse drug delivery particles, patterns were first drawn 
in L-Edit, a CAD type program, and converted for use with the (JEOL JBX-6000 FS/E) 
e-beam lithography tool. For the nanoimprint lithography process a reusable nanoimprint 
template with various shapes and sizes was created using electron beam lithography 
(EBL) and reactive ion etching (RIE). A schematic of the process is shown in Figure 4.6. 
In brief, four inch p-type <100> silicon test wafers were pre-cleaned with Piranha.  The 
wafers were then pre-baked (180oC, 2 min), spin coated with ZEP520 (3000 rpm for 60 
s), and finally post-baked on a hotplate (180oC, 2 min).  Next the wafers were patterned 
using e-beam lithography (JEOL JBX-6000FS/E) with the following process parameters:  
EOS mode 7, 50 kV, 100 pA, exposure level/dose: 20 to -20.  Following this the wafers 
were developed with ZED n50 (60 s), and rinsed with IPA (30 s).  
In order to create patterns of precise size and shape in silicon templates, dose 
testing was performed with varying e-beam exposure time and developing times to find 
the optimal parameters for varying shapes and sizes. Different sizes of nanocontainer-
shaped features ranging from 100 to 800 nm were exposed at various exposure levels and 
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developed at various times. Microscopy and SEM were used to determine the parameters 
that yielded the most distinct features. 
After developing the wafer, they were dry etched (3 min 30 s) using a Plasma 
Therm 790 Series Reactive ion etcher (RIE) at a pressure of 80 mTorr, a power of 200 
Watts and the following gases: HBr (49) , Cl2 (5), He (80) to etch the silicon surface 
below.  In order to make container shaped features, the e-beam and RIE process was 
performed again, utilizing alignment marks that were fabricated during the first process.  
Subsequently, the wafers were diced to a size of ~ 1 mm and cleaned with Piranha. 
4.2.2.2 Step and Flash Imprint Lithography Template 
Figure 4.7 shows the structure and layout of a typical template. Four quartz 
templates are diced from a larger 6” x 6” substrate.  The template contains two primary 
regions, the active field area and the 15 μm recessed non-active area. The active field is 
called the mesa. The mesa can be fabricated in a wide variety of sizes ranging and is the 
area where patterns are created.  In order to make monodisperse drug delivery particles, 
patterns were first drawn in L-Edit, a CAD type program, and converted for use with the 
(JEOL JBX-6000 FS/E) e-beam lithography tool. To create features in the mesa of the 
quartz template (see Figure 4.8) a 100 Å layer of chromium was evaporated on the 
surface of a two inch square quartz template with a pre-fabricated mesa, using the CHA 
Evaporator. Next, the quartz template was spin coated with ZEP 520 (3000 rpm for 60 s), 
and finally post-baked in an oven (180oC, 10 min).  Prior to actual e-beam writing, the 
true center of the mesa was found by locating the X and Y edges of the mesa, using the 
 106
SEM capabilities of the e-beam, and calculating the center point. This center point was 
then subtracted from the center point of the e-beam, and the offset parameters were input 
into a recipe.  
The quartz template was then patterned using e-beam lithography (JEOL JBX-
6000FS/E) with the following process parameters:  EOS mode 7, 50 kV, 100 pA, 
exposure level/dose: 60 to -60.  The template was then developed with ZED n50 (2 min), 
rinsed with IPA (30s). Prior to actual etching of the mesa, dose tests were performed each 
time to find the optimum parameters for the e-beam dose as well as the development 
times due to variability of the e-beam.  The templates were then etched with two RIE 
processes: one to etch the chromium and one to etch the quartz. For the template with the 
25 x 25 mm mesa, the chromium layer was dry etched using a Plasma Therm Batchtop 
RIE for 2 minutes.  Subsequently the quartz layer was dry etched with an Orange RIE 
with a power of 150 Watts and the following gases:  CHF3 (60), O2 (40) for 7 min. The 
chromium layer was then removed with a wet etch (chromium etchant 1020) at 40oC for 
several minutes.  
For the templates with the 12.5 x 12.5 mm mesa and the 10 x 10 mm mesas, the 
chromium layer was dry etched using a Trion RIE. First a descum was used to remove 
any residual ZEP520 at a pressure of 35 mTorr, a power of 20 Watts and the following 
gases:  O2 (2), He (70) for 90 seconds. Following this, the chromium layer was etched at 
a pressure of 30 mTorr, a power of 80 Watts and the following gases:  O2 (10), He (70) 
for 180-200 seconds. Subsequently the quartz layer was dry etched in the same tool at a 
pressure of 15 mTorr, a power of 130 Watts and the following gases:  CF4 (15) and He 
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(40) for times ranging from 400 to 1000 seconds. The chromium layer was then removed 
with a wet etch (chromium etchant 1020) at 40oC for several minutes. The chrome etch 
time was optimized for chrome removal of 15 nm, and the quartz etch process was 
specified for an average etch rate of 30 nm/min depending on the feature sizes. For the 
12.5 x 12.5 mm mesa the quartz was etched 540 seconds. For the 10 x 10 mm mesa, 400 
and 200 nm features were etched for 1000 seconds, and the 100 and 50 nm features 
etched 400 seconds. After each processing step the template was viewed using 
microscopy or AFM to see if the etched layer was removed.  
4.2.3 Thermal Imprint Lithography Process Development 
4.2.3.1 Template Release Layer Preparation 
Prior to imprinting, a release layer was placed onto the template to prevent 
adhesion to the template. Dow Corning (DC 20) was diluted 1:8:1 in isopropanol (IPA) 
and toluene, respectively. This solution was then diluted 1:200 in xylene and spin-coated 
onto the stamp at 5000 rpm for 30 seconds, as described by Chen and colleagues [29]. 
The template was then oven baked (10 min, 180oC). 
4.2.3.2 Imprinting PMMA 
The setup for the thermal imprinting process included a chromium coated ceramic 
heater chuck and a micromanipulator with a built in force-sensor connected to power 
supplies, multimeters, and a thermocouple. Prior to imprinting, the sensor and metal base 
were cleaned using acetone to remove any particles and double-sided sticky tape was 
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placed on the base of the device and the sensor. This allowed the substrate to adhere to 
the base of the device and the template to adhere to the sensor. Prior to imprinting, the 
imprint template was treated with a self-assembled monolayer (SAM) of Dow-Corning 
release agent 20 in order to facilitate the separation of the template from the substrate.  
Small silicon wafers pieces were diced and primer was spin-coated at 4000 rpm for 30s 
onto the wafer pieces.   
Next, 11% (w/v) PMMA (MW 950k) in Anisole was spin-coated onto the wafer 
pieces for an optimal thickness of 300 nm, based on the manufacturers spinning 
specifications. Subsequently the substrate was adhered to the base, and the template was 
adhered to the sensor. The sensor was then aligned to the metal conducting base such that 
the surfaces would be parallel. The PMMA film was then heated above its glass transition 
temperature (105oC) using a heater chuck under the wafer (the base was left to heat up to 
150 – 200oC). Following this the imprint template was pressed into the PMMA for 10 – 
15 minutes using the micromanipulator with a built-in force sensor.  A voltage of 3.9 – 
3.8 mV was optimized for an imprint depth of about 200 nm. Subsequently, the 
micromanipulator was raised and the wafer substrate was removed. Finally, residual 
PMMA was removed with a timed oxygen plasma cleaning using a Plasma Therm 790 
Series Reactive ion etcher (RIE) with a pressure of 180 mTorr, a power of 50 Watts and 
O2 (80) to etch the silicon surface below.  The PMMA particles were removed by 
sonication in dH2O. 
 109
4.2.3.3 Characterizing PLGA Thickness for Imprinting 
In order to determine the thickness of PLGA for spinning onto wafers and for use 
with thermal imprinting, various poly(lactic-co-glycolic acid) (PLGA) concentrations and 
solvents were utilized. Resomers 502H, 503H and 502A were dissolved in either acetone 
or dicloromethane (DCM) to form 3 – 8% (w/v) concentrations and were spin coated at 
various speeds and times onto primed silicon wafer pieces. Following spin-coating, four 
or more samples of each variation were analyzed with an M-2000D1 Ellipsometer using a 
wavelength range of 400 – 1200 nm. Subsequently, the Cauchy characteristics were fitted 
and the sample thicknesses were determined using the Ellipsometer and a NanoSpec 
AFT.  
4.2.3.4 Imprinting with PLGA 
The thermal nanoimprint process was performed on poly(lactic-co-glycolic acid) 
(PLGA), Resomers 502H, 503H and 502A, and dissolved in either acetone or 
dicloromethane (DCM) to form 3 – 8% (w/v) concentrations. Prior to imprinting, the 
imprint template was treated with a self-assembled monolayer (SAM) of Dow-Corning 
release agent 20 (DC20) in order to facilitate the separation of the template from the 
polymer layer. Next, wafer pieces were diced and a PLGA layer was spun on the silicon 
wafer pieces based on the spin-speed curve generated previously. The PLGA was heated 
slightly above its glass transition temperature (52oC) using a Kapton thin film heating 
element (Watlow) under the wafer.  Subsequently, the imprint template was pressed into 
the PLGA for 10 minutes using a micromanipulator with a built-in force sensor. The 
 110
template was then lifted using the micromanipulator and separated from the wafer after 
the wafer temperature had reduced to 40oC. 
 
 
4.2.4 Step and Flash Imprint Lithography Process Development 
4.2.4.1 Template Release Layer and Substrate Optimization 
In order to imprint whole wafers without the PEGDA solution adhering to the 
template, two different template coating layers were evaluated: Relmat and a self-
assembled monolayer (SAM) of (Tridecafluoro-1,1,2,2-Tetra-Hydrooctyl) 
Dimethylchloro-silane. Before applying the release layers the quartz template was 
cleaned using a 30 minute Piranha treatment. If the template was exceptionally dirty, an 
NMP clean was performed for a minimum of 2 hours, followed by another Piranha 
treatment. Following this the template was rinsed 5 times in water, post baked in a 90oC 
oven and then rinsed with IPA to provide a clean hydroxylated surface.  
The Relmat was applied using a dropper. Two to three drops of Relmat were 
placed onto the mesa of the quartz template and subsequently blown dry with Nitrogen.  
In order to coat the template with the SAM, 100 mL of a 0.5% (v/v) solution of 
(Tridecafluoro-1,1,2,2-Tetra-Hydrooctyl) Dimethylchloro-silane in toluene was placed in 
a glass container. The quartz template was then placed in the solution for a minimum of 2 
hours. The SAM is formed by reacting the hydroxylated surface of the quartz template 
with the silane to create a networked siloxane monolayer.  
After employing the Relmat and SAM on the quartz template, contact angle 
measurements were taken using a goniometer (First Ten Angstroms (FTA)) to see the 
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difference in wettability of the two templates (n=3). The templates were used to imprint 
various polyethylene glycol (PEG) polymers (PEGDA MW 3400 and MW 700) with and 
without a peptide-crosslinker, and with a variety of encapsulated proteins as well as 
DNA. 
The initial imprints were performed using a standard Relmat release and a single-
side polished test silicon wafer. Following this, imprints were attempted using Relmat 
and a 100 nm layer of 5% (w/v) PMMA (MW 450k) which was spin-coated on the 
silicon wafer. Subsequently imprinting was attempted using Relmat and a double-side 
polished wafer with PMMA. Following this, imprints were performed using a double-
side polished wafer and an anti-reflective coating, BARC. Double-side polished wafers 
were spin-coated with a 60 nm BARC layer (3000 rpm, 60 s). Subsequently, imprinting 
was performed using the template coated with a SAM of 0.5% (v/v) (Tridecafluoro-
1,1,2,2-Tetra-Hydrooctyl) Dimethylchloro-silane in toluene and a wafer with BARC. 
Finally imprints were performed with the SAM, BARC and a double-side polished 
silicon wafer with an epitaxial layer of silicon. 
4.2.4.2 PEGDA Viscosity Measurements and Dispense Tip Calibration 
In order to dispense polymer solution from the dispense tips in the IMPRIO, the 
viscosity of various concentrations of PEGDA solutions was measured using a 
viscometer. PEGDA (MW 700) was dissolved in dH2O to form various weight 
percentages ranging from 25%, 33%, 50%, 60% and 75% w/v. Five milliliters of pre-
polymer solution was placed into the large tube of the viscometer and suctioned into the 
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measuring area using a large bulb. Once the bulb was removed, the time for the solution 
to travel from mark A to B was measured. The experiments were performed in triplicate. 
The kinematic viscosity of the solution was calculated by multiplying the time for the 
solution to travel from A to B, by an intrinsic constant of the viscometer. The dynamic 
viscosity was then calculated by multiplying the kinematic viscosity by the bulk density 
of PEG (1.12 g/mL). Based on the viscosity results, Molecular Imprints calibrated the 
imprint tip to dispense the polymer solution. Prior to dispensing, the solution was filtered 
with a maximum 4 nm filter. 
4.2.4.3 Imprinting PEGDA 
Step and Flash Imprint Lithography was performed using the IMPRIO 100 SFIL 
system (Molecular Imprints, Austin TX) with various macromers that were drop-cast 
either manually or through the IMPRIO automated dispenser onto 4 inch silicon wafers. 
nanoimprinting was evaluated using various polyethylene glycol (PEG) polymers 
(PEGDA MW 3400 and MW 700) with and without a peptide-crosslinker, with 
concentrations varying from 25% to100% w/v. Volumes of 0.5 μL (for manual 
dispensing) to 0.019 μL (for automated dispensing) were evaluated along with an 
imprinting force of 2-18 N. The pre-polymer solution was prepared in dH2O and 0.05 to 
0.07  wt% of the UV photoinitiator, Irgacure 2959. The UV exposure time was varied 
from 5 to 30 seconds, and the pre-exposure delay was varied from 120 seconds to 450 
seconds.  
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Figure 4.9 shows a schematic of the process used to create PEGDA nanoparticles 
of precise size and shape. Prior to imprinting, the template was coated with a SAM of 
0.5% (v/v) (Tridecafluoro-1,1,2,2-Tetra-Hydrooctyl) Dimethylchloro-silane in toluene. 
Subsequently, four inch silicon wafers were spin-coated with a 60 nm BARC layer (3000 
rpm, 60 s). To allow for particle release, a second layer (53 nm) of water soluble 2% 
(w/v) poly(vinyl alcohol) (PVA, MW 31000) was spin-coated on the BARC (3000 rpm, 
60 s). The PEG macromer solution was then imprinted at low pressure and with UV light 
in order to polymerize the solution. In order to isolate the imprinted particles, the residual 
layer between the nanoparticles was removed by an oxygen or helium plasma etch using 
a Plasma Therm 790 Series RIE, or with no etching. To release the imprinted 
nanoparticles, dH2O was applied to the imprints and gently pipetted up and down to help 
dissolve the water soluble PVA release layer. 
4.2.4.4 Residual Layer Optimization 
In order to optimize the residual layer for PEGDA (MW 700) of various 
macromer concentrations ranging from 75% (w/v) to 25% (w/v) were imprinted with an 
array of parameters. The dispensing parameters, imprint force, exposure time and pre-
exposure delay was optimized. In order to optimize the dispensing parameters, the drop 
box size, drop location, volume per drop, and overall volume were optimized to provide 
an even imprint with the lowest possible overall volume of solution and the least number 
of air bubbles. The dispensing parameters were first optimized using a drop simulation 
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model, and then through imprinting. The PEGDA residual layer thickness was 
determined used an SEM, an M-2000D1 Ellipsometer, and a NanoSpec AFT. 
4.2.4.5 Optimization of Isolation and Harvesting of Nanoparticles 
In order to isolate and release the imprinted nanoparticles from the silicon wafer it 
is many times necessary to first remove the residual layer in between the particles. This 
was initially performed by oxygen plasma etching (Plasma Therm 790 Series Reactive 
Ion Etcher (RIE)). For oxygen etching, the residual layer was etched at a pressure of 180 
mTorr, a power of 50 Watts and oxygen: O2 (18) for 20-60 seconds. Once the residual 
layer was further optimized, helium etching was also performed at a pressure of 180 
mTorr, a power of 50 Watts and helium:  He (85) for 20 seconds. To verify that the 
imprinted particles retain their 3D structure after etching and to measure the feature 
height, particles were analyzed using atomic force microscopy (AFM). XPS was used to 
see any change that occurred to the PEGDA surface due to the etching process.  
In order to release the nanoparticles, a sacrificial layer of water soluble poly(vinyl 
alcohol) (PVA) (53 nm) was spin coated (3000 rpm, 60 seconds) on top of a BARC layer 
(60 nm) prior to macromer dispensing and imprinting. PEGDA solutions of varying 
concentration were dispensed and imprinted on the BARC and PVA coated wafer. 
Following residual layer etching, 20 μL of dH2O was placed on the imprint and rinsed 
with pipetting. Upon optimization of the residual layer, particles were released without 
the need for etching. SEM was used to verify particle release of both etched and non-
etched released particles. 
4.2.4.6 Theoretical Number of Nanoparticles and Drug Loading Capacity 
The theoretical number of particles per template and per wafer was calculated 
based on varying template size, wafer size, and particle size, shape, and spacing. From 
this, the theoretical loading capacity was calculated assuming a 10 mg/mL solution of 
model drug in macromer. The actual number of particles for the latest fully patterned 10 x 
10 mm mesa was also calculated, as well as the theoretical loading capacity. To get the 
number of particles per mesa (M), the following equation was used: 
 
ACM *=   (1)
 
 
where C is the number of features in a chip (dictated by the number drawn in L-edit) and  
A is the number of times the chip is arrayed in the e-beam to pattern a mesa of a given 
size. To get the number of particles per wafer (W) the following equation was used,  
 
FMW *=   (2) 
where F is the number of imprintable fields for a given wafer size. The number of 
imprintable fields (Table 4.1) was given by the manufacturer’s literature and/or estimated 
through discussions with technicians.  In order to calculate the mass of drug per imprint 
(DM), the following equation was used: 
 
CVMDM **=   (3) 
where V is the volume of the particle shape, and C is the concentration of the drug in the 
macromer solution. To get the mass of drug per wafer (Dw), the following equation was 
used:   
 
FDD MW *=   (4) 
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and to calculate the loading level per number of particles, Dw was divided by W. 
 
4.3 RESULTS 
4.3.1 Template Process Development 
4.3.1.1 Thermal Imprint Lithography Templates 
In order to create patterns of precise size and shape in silicon templates, dose 
testing was performed to find the optimal parameters. Figure 4.10 reveals a typical dose 
test that was performed. Using the dose tests, the template fabrication parameters were 
optimized to an exposure level/dose: 20 to -20, with a development in ZED n50 of 60 s, 
and a rinse time of 30 sec with IPA. The SEM images in Figure 4.11 demonstrate the 
results of the optimized parameters along with reactive ion etching to create nanofeatures 
in the silicon template. Large-area, dense arrays of nanocontainer features with sizes 
ranging from 100 to 800 nm were successfully patterned into the silicon (Figure 4.11A-
D). The smaller features have more noticeably rounded corners due to the resolution 
limits of the e-beam process, and no longer appear square. Figure 4.11E-F shows a 
profile view of the nanofeatures after reactive ion etching to reveal a depth of 
approximately 200 nm with anisotropic side walls. 
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4.3.1.2 Step and Flash Imprint Lithography Templates 
In order to create patterns of precise size and shape in quartz templates, dose 
testing was performed to find the optimal parameters as described for the silicon 
template. Using the dose tests, the template fabrication parameters were optimized to an 
exposure level/dose: 60 to -60, with a development in ZED n50 of 2 min, and a rinse time 
of 30 sec with IPA. Figure 4.12A-C shows a schematic of the varying template mesa 
sizes that were patterned. 25 x 25, 12.5 x 12.5 and 10 x 10 mm mesas were patterned with 
varying shapes, sizes and spacing ranging. For the 10 x 10 mm mesa with 50 nm features, 
Figure 4.12C, the dose level was optimized to be: 5 to -5. This schematic also shows that 
two patterned areas were not centered correctly due to the initial process of inputting an 
offset value for the center of the mesa. Figure 4.12D shows a schematic of a fully 
patterned 10 x 10 mm mesa with 100 nm features and 2:1 spacing, and Figure 4.12E 
shows a fully patterned mesa donated by Molecular Imprints with various spacing and 
feature sizes ranging from 80 to 100 nm. 
SEM images of the patterned mesas, as seen in (Figure 4.13), show large-area, 
dense arrays of features with sizes ranging from 50 to 400 nm. Pentagons, squares, 
triangles and boxes were successfully patterned with precise size and shape. The smaller 
features (< 100 nm) have more noticeably rounded corners due to the resolution limits of 
the e-beam process, and no longer appear square. 
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4.3.2 Thermal Imprint Lithography Process Development 
4.3.2.1 ThNIL Imprinted PMMA Nanocontainers 
As demonstrated in Figure 4.14, pattern transfer was successfully achieved and 
three-dimensional PMMA nanocontainers of sizes 100 nm (not shown) up to 800 nm 
were successfully fabricated using the thermal nanoimprint lithography techniques. The 
200 nm nanocontainers, shown in Figure 4.14, contained side walls that were 50 nm 
thick, with a 100 nm open container.  
4.3.2.2 PLGA Thickness Measurements 
In order to first determine the PLGA thickness the Cauchy characteristic values 
were determined using the M-2000D1 Ellipsometer (Figure 4.15A). The Cauchy 
characteristics provide a means to calculate the refractive index. The (A) value can be 
taken to be roughly the refractive index of the material. The refractive index for the 
PLGA with various formulations ranged from 1.46 to 1.52. Using the refractive index, we 
were able to determine the thickness using both the M-2000D1 and the NanoSpec AFT. 
Figure 4.15B shows the spin-speed thickness curve for an optimized spin time of 50 
seconds. The PLGA 502A and the 502H in acetone had a clear appearance after spinning, 
while the 503H and 502H in DCM appeared cloudy. The results of the spinning study 
indicated that for a 200 to 300 nm thick film, the 5% (w/v) 503H, the 3% and 5% (w/v) 
502A, and the 5% (w/v) 502H would be the best candidates for imprinting with our 
template. 
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4.3.2.3 ThNIL Imprinted PLGA Nanofeatures 
Imprinted features were obtained with the PLGA 502H at 5% (w/v) in acetone 
and DCM with a spin speed of 3500 rpm. Figure 4.16A demonstrates imprinted PLGA 
features using DCM as a solvent, and Figure 4.16B demonstrates imprinted PLGA 
features using acetone. The features appear to be shallow and slightly defined, and the 
PLGA in acetone appears to have gaps in the film. 
4.3.3 Step and Flash Imprint Lithography Process Development 
4.3.3.1 Template Release Layer and Substrate Optimization 
The contact angle measurements, shown in Table 4.2, revealed that the contact 
angle of the Relmat on the 10 x 10 mm mesa with 100 to 400 nm features was roughly 
92.7o over the patterned features and 92o over the smooth quartz surface. Meanwhile, the 
contact angle of the SAM varied from 109 to 102o over the 400 to 100 nm patterns, 
respectively. The fully patterned 10 x 10 mm mesa with the SAM had a contact angle of 
101.5o over the 100 nm features. The contact angle over the smooth quartz surface with 
the SAM was roughly 98.2o. Thus the SAM provided a better non-wetting surface. 
Using the SAM and a double-side polished wafer, whole wafers of PEGDA, 
peptide-functionalized PEGDA, and peptide-functionalized PEGDA with encapsulated 
proteins and DNA were successfully imprinted. Figure 4.17 shows an initial whole 
imprinted wafer using various imprinting parameters that had not yet been optimized. For 
imprinting, the typical release force was 7 to 12 Newtons.  Subsequently, a double-side 
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polished silicon wafer with an epitaxial layer of silicon was used for imprinting and 
proved to allow for more uniform imprints with thinner residual layers. The optimized 
wafer and template materials for imprinting included the SAM, the BARC and the 
double-side polished silicon wafer with the epitaxial layer. 
4.3.3.2 PEGDA Viscosity Measurements and Dispense Tip Calibration 
In order to dispense polymer solution from the dispense tips in the IMPRIO, the 
viscosity of various concentrations of PEGDA solutions was measured using a 
viscometer (assuming a constant density for PEGDA). Table 4.3 shows the viscosity 
measurements taken for 75,2 60, 50, 33 and 25% (w/v) PEGDA (MW 700). The 
viscosities range from 40.6 cP down to 2.0 cP. The corresponding equations for 
dispensing the solution are shown to the right of the viscosity value and were calibrated 
by Molecular Imprints. The IMPRIO 100 already had a calibration value corresponding 
to 2-3 cP, the viscosity of the silicon-containing monomer. In order to get thinner residual 
layers, optimizing was focused on using the 25% and 33% (w/v) PEGDA (MW 700) 
concentrations using the pre-programmed equation for dispensing. 
4.3.3.3 Optimized Residual Layer 
In order to optimize the residual layer for PEGDA (MW 700), the dispensing 
parameters, imprint force, exposure time and pre-exposure delay was optimized. In order 
to optimize the dispensing parameters, the drop box size, drop location, volume per drop, 
and overall volume were optimized to provide an even imprint with the lowest possible 
 
2 Value courtesy Mary C. Moore. 
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overall volume of solution and the least number of air bubbles. The dispensing 
parameters were first optimized using a drop simulation model on the IMPRIO, and then 
through imprinting.  
Figure 4.18 through Figure 4.21 show the different parameters that were 
compared to optimize the residual layer. All experiments were done with n > 4. PEGDA 
(MW 700) with concentrations of 25% (w/v) and 33% (w/v) were evaluated because 
these polymers have the lowest viscosities and could yield a lower residual layer. 
Furthermore the imprinting force values had been narrowed down to 7 to 12 Newtons, the 
pre-exposure time was narrowed down to 300 to 360 seconds, the exposure time was 
narrowed down to 5 to 7 seconds and the minimum volume obtained had been 0.025 μL.  
Figure 4.18 demonstrates a comparison between  the residual layer thickness 
versus pre-delay time for 25% and 33% (w/v) PEGDA (MW 700) using an overall 
volume of 0.025 μL, an imprint force of 7 Newtons and a 7 second UV exposure. The 
data demonstrates that the longer pre-delay time, 360 seconds, successfully lowers the 
residual layer as expected. For the 25% (w/v) the residual layer is lowered from 
approximately 20 nm to 15 nm. A t-test was performed for each comparison and each had 
a p-value < 0.001.  
Figure 4.19 demonstrates a comparison between  the residual layer thickness 
versus the imprint force for 25% and 33% (w/v) PEGDA (MW 700) using an overall 
volume of 0.025 μL, a pre-delay of 300 seconds and a 7 second UV exposure. The data 
demonstrates that there is no significant decrease in residual layer when using these two 
forces. For the 25% (w/v) the residual layer remains at approximately 23 nm. A t-test was 
 122
performed on both comparisons and they were found to not be statistically significant. 
Typically, changing forces can change the thickness of the residual layer. 
Figure 4.20 demonstrates a comparison between  the residual layer thickness 
versus the UV exposure time for 25% and 33% (w/v) PEGDA (MW 700) using an 
overall volume of 0.025 μL, a pre-delay of 300 seconds and an imprint force of 7 N. The 
data demonstrates that there is no significant difference in residual layer between the 7 
and 10 seconds exposures. The 5 second exposure shows a slightly larger residual layer. 
For the 25% (w/v) the residual layer remains at approximately 23 nm. A t-test was 
performed for both the 25 and 33% (w/v) and only the 33% (w/v) showed a significant 
difference with p < 0.05. The larger thickness may be due to the fact the full 
polymerization may not have been achieved at this exposure time for the larger PEGDA 
concentration. 
Using a force of 7 Newtons, a pre-delay of 300 seconds and UV exposure time of 
7 seconds, the total volume of 33% (w/v) and 25% (w/v) were varied to determine the 
thickness provided by each volume. Figure 4.21 demonstrates that as the overall volume 
decreases, the residual layer decreases as well. The largest volumes of 0.3 μL and 0.174 
μl were hand dispensed. A 33% (w/v) solution imprinted with 0.3 μL is approximately 
450 nm thick. Using these parameters and further optimizing the drop pattern, a 
minimum volume of 0.019 μL was achieved. We also see that a larger PEGDA 
concentration will yield a larger residual layer thickness. 
Figure 4.22 shows an optimized drop pattern using a bounding box size of 9.25 
mm and a minimum volume per drop of 4.922 x 10-4. The drop pattern is designed such 
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that the pre-polymer solution radiates out from the center and has channels to flow out to 
the edges, thus avoiding gas entrapment. The optimized drop volume was 0.019 μL per 
imprint, with a force of 7 N, a UV exposure time of 7 seconds and a pre-delay of 300 
seconds.  As seen in Table 4.4 using the 0.019 μL over volume, residual layers of 2 nm 
to 27 nm were achieved over a majority of the imprint for 25% (w/v) and 75% (w/v) 
PEGDA (MW 700), respectively. However, the center of the imprint remained slightly 
thicker, in part due to the back pressure of the template. Figure 4.23 demonstrates SEM 
images of varying residual layers of PEGDA imprints. Figure 4.23A demonstrates the 
initial hand imprints performed using 75% (w/v) PEGDA (MW 700), showing a large 
1.36 μm residual layer that would not be successful in creating and releasing 
nanoparticles. Figure 4.23C shows a 15 nm residual layer with 50% (w/v) PEGDA (MW 
700) and Figure 4.23D shows a 31 nm residual layer for a 75% (w/v) PEGDA (MW 
700), both imprinted with 0.019 μL of pre-polymer solution. The thickness values from 
the SEM are estimates due to the resolution limits of the SEM. Furthermore, after cutting 
the wafers, the residual layer would curl over the edge of the wafer, making an actual 
determination of the thickness difficult. 
4.3.3.4 Step and Flash Imprinted PEGDA Nanoparticles 
Figure 4.24 demonstrates the variety of shapes and sizes that the SFIL process is 
capable of imprinting. Dense arrays of three-dimensional nano-sized squares, triangles, 
containers and pentagons ranging from 50 nm to 800 nm were successfully fabricated 
with little to no variation. Features sizes larger than 100 nm showed a variation of ± 0.2 
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nm, while 50 nm features showed a variation of ± 1.5 nm based on SEM measurements.  
Larger features sizes had more precise and sharp corners, while the smaller features had 
rounded corners due to the resolution limits of the e-beam lithography process.  
The optimized imprinting process involved dispensing 0.019 μL of pre-polymer 
solution, a pre-delay of 300 seconds and UV exposure for 7 seconds, and a force of 7 N. 
Dosimeter measurements showed that the UV intensity at the template interface was 2 
mW/cm2. Figure 4.25 demonstrates the use of varying PEGDA concentration to fabricate 
100 nm (rounded) square nanoparticles using a 10 x 10 mm fully patterned mesa. 
PEGDA concentrations ranging from 75% (w/v) to 25% (w/v) were successfully 
patterned using the optimized imprinting process and showed no difference in size. All 
particles had dimension of 97.3 ± 0.2 nm based on SEM measurements. Because no 
images of the template were taken we can’t compare the pattern transfer. Figure 4.25D 
shows a profile view demonstrating anisotropic side-walls of the features. 
4.3.3.5 Isolation of Nanoparticles 
In order to isolate and release the imprinted nanoparticles from the silicon wafer it 
is many times necessary to first remove the residual layer in between the particles. This 
was initially performed by oxygen plasma etching. Once the residual layer was further 
optimized, helium etching was also performed. Etching was performed on 33% (w/v) 
PEGDA (MW 700) imprint with 0.025 μL, a pre-exposure delay of 300 seconds, a force 
of 7 N, and a UV exposure time of 7 seconds. Table 4.5 shows that after 20 seconds the 
entire residual layer was removed using an oxygen etch. With the helium etch, 2 nm of 
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residual layer remained. The AFM images in Figure 4.26 demonstrate that there is no 
height difference between particles before and after oxygen etching, and before and after 
helium etching. Figure 4.26A-C demonstrates 50 nm particles before and after oxygen 
etching. Before etching, the particles were on average 93 ± 2 nm in height. After etching 
the particles were on average 94 ±2 nm in height. Figure 4.26D-F demonstrates 100 nm 
particles after before and after helium etching. Before etching the particles demonstrated 
a height of 127 ± 2 nm and after etching the particles demonstrated a height of 129 ± 2 
nm. The particles demonstrate little no to change. Figure 4.26G demonstrates an etched 
200 nm particle with a 413 ± 2 nm, and Figure 4.2H-I, demonstrates an etched 400 nm 
particle with a 626 ± 2 nm. 
To further study the effect of the oxygen etching and helium etching on the 
PEGDA surface, XPS was performed. Initial scans showed a charging effect, therefore 
scans were charge neutralized. Figure 4.27 demonstrates high resolution C1s scans of 
PEGDA samples on BARC and silicon. The thicker sample of 75% (w/v) PEGDA 
formed by hand imprinting with 0.174 μL shows no difference in the C-O peak (shifted 
1.5 eV from the C-C peak) between the non-etched PEGDA and the oxygen etched 
PEGDA (Figure 4.27B); however there is slight increase in the C-C peak. The helium 
etching shows no change in the C-O peak, but shows an increase in the C-C peak. Both 
oxygen and helium etching show an increase in the C=O peak. The slight change in the 
C-C peak with oxygen etching could indicate some slight reactivity, while the C-C peak 
with helium etching could indicate the deposition of hydrocarbons. 
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The thinner sample of 75% (w/v) PEGDA formed using 0.025 μL shows the 
PEGDA with a larger C-C peak (Figure 4.27B). Furthermore we see that the C-O peak 
decreases with oxygen etching and decreases less with helium etching. Once again, both 
oxygen and helium increase the C-C peak and the C=O peak. With helium etching it is 
likely that hydrocarbons are depositing, while with oxygen it may indicate reactivity. The 
growing C-C peak and diminishing C-O peak may be describing the etching of the 
PEGDA to reveal the surface below.  
Upon optimization of the residual layer to a 2 nm thickness etching was no longer 
required. 
4.3.3.6 Harvesting of Nanoparticles 
In order to release the nanoparticles, a sacrificial layer of water soluble poly(vinyl 
alcohol) (PVA) (53 nm) was spin coated (3000 rpm, 60 seconds) on top of a BARC layer 
(60 nm) prior to dispensing and imprinting the pre-polymer solution. PEGDA solutions 
of varying concentration were dispensed and imprinted on the BARC and PVA coated 
wafer. Following residual layer etching, 20 μL of dH2O was placed on the imprint and 
rinsed with pipetting. Figure 4.28 demonstrates successfully released 33% (w/v) PEGDA 
nanoparticles, ranging from 50 nm to 400 nm, fabricated using 0.025 μL of pre-polymer 
solution after helium etching. Upon optimization of the residual layer, particles were 
released without the need for etching. 33% (w/v) PEGDA nanoparticles, imprinted using 
0.019 μL, with a 2 nm residual layer were successfully released in water by dropping on 
20 μL of dH2O and gently pipetting, as shown in Figure 4.29C-D. The particles were 
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imaged in the same location they were fabricated instead of pipetting them onto a clean 
silicon surface, therefore the images appear dirty. 
4.3.3.7 Theoretical Number of Nanoparticles and Drug Loading Capacity 
The theoretical number of particles per template and per wafer was calculated 
based on varying template size, wafer size, and particle size, shape, and spacing. From 
this, the theoretical drug loading capacity was calculated. Figure 4.30 demonstrates the 
number of particles that could be generated using different sized templates. We see that 
overall, the 50 nm particles with 1:1 pitch allows for the production of the most particles. 
The 25 x 25 mm template shows the greatest number of particles per imprint (Figure 
4.30A); however, once an entire 4 inch wafer is imprinted, the 10 x 10 mm template can 
produce more particles per wafer (Figure 4.30B). If an 8 inch wafer is used, the 25 x 25 
mm mesa shows the highest production of particles once again (Figure 4.30C). As an 
example, if 100 nm square particles with a 1:1 spacing are created, we could achieve 
approximately 1011 particles per 4 inch wafer and 4 x 1011 particles per 8 inch wafer.  
Figure 4.31 demonstrates the theoretical loading of particles of various size, 
shape and spacing, assuming the use of a 10 x 10 mm mesa and an initial loading of a 
model drug in pre-polymer solution at 10 mg/mL. We can see that 400 nm square 
particles with a spacing of 1:1 can load the most drugs, followed by the cylindrical 
particles and then the triangular particles. Using the data from Figure 4.31, the loading 
level for 100 nm square particles with a 1:1 spacing is approximately 1 μg/1011 particles 
for a 4 inch wafer and 4 μg/1011 particles for an 8 inch wafer.  For a 50 mg/ml 
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concentration of protein in the pre-polymer solution, the loading level is approximately 5 
μg/1011 particles for a 4”wafer and 10 μg/1011 particles for an 8” wafer.  By doubling the 
aspect ratio of the particle, creating a 100 x 100 x 200 nm particle, the loading level 
would be doubled. 
 Currently, the fully patterned 10 x 10 mesa with 100 nm square particles has a 1:2 
spacing and can produce 4.7 x 1010 particles per 4 inch wafer (Table 4.6). Assuming a 10 
mg/mL concentration of drug in pre-polymer solution and a square shape, each imprint 
has a loading level of 13.5 ng, and an imprinted 4 inch wafer has a loading level of 700 
ng. This correlates to a loading level of 150 ng/1010 particles per 4 inch wafer. If the 
particle is more spherical each imprint has a loading level of 10.6 ng, and an imprinted 4 
inch wafer has a loading level of 550 ng. This correlates to a loading level of 117.5 
ng/1010 particles per 4 inch wafer. The 10.5 x 10.5 mm template provided by Molecular 
Imprints can produce 7.1 x 1010 particles per 4 inch wafer (Table 4.6). Assuming a 10 
mg/mL concentration of drug in pre-polymer solution and a circular shape, each imprint 
has a loading level of 7.83 ng, and an imprinted 4 inch wafer has a loading level of 410 
ng. This correlates to a loading level of 57.6 ng /1010 particles per 4 inch wafer. 
 
4.4 DISCUSSION 
The overall goal of this research was to optimize nanoimprint lithography 
techniques to create monodisperse, size and shape-specific, biocompatible, nanoparticles 
with the potential for injectable and intracellular drug delivery. Because nanoimprint 
lithography is a direct pattern transfer process, the creation of the template is one of the 
most critical aspects of the process. To pattern the template many parallel processing 
techniques are required to create nanofeatures that have well-defined geometry and that 
are uniform and reproducible. As can be seen in the SFIL and ThNIL templates (Figure 
4.11 and 4.13), shape and size specific features were successfully created. As the feature 
size decreases, the corners of the patterns tend to become more rounded. This is 
especially apparent in the 50 nm features; however the rounding may be beneficial for 
drug delivery applications. 
The rounding is due to the resolution limit of the e-beam lithography process. The 
spot size of the beam, the exposure time, the current, the dose, the way in which the e-
beam writes the patterns, and the photoresist used, all dictate the resolution of our 
features. In order to create such high density patterns with small feature sizes the 







TIQ =   (5) 
 
where Q is the sensitivity of the resist (C/cm2),   I is the current (A),  T is the shot time 
(sec) and P is the shot pitch (cm). For a setting of 50 kV in 5th lens, the minimum pixel 
size is 1.25 nm. For 5th lens and a shot parameter of A,2 this yields a shot every other 
pixel (2*1.25 nm spacing). The beam diameter is 7 nm, and in order to successfully 
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pattern the template the minimum pixel*spacing was optimized to be less than the beam 
diameter. As a note, the patterning of full mesas can take up to two to three days. The e-
beam can drift 100 nm every 6 hours, therefore special attention was taken to allow for 
the drift. 
 To create precise features in the template, ZEP 520 was used as used a photomask 
because of its enhanced sensitivity for e-beam lithography and its sensitivity as a mask in 
reactive ion etching. Because it is a positive resist, the e-beam exposure causes the 
molecular linear chains to break and increases the solubility of the resist. This allows the 
developer to remove the exposed area to create a pattern in the resist. To create patterned 
cavities in the silicon and quartz templates, the selection of etching criteria was 
important. The etch rate, selectivity, anisotropy, and feature size control are important 
considerations. Many bulk micromachining techniques utilize wet etching; however this 
process typically creates isotropic features and is not suitable for creating nanoscale 
features. Therefore, reactive ion etching was utilized. Reactive ion etching acts to remove 
material by a combination of physical and chemical bombardment. Plasma is formed by 
applied RF potentials and consists of gas molecules that have been broken down into 
fragments and radicals. In the plasma, the fragments are ionized and accelerated toward 
the sample, thus etching the material.  
To create recipes for etching silicon, resist, and organic materials, recipes were 
modified from standard processes. In each case the selectivity of the gases, the RF power, 
and the pressure were optimized to provide anisotropic etching. Plasma pressure plays an 
important role in the development of the etch process and can control the ratio of physical 
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and/or chemical etching that occurs. At low pressures, ion bombardment is dominant and 
there is higher ion energy. With a long mean-free path of ions, this can result in an 
anisotropic etch. Furthermore, lower pressures are less contaminating because reaction 
by-products show more volatility at lower pressure and can be removed easily from the 
etch chamber. One drawback is that at low pressure the ion density drops off quickly thus 
there is lower etch rate.  
Higher pressures result in more reactive species, thus chemical etching is 
enhanced. At higher pressure the ion energy is lower, there is a shorter mean-free path of 
ions and this can result in an isotropic etch. Increasing the power will increase the etch 
rate because the remaining ions become more energetic. The use of reactive ion etching 
allowed for the creation of anisotropic features etched into the templates. As seen in the 
silicon etching recipe, a low pressure was used, chlorine was used as a reactive gas to 
chemically assist ion etching to provide anisotropy, and helium was used to stabilize the 
plasma and assist with anisotropy. Using these parameters allowed for the creation of 
well-defined anisotropic side-walls in the silicon templates, as seen in Figure 4.11E-F.  
 With the successful creation of a silicon template, thermal imprinting was 
performed on PMMA and PLGA. With thermal imprinting, the layer thickness that is 
spin-coated on the wafer is critical with respect to the filling in the feature cavities in the 
silicon template. The initial layer thickness should be 50 to 100 nm thicker than the 
height required to fill the feature cavities in the template [30]. Using these guidelines, the 
PMMA imprints demonstrated precisely patterned nanocontainers with wall thicknesses 
as low as 50 nm. After oxygen etching the containers were released in water using 
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sonication; however, sonication would not be desirable for releasing drug-loaded 
nanoparticles. 
With the measurement of the Cauchy characteristics for PLGA, we were able to 
determine the spinning parameters needed to achieve a desired PLGA thickness of 200 to 
300 nm. Although variations in time, pressure applied, and PLGA concentration were 
studied, the results showed the creation of shallow patterns only in the 5% (w/v) R502H 
(MW 11,000). Schulz and colleagues have modeled the affect of molecular weight and 
viscosity of on thermal imprinting of polystyrene and have concluded that polymers with 
differing molecular weights cannot necessarily be imprinted at the same level above Tg 
due to differences in the shear rate and mechanical properties [30]. Furthermore they 
demonstrated that the lower viscosity solutions tended to underfill cavities or fill them 
irregularly. Potentially the imprints may not have been heated to a high enough 
temperature and may not have completely filled the cavities. The DCM however, is very 
viscous and did not show better results. Once again this could be due to the need for a 
higher temperature. 
Although the thermal imprint lithography process does demonstrate the ability to 
create well defined features in PMMA, the fabrication process may involve temperatures 
not suitable for encapsulation of biological agents and involves using a high imprinting 
force. Also, imprinting with different polymers would require optimization each time. 
Depending on the polymer used, and the molecular weight and viscosity of the polymer, 
the imprinting temperature would need to be optimized each time. Furthermore, 
depending on the feature depth in the template, further spinning studies for each polymer 
variation would need to be performed and optimized. For these studies, the thermal 
imprint lithography set-up was only capable of imprinting small wafer pieces using a ~ 1 
mm template. In order to have high-throughput capabilities for imprinting nanoparticles 
for drug delivery, a full-wafer imprinting tool such as the Obducat Soft Press (Obducat) 
would be required. 
Using the Step and Flash Imprint Lithography technique we successfully 
demonstrated the creation and release of three-dimensional, size and shape-specific 
PEGDA nanoparticles as small as 50 nm. The first critical aspect of the process was the 
ability to optimize the substrate and template release layer. An interesting note 
considering the release layer is that the pre-polymer solution must wet the template well 
enough to fill in the topography of the template, but it must also release from the template 
after UV exposure without causing damage to the imprinted nanofeatures. The filling of 
the template is achieved through capillary action. Colburn and colleagues have modeled 
the rate that the fluid fills the gap between the substrate and template using the work-
adhesion equation [19]: 
 
ABBAAdhW γγγ −+=   (6) 









=   (7) 
where Wadh is the work of adhesion and is governed by γA, the surface tension or surface 
energy of the pre-polymer solution, dx/dt is the rate of fill of the template feature and μ is 
the viscosity of the pre-polymer solution. Increasing the surface tension will increase the 
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work of adhesion but will also maximize the rate of fill of the template feature. The rate 
of fill is also inversely proportional to the viscosity of the pre-polymer solution. 
Furthermore, the viscosity is directly proportional to polymer concentration and the rate 
of cure [19]. Therefore the surface tension must be balanced to create an easy to release 
template and a pre-polymer solution with a fast filling and curing time. This is a key 
consideration in designing templates for nanoimprinting with biomolecules, especially 
since many peptides are adhesive to surfaces [31]. 
The results of the contact angle study demonstrated that the SAM of 0.5% (v/v) 
(Tridecafluoro-1,1,2,2-Tetra-Hydrooctyl) Dimethylchloro-silane in toluene coated 
template proved to have a higher contact angle than the Relmat, and consequently a lower 
surface energy. Studies of similar release layers and the formation of these self-
assembled monolayers have been extensively performed for quartz imprinting templates 
[32, 33].  The SAM significantly reduced the adhesion to the PEGDA polymer and the 
peptide-functionalized PEGDA crosslinked networks, as well as the PEGDA polymers 
incorporating a model drug. 
The choice of the correct silicon substrate was also necessary in order to provide 
the best adhesion of the polymer to the substrate and the lowest residual layer. The 
flatness of the wafer can dictate the variation of the residual layer. Furthermore, a smooth 
adhesion layer can help minimize variations in the flatness of the wafer. Using BARC 
along with the double-side polished wafer with an epitaxial layer of silicon provided 
uniform imprints with the lowest overall residual layer values. Using the SAM and the 
optimized substrate allowed for successful imprinting of whole wafers. 
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 In order to dispense the pre-polymer solution from the dispense tips in the 
IMPRIO, the measurement of the PEGDA viscosity properties and the corresponding 
volume/voltage equations were invaluable. The viscosity values are only meant to give a 
close estimate of the viscosity because the bulk density of PEGDA (MW 700) was held 
constant at 1.12 g/mL. For actual viscosity determination the density value would 
increase as the polymer concentration increased. A study by Saluja and colleagues 
demonstrated that PEG 400 behaved as a Newtonian fluid, and for a 40% to 100% (w/v) 
solution the density changed by only 0.056 g/mL [34]. A key feature of this method is the 
ability to use a variety of biocompatible polymer solutions of varying concentrations. By 
determining the viscosities of these solutions they can be successfully imprinted with a 
corresponding calibrated dispensing equation.  
With the ability to dispense a variety of PEGDA pre-polymer solutions, we were 
successfully able to vary the parameters of the tool in order to create imprints with 
residual layers as low as 2 nm. Our results from the optimization show that the pre-
exposure delay can significantly lower the residual. The results from the small change in 
imprint force did not equivocally show an improvement in residual layer thickness; 
however literature has shown that a greater pressure does indeed lower the residual layer 
[35]. Furthermore, we found that a UV exposure time of 5 seconds showed a larger 
residual layer than a 7 second UV exposure. This suggests the exposure time may be too 
small, in particular for PEGDA concentrations larger than 33%. Acrylate polymerization 
is known to be accompanied by volumetric shrinkage as a result of chemical bond 
formation [24], thus the polymer may not be fully polymerized. We also saw a strong 
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dependence in the residual layer versus overall imprint volume as well as polymer 
concentration.  
With the optimized imprinting process we successfully achieved residual layers as 
low as 2 nm over 80% of the imprint for the 0.019 μL, 25% (w/v) PEGDA (MW 700) 
pre-polymer solution; however the residual layer height in the center of the template 
remained slightly thicker. Despite lowering the total volume to the smallest possible 
value, the center remained thicker for all variations. Because the trend was the same for 
all the imprints ranging from 25% to 75% w/v we believe that the back-pressure on the 
template was too low. This can be known to cause a thicker residual layer in the middle 
with all edges and corners having the same thickness.  
Using the optimized imprinting parameters we were also successfully able to 
create monodisperse, shape-specific particles. The SEM images show little to no 
variation in size and all patterns showed no defects for incomplete filling of the template 
feature. Furthermore, we were able to create higher aspect ratio particles, such as the 200 
nm particles with 413 nm heights and the 400 nm particles with 626 nm heights. The 100 
nm features in the fully patterned quartz template created 97 nm square nanoparticles. 
The discrepancy may be due to a shrinkage that is known to occur with acrylate 
polymerization [24] or may be due to the patterned features in the 10 x 10 mm mesa not 
being fully developed during the e-beam lithography process. The 10 x 10 mm fully 
patterned mesa was not characterized with SEM and thus the uncertainty exists. However 
all previous imprints showed direct pattern transfer. 
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Of key importance to the imprinting of biopolymers and encapsulated biologics is 
the ability to successfully isolate and release the nanoparticles from the silicon wafer. 
Through optimization of the residual layer (2 nm) we were successfully able to release 
the particles with no required etching. However, for higher concentration polymers with 
thicker residual layers, mild etching may still be required. When isolating the 
nanoparticles both helium and oxygen plasma etching were used with a low power setting 
and moderate pressure. The etching process can create dangling bonds and dislocations in 
the material making it reactive, and can at times cause polymer formation (hydrocarbons) 
on the surface.  
Oxygen ions are highly reactive and known to be selective for etching organic 
compounds. Etching with oxygen provides more of a chemical etch. Meanwhile, helium 
is an inert gas wherein the etching is primarily a mechanical/physical bombardment. The 
XPS data for the thick PEGDA film suggests that the mild etching processes are not 
chemically modifying the surface. The oxygen etching does however show a slight 
increase in the C-C peak which may indicate some reactivity, and it appears that the 
helium etching is causing a deposition of hydrocarbons.  
It is interesting to note that the PEGDA peaks seen in the high resolution C1s scan 
show the thinner PEGDA with a larger C-C peak. XPS is known to analyze the first 50 to 
100 Å of a surface, therefore it is likely that we may be seeing the surface below the 
PEGDA. Desai and colleagues have extensively studied thin PEGDA films on silicon 
using XPS analysis [36-39]. Their results show that increasing PEG concentrations (see 
Figure 4.32) and increased PEG immobilization times increase the C-O peak in a C1s 
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scan. However, their data also shows that films of low PEG concentration show both a 
large C-O and C-C peak. This suggests that we may be seeing the silicon or BARC layer 
below the PEGDA. 
To address the issue of efficient harvesting of intact imprinted particles without 
physical scraping from the wafers, we have employed a simple release layer-based 
approach [40].  This allows direct, one-step release of the nanocarriers from the silicon 
wafer. Since the PVA release layer dissolves in water [40] while the crosslinked 
nanoparticles do not, this process allows for efficient and mild harvesting of the 
nanoimprinted particles directly into aqueous buffers suitable for biological studies. This 
release technique is high-throughput, commercially viable and avoids high temperature or 
physical force-based removal, both of which could potentially damage the nanoparticles 
or their content. The process could also be beneficial since it allows for the presence of 
PVA in the particle suspension. PVA is a well studied polymer/stabilizer used to prevent 
particle aggregation in colloidal suspensions, especially for drug delivery [41-43].  
It is worth noting that the system and polymer choices as described here 
essentially generate nano-sized hydrogels as drug carriers. A key feature of this method is 
the ability to vary the crosslink density and composition of the particle matrix using 
different polymer concentrations, PEGDA to peptide ratio, and peptides of varying 
degradation kinetics, thus potentially controlling drug release and particle dissolution 
kinetics. It is important to note that with the SFIL technique, varying concentration or 
molecular weight of the polymer solution has little effect on the size and shape of the 
nanoparticle; unlike emulsion or self-assembled particles, SFIL particle formation is not 
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controlled by phase separation or emulsion stabilization. The molecular weight, in 
particular the viscosity, of the pre-polymer solution prior to cross-linking does affect the 
dispensing efficiency of the solution, the filling and the cure rate. The IMPRIO tool is 
calibrated for specific viscosity ranges to enable reproducible dispensing and imprinting 
of pre-polymer solutions.  The tool can also be re-calibrated when polymers of higher or 
lower viscosities are used. 
Since this is a hydrogel encapsulation process, 100% of the encapsulant is trapped 
inside the photo polymerized gel. The encapsulation efficiency and loading level is 
controlled by the pattern density in the template (how close or how far apart the particle 
patterns are in the quartz template). As demonstrated through the theoretical calculations 
this method can allow for large scale fabrication of nanoparticles. For a 50 mg/ml 
solution of protein in pre-polymer solution, the loading level is approximately 5 μg/1011 
particles for a 4 inch wafer and 10 μg/1011 particles for an 8 inch wafer.  By knowing the 
number of particles and loading levels based on size and shape, we may at some point be 
able to create a treatment dosing schedule for patients based on particle size and shape. 
We can also determine the needed number of particles for a dose. Doses for several 
anticancer drug-GFLG-HPMA conjugates, using doxorubicin and paclitaxel, range from 
17 – 320 mg/m2, as tested in clinical trials [44-46]. 
By doubling the aspect ratio of the particle to create a 100 x 100 x 200 nm particle 
the loading level would be doubled; thus a higher dose of drug could be achieved at a 
target site.  This is in agreement with Discher and Ferrari’s groups, demonstrating that 
spheroidal particles can carry more drugs than spherical drugs [5, 7]. Discher and 
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colleagues demonstrated that filamentous particles with very high aspect ratios (less than 
100 nm diameter with several microns in length) showed an increase in dosage of drug to 
a tumor site [5]. Using the SFIL technique, monodisperse nano-sized rectangles or rods 
with very large aspect ratios could be created in order to deliver a large dose of drug and 
to enhance the delivery efficiency of drugs or contrast agents to tumor tissues.   
Using the SFIL technique to create size and shape-specific, monodisperse 
nanoparticles can provide for a reliable study of the effect of shape on in-vivo drug or 
contrast agent release, and may allow for future tunable in-vivo release and targeting 
properties. The monodisperse particles could be used to study the affect of shape on 
particle velocity, diffusion and adhesion to walls in blood vessels [4]. Furthermore, 
studies could be performed to evaluate the particle’s targeting ability, internalization in 
cells, and ability to target tumor cells. Because UV-crosslinkable polymers can 
successfully be imprinted, it is conceivable that degradable polymers such as PEG-
PLGA-PEG triblock copolymers could be fabricated and studied for shape-specific 
degradation. 
In conclusion, the research presented here provides a novel application of imprint 
lithography techniques to fabricate biocompatible, easily-harvestable, nanoparticles (as 
small as 50 nm) of precise sizes, shapes and compositions. We demonstrate that the SFIL 
technique has the potential to create well-defined and characterized drug delivery 
particles without the limitations of the PRINT process, emulsion, and micelles formation 
techniques.  We have demonstrated full wafer imprinting and successful isolation and 
release of the particles from the wafer using a mild harvesting method. The use of a top-
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down approach ensures precise control of particle size and geometry, creating a 
monodisperse population of particles; therefore allowing for better reproducibility and 
prediction of properties.  The top-down technique also avoids high shear and mechanical 
forces typical for emulsion-based encapsulation, which in turn may improve 
encapsulation efficiency and drug stability. Furthermore, the SFIL technique can easily 
fabricate drug delivery devices using a wide variety of currently available biocompatible 
polymers. 
This research provides a significant advance in the creation of monodisperse, 
injectable nanocarriers of specific geometry and can provide a characterized environment 
for the study of the effect of size and shape in in-vivo release properties of nanoparticles.  
It is also conceivable that nano-sized, injectable drug carriers having precise geometry 
and environmentally-responsive release mechanisms could provide targeted, disease-
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Figure 4.3  IMPRIO 100 Process Tool: (A) Tool with computer controller, (B) front 
sash closed with wafer and template loading stations, (C) front sash 
opened to show entire system, (D) close up view of the wafer chuck and 





Figure 4.4  Interior View of Z-head, Template location, and Wafer location. The 
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Figure 4.6  Schematic of a Template Fabrication Process for ThNIL: (A) A wafer is 
spin-coated with ZEP 520 resist, (B) the resist is exposed to e-beam and 
patterned, (C) the resist is developed, (D) the exposed silicon is etched 
with RIE (for single shapes the process ends here), (E) to create 
nanocontainers a 2nd layer of resist is spin-coated on the wafer, (F) the 
resist is exposed to e-beam and patterned, (G) the resist is developed, 













Figure 4.7  Schematic of a Quartz Template.  Four quartz templates are diced from 
a larger 6” x 6” substrate*1.  Each template has a varying size mesa, 




*1 Reprinted from I. McMackin, P. Schumaker, D. Babbs, J. Choi, W. Collison, S. V. 
Sreenivasan, N. Schumaker, M. Watts, and R. Voisin, Design and Performance of a 
Step and Repeat Imprinting Machine Proc SPIE, Emerging Lithographic Technologies 









Figure 4.8  Template Fabrication Process for SFIL: (A) 15 nm chromium is 
deposited on a quartz template, (B) the wafer is spin-coated with ZEP 
520 resist, (C) the resist is exposed to e-beam, patterned and developed, 
(D) the chromium layer is etched, (E) the chromium layer is etched, (E) 















Figure 4.9  Schematic of PEGDA Nanoparticle Formation using SFIL: (A) Orient 
the substrate and treat the template with a water soluble layer and 
adhesive layer, (B) dispense the macromer solution, (C) imprint with 
low pressure and UV exposure, (D) separate the template and substrate, 










Table 4.1 Imprintable Fields per Wafer (as referenced from the Molecular 
Imprint’s IMPRIO100 Manual and estimated by technicians).  
  
Mesa Size 4 inch 8 inch 
10 mm mesa 52 186 
12.5mm mesa 32 94 
















Figure 4.10  Optimization of EBL Parameters Template Fabrication. (A) The 
schematic indicates a single wafer in which feature size, development 
time of the e-beam resist ZEP 520A (1, 1.5, 2 and 3 minutes) and the 
dose level of the e-beam (from -5 to 110) were studied. (B) The SEM 
image demonstrates a single development time, with the e-beam dose 





Figure 4.11  SEM images of Patterned Silicon Template using E-beam Lithography 
and Reactive Ion Etching:  (A) 100 nm boxes (scale bar = 200nm), (B) 
200 nm boxes(scale bar = 200nm), (C) 400 nm boxes(scale bar = 1μm), 
(D) 800 nm boxes(scale bar = 1μm), (E) side profile of 400 nm boxes 
(scale bar = 400nm), and (F) side profile of 800 nm boxes, with etch 






Figure 4.12  Layout of Quartz Template Mesas:  (A) 25 x 25 mm mesa with, (B) 12. 5 
x 12.5 mm mesa, (C) 10 x 10 mm mesa, (D) fully patterned 10 x 10 mesa 
with 0.9 billion, 100 nm features, (E) fully patterned 10.5 x 10.5 mm 
mesa with 1.369 billion, 80 -100 nm features. 
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Figure 4.13  SEM Images of Patterned Quartz Template using E-beam Lithography 
and Reactive Ion Etching:  (A) 50 nm squares (scale bar = 200nm), (B) 
100nm squares (scale bar = 200nm), (C) 200 nm pentagons (scale bar = 
200nm),  (D) 200 nm triangles (scale bar = 200nm), (E) 200 nm squares 







Figure 4.14  Three-dimensional Poly(methyl methacrylate) (PMMA) 
Nanocontainers Fabricated using ThNIL: (A) 200 nm nanocontainers 
(scale bar = 200nm), (B) 400 nm nanocontainers (scale bar = 200nm), (C) 
800 nm nanocontainers (scale bar = 1μm),  and (D) a dense array of 400 










Figure 4.15  PLGA Characterization and Spinning Study Results: (A) Average 
Cauchy Characteristics needed to determine film thickness, and (B) 
film thickness of various PLGA concentrations in solvents, acetone and 








Figure 4.16  PLGA Features Patterned with ThNIL: (A) shallow features in 5% 
(w/v) PLGA 502H in DCM scale bar = 4μm), (B) shallow features in 5% 






Table 4.2  Contact Angle Measurements for Template Release Layer.  
 











over 400nm squares  109.19  na  93.31 
over 200nm squares  108.21  na  93.19 
over 100nm squares   107.89  101.5  92.79 
over 50nm squares  102.31  na  92.31 
over unpatterned 
quartz surface  98.75  97.8  92.04 
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Figure 4.17  Initial Whole Imprinted Wafer. As a note, this wafer was used for 














Table 4.3  Viscosity Values for PEGDA (MW 700).  The values are based on the 
bulk density of PEGDA (1.12g/mL) and show the corresponding 







Calibration Equation for 
Dispensing PEGDA in IMPRIO 
x = volume (mL), y = voltage (V)
75 40.61*1  y = 154862x + 24.596*2  
60 18.33 0.12 y = 137866x + 25.564*2  
50 11.10 0.1     
33 4.77 0.05  
25 2.06 0.01     
 
*1 Value courtesy Mary C. Moore. 










Figure 4.18 Residual Layer Thickness versus Pre-Delay Time. 25% and 33% (w/v) 
PEGDA (MW 700) using an overall volume of 0.025 μL, an imprint 















Figure 4.19  Residual Layer Thickness versus Imprint Force. 25% and 33% (w/v) 
PEGDA (MW 700) using an overall volume of 0.025 μL, a 7 second UV 














Figure 4.20  Residual Layer Thickness versus UV Exposure Time. 25% and 33% 
(w/v) PEGDA using an overall volume of 0.025mL, an imprint force of 














Figure 4.21  Residual Layer Thickness versus Total Imprint Volume. 25% and 33% 
(w/v) PEGDA using an imprint force of 7 N, a 7 second UV exposure, 














Figure 4.22  Optimized Drop Pattern. The image shows the optimized pattern only. 





Table 4.4  Residual Layer Thickness versus PEGDA Concentration.  Used an 
optimized setting of 0.019 μL imprint volume, 300 second pre-exposure 








25  2.1 1.1 9.1  1.3
33  8.7 1.4 15.1  1.2
50  15.6 1.2 22.2  2.1
75  27.0 1.4 30.7  2.6
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Figure 4.23  SEM images of PEGDA (MW 700) Residual Layer:  (A) manually 
dispensed macromer with 1.36 μm residual layer (scale bar = 2μm), (B) 
25% (w/v) (scale bar = 200nm), (C) 50% (w/v) with 15 nm residual layer 
(scale bar = 300nm),  (D) 75% (w/v)  with 31 nm residual layer (scale bar 






Figure 4.24  SEM images of Three-dimensional PEGDA Nanoparticles:  (A) 50 nm 
squares in 33% (w/v) PEGDA (MW 700) (scale bar = 200nm), (B) 100 
nm squares in 100% (w/v) PEGDA (MW 1000) (scale bar = 200nm), (C) 
200 nm pentagons in 100% (w/v) PEGDA (MW 1000) (scale bar = 
200nm),  (D) 200 nm triangles in 100% (w/v) PEGDA (MW 1000) (scale 
bar = 200nm), (E) 200 nm squares in 100% (w/v) PEGDA (MW 1000)  
(scale bar = 300nm), and (F) 400 nm pentagons in 100% (w/v) PEGDA 
(MW 1000) (scale bar = 400nm), (G) 400 nm triangles in 100% (w/v) 
PEGDA (MW 1000) (scale bar = 400nm), (H) 400 nm squares in 100% 
(w/v) PEGDA (MW 1000) (scale bar = 400nm), and (I) 400 nm 









Figure 4.25  SEM images of Monodisperse PEGDA Nanoparticles. 100 nm (97.3 ± 
0.2 nm) rounded squares in PEGDA (MW 700) with varying macromer 
concentrations using 0.019 μL of solution in a 10 x 10 fully patterned 
mesa:  (A) 25% (w/v) (scale bar = 200nm), (B) 33% (w/v) (scale bar = 
200nm), (C) 50% (w/v) (scale bar = 200nm),  (D) profile view of 75% 











Table 4.5  Residual Layer Thickness of PEGDA Before and After Etching. 33% 
(w/v) PEGDA (MW 700) imprints were created using a volume of 0.025 
μL, an imprint force of 7 N, a pre-exposure delay of 300 seconds and a 






















Figure 4.26  AFM Images of Particle Heights Before and After Etching: (A) 50 nm 
particles before etching, (B) 50 nm particles after etching, (C) top view 
of 50 nm particles, (D) 100nm particles before etching, (E) 100 nm 
particles after etching, (F) top view of 100 nm particles, (G) 200 nm 
particles after etching, (H) 400 nm particles after etching, (I) isometric 










Figure 4.27  C1s Scans of PEGDA Before and After Etching. Comparison of 75% 
(w/v) PEGDA (MW 700) on BARC and silicon, before and after oxygen 
and helium etching. (A) 0.174 μL PEGDA sample, and (B) 0.025 μL 
PEGDA sample. Charge neutralization was utilized and the C-C peak 
placed at 285 eV. 
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Figure 4.28  Harvested 33% (w/v) PEGDA Nanoparticles After Helium Etching:  (A) 
400 nm squares (scale bar = 1μm), (B) 100 nm and 50 nm particles 
(scale bar = 200nm), (C) magnified view of 100 nm square particle (scale 
bar = 200nm),  (D) 100 nm square particles (scale bar = 200nm), (E) 100 
nm squares particle (scale bar = 200nm), and (F) 50 nm square particles 




Figure 4.29  Harvested 25% (w/v) PEGDA Nanoparticles Without Etching:  (A) 400 
nm square particle (scale bar = 1μm), (B) 400 nm and 200 nm particles 
(scale bar = 2μm), (C) magnified view of 100nm square particle (scale 
bar = 300nm),  (D) 200 nm square particles (scale bar = 1μm), (E) 400 
nm squares particle (scale bar = 400nm), and (F) 400 nm square 






Figure 4.30  Theoretical Number of Particles Generated using SFIL. Particle 
number based on varying spacing, feature size, and template size: (A) 
number of particles per template, (B) number of particles per imprinted 





Figure 4.31  Theoretical Loading Level of Particles. For a 10 x 10 mm mesa using a 
10 mg/mL solution of model drug in macromer for various particle 
shapes, sizes and spacing: (A) mass of model drug per imprint, (B) mass 
of model drug per imprinted 4” wafer, and (C) mass of model drug per 






Table 4.6 Actual Number of Particles per 10 x 10 mm Template Mesa, Estimated 
Number of Particles per Wafer, and Theoretical Loading Level for the 
10 x 10 mm fully patterned mesa with 100 nm square features and 1 to 2 
spacing and the 10.5 x 10.5 mm fully patterned mesa (assuming initial 
10 mg/mL solution of model drug in macromer). 
 



























































9 4.68 1.67 52.99 2.76 9.86 67.50 3.51 12.56
MI's 














Figure 4.32  C1s Scans of Varying PEGDA Concentrations on Silicon: (A) 5mM, (B) 
10mM, (C) 20mM, and (D) 50 mM. Reprinted from Biosens Bioelectr, 20, 
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Stimuli-Responsive Nanoimprinted Nanocarriers: Swelling, Enzymatic 
Degradation and In-vitro Release Studies  
 
5.1 INTRODUCTION   
A major milestone in creating nanoscale, intravenously injectable delivery 
systems is the incorporation of multiple functions such as: shape-specificity, targeting, 
loading of multiple agents, and incorporating stimuli-sensitive properties. Current 
polymeric and liposomal-based nanocarriers have been well studied and optimized in 
preclinical and clinical settings, and surface modification of these carriers has led to 
advances in stability, half-life, biodistribution, targeting, and in-vivo efficiency [1-5]. The 
synthesis of these drug nanocarriers primarily involves self-assembled or emulsion-based 
spherical particles that release drugs through diffusion or hydrolytic degradation. 
Although significant progress has been made in polymeric or liposomal drug delivery 
systems, there remain critical limitations in synthesizing nanocarriers with highly 
controllable architecture and drug release properties. Our ability to precisely manipulate 
size, shape, composition, and drug release mechanism of nanoparticles is essential for 
controlling their in-vivo transport, biodistribution, and therapeutic efficacy [6-8].   
Disease-responsive release is a key issue in ‘intelligent’ nanocarrier design. 
Intravenously injectable nanocarriers, that can efficiently deliver drugs or contrast agents 
to target tissues only in response to cellular or disease-specific signals, could significantly 
improve therapeutic and diagnostic care of complex diseases [6, 9].  Despite current 
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efforts to target drug nanoparticles and liposomal drug carriers to diseased cells in-vivo, 
significant amounts of toxic drugs diffuse to normal tissues during transport [10-13]. If 
the encapsulated cargo can be released preferentially at a particular diseased tissue or cell 
or inside a specific cellular compartment, it could provide significant improvement in 
patient compliance, especially for highly toxic chemotherapeutic drugs or for molecules 
with short half-life.   
Although stimuli-responsive release mechanisms are well established for 
macroscale devices and hydrogels [14-16], reports on nanocarriers incorporating 
environmental- or disease-triggered release of drugs are limited to only pH-responsive 
systems [17, 18].  Polymer-based pro-drugs combine multiple functionalities [19, 20]; 
however, they do not allow for simultaneous delivery of multiple agents (drugs, contrast 
agents etc.).  The design of carriers at the nanometer length scale that incorporate such 
triggered-release mechanisms has remained elusive because of the lack of flexible 
fabrication methods that can incorporate responsive bio-molecules within a nanoparticle 
matrix. Recent advances in nanoscale fabrication methods could provide unique solutions 
to manufacture stimuli-sensitive nanocarriers for drug delivery in a high-throughput 
manner.  
Using Step and Flash Imprint Lithography (SFIL), discussed in Chapter Four, we 
have already demonstrated the ability to imprint on a wafer scale and ensure precise 
control of particle size, shape, and geometry [21]. DeSimone and colleagues have also 
reported the ability to form nano-size poly(ethylene glycol) (PEG) and poly(lactide) 
(PLA) particles using a top-down particle nano-replication (PRINT) method, which is 
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similar to nanoimprint lithography [22-24]. Although nanoparticle synthesis was 
demonstrated using the PRINT method, stimuli-responsive nanoparticle fabrication has 
not been demonstrated. Top-down nanofabrication methods to generate particles with 
precise size and shape that also incorporate environmentally-triggered drug release have 
yet to be reported.  
In this research we discuss the fabrication of particles with precise size and shape 
that also incorporate environmentally-triggered drug release, with features as small as 
100 nm, using SFIL. We hypothesized that after imprinting of the PEGDA-GFLGK-DA 
stimuli-responsive hydrogel material, developed in Chapter Three, the crosslinked 
network would degrade in the presence of the tumor-specific enzyme Cathepsin B and 
display stimuli-responsive release. In this research we demonstrate enzymatic 
degradation of the imprinted PEGDA-GFLGK-DA nanofeatures. We further demonstrate 
that biological agents can be successfully incorporated within stimuli-responsive 
nanoparticles during the imprinting process by simply mixing the agents with the 
macromer solution prior to polymerization. In order to show release of both a nucleic 
acid and a protein, plasmid DNA and a fluorescently-labeled IgG were each encapsulated 
in PEGDA-GLFLG-DA and imprinted.  The release studies performed demonstrate 
successful retention of the model drug in the absence of tumor-specific enzymes (with an 
initial leakage) and an enzyme-triggered release of model drug upon the addition of 
Cathepsin B.  Swelling studies had been performed on macroscale PEGDA hydrogels in 
Chapter Three, and we further characterize the change in PEGDA nanoparticle 
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morphology utilizing scanning electron microscopy (SEM) and atomic force microscopy 
(AFM) before and after swelling of the particles.   
 
5.2 MATERIALS AND METHODS 
5.2.1 Polymers and Reagents 
The peptide sequence Gly-Phe-Leu-Gly-Lys (GFLGK) (MW 527) was purchased 
from Bachem and acrylated in dH20 as described in Chapter Three.  Poly(ethylene 
glycol) diacrylate (PEGDA, MW 700) was purchased from Sigma Aldrich. Phosphate 
buffered saline (PBS, pH 7.4) was purchased from Sigma Aldrich. The ultraviolet (UV) 
photoinitiator, 2-hydroxy-1-[4-(hydroxyethoxy) phenyl]-2-methyl-1 propanone (I2959) 
was purchased from Ciba Geigy. Plasmid DNA, pgWiz β-galactosidase (8500 bps), was 
purchased from Aldevron. The Picogreen assay was purchased from Invitrogen. 
Fluorescently-labeled antibody, Alexa Fluor 594 labeled goat anti–mouse IgG, was 
purchased from Invitrogen. Cathepsin B from bovine spleen was purchased from Sigma 
Aldrich. BARC DUV-30J (Brewer Sciences) was supplied by NNIN and the MRC at the 
University of Texas Pickle Research Center. Tridecafluoro-1,1,2,2-Tetra-Hydrooctyl 
Dimethylchloro-silane was purchased from Gelest Inc, and toluene was purchased from 
Sigma. Four inch p-type <100>, double-sided polished, prime silicon wafers with an epi-
layer of silicon on one side were purchased from Montco Silicon Technologies. 
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5.2.2 Cathepsin B Mediated Degradation of PEGDA-GFLGK-DA 
A 1:1 molar ratio of 100% (w/v) PEGDA (MW 700) and diacrylated GFLGK was 
prepared, and 0.07 wt% I2959 was added to generate free radicals to induce chain 
polymerization. Prior to imprinting the polymer solution, the template and the wafer were 
prepared.  A self-assembled monolayer (SAM) of 0.5% (v/v) (Tridecafluoro-1,1,2,2-
Tetra-Hydrooctyl) Dimethylchloro-silane in toluene was applied to the quartz template, 
as described in Chapter Four, the day prior to imprinting. Subsequently, a four inch 
silicon wafer was spin-coated with BARC (3000 rpm, 60 s). Nanoimprinting was 
performed using the IMPRIO 100 SFIL system (Molecular Imprints). The automated 
dispensing system was inactivated and 0.2 μL of polymer was dispensed onto the wafer 
prior to each imprint.  The solution was then imprinted with an imprint force of 12 N, a 
UV exposure of 7 seconds and a pre-delay of 300 seconds.  
After imprinting, the nanoimprinted polymer membranes (containing 100 nm 
square shaped particles) were subsequently exposed to 25 U/mL Cathepsin B (Sigma-
Aldrich) in PBS pH 5 for varying time periods. SEM images were taken of individual 
imprints after 30 min, 2 hrs, 4 hrs, 8 hrs, 12 hrs and 48 hours of enzyme exposure. A 
control sample that was not exposed to Cathepsin B was left in dH2O for the duration of 
the 48 hrs to evaluate if any degradation occurs in the absence of the enzyme. The 
experiment was performed in triplicate and scanning electron microscopy (SEM) was 
used to verify degradation of the nanoparticles. 
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5.2.3 Enzyme-Triggered Release of Biologics  
5.2.3.1 Stimuli-Responsive Release of DNA 
The enzyme-triggered release kinetics of encapsulated plasmid DNA, pgWiz β-
galactosidase (8500 bps), from PEGDA-GFLGK-DA imprints with square-shaped 
nanoparticles were evaluated in vitro.  A 1:1 molar ratio of 75% (w/v) PEGDA (MW 
700) and diacrylated GFLGK was prepared with 0.16 % plasmid DNA (w/w of polymer) 
and 0.07 wt% I2959. The experiment was performed in triplicate in 0.01 M PBS solution 
(pH 7.4). 0.174 μL of the macromer-DNA mixture was dispensed onto a double-sided 
polished 4” silicon wafer with an epi-layer and BARC. The solution was then imprinted 
with the IMPRIO 100 (Molecular Imprints) using an imprint force of 18 N, a UV 
exposure of 7 seconds and a pre-delay of 300 seconds.  
Subsequently the imprints (without etching) were rinsed in PBS for 30 minutes, 
placed in 500 μL PBS and incubated at 37oC. At various time intervals (4 hrs, 8 hrs, 12 
hrs, 24 hrs), buffer samples were collected and replaced with fresh solution. At 24 hrs, 
the entire buffer was removed and a 500 μL solution of Cathepsin B (20 U/mL in PBS 
pH 5) was added to each sample, except the control samples which continued to be 
incubated in PBS.  Samples were returned to the incubator and at various intervals (4 hrs, 
8 hrs, 12 hrs, 24 hrs, and 48 hrs), buffer was collected. Each time 100 μL of enzyme 
solution was removed, and 100 μL of fresh enzyme solution was replaced. The amount of 
plasmid DNA released into the buffer was measured using a Picogreen Assay, an ultra-
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sensitive fluorescent nucleic acid stain used for quantification of double stranded DNA, 
and a fluorescence plate reader (DTX 880, Beckman Coulter). 
5.2.3.2 Stimuli-Responsive Release of Fluorescently-labeled Antibody 
The stimuli-responsive release of encapsulated antibodies (Alexa Fluor 594 
labeled goat anti–mouse IgG, Invitrogen) from PEGDA-GFLGK-DA imprints with 
square-shaped nanoparticles was evaluated in-vitro. A 1:1 molar ratio of 100% (w/v) 
PEGDA (MW 700) and diacrylated GFLGK was prepared with 0.075% (w/w of 
polymer) antibody and 0.07 wt% I2959. The experiment was performed in triplicate in 
0.01M PBS solution (pH 7.4). 0.174 μL of the macromer-Antibody mixture was 
dispensed onto a double-sided polished 4” silicon wafer with an epi-layer and BARC. 
The solution was then imprinted with the IMPRIO 100 (Molecular Imprints) using an 
imprint force of 18 N, a UV exposure of 7 seconds and a pre-delay of 300 seconds.  
Subsequently the imprints (without etching) were rinsed in PBS for 30 minutes, 
placed in 500 μL PBS and incubated at 37oC. At various time intervals (4 hrs, 8 hrs, 12 
hrs, 24 hrs), buffer samples were collected and replaced with fresh solution. At 24 hrs, 
the entire buffer was removed and a 500 μL solution of Cathepsin B (20 U/mL in PBS 
pH 5) was added to each sample, except the control samples which continued to be 
incubated in PBS.  Samples were returned to the incubator and at various intervals (4 hrs, 
8 hrs, 12 hrs, 24 hrs, and 48 hrs), buffer was collected. Each time 100 μL of enzyme 
solution was removed, and 100 μL of fresh enzyme solution was replaced. The amt of 
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fluorescently labeled antibody released into buffer was measured for each time point 
using a fluorescence plate reader (DTX 880, Beckman Coulter). 
5.2.4 Imprinted PEGDA Swelling Morphology 
PEGDA (MW 700) was dissolved in dH20 to form various concentrations ranging 
from 25%, 33%, 50%, and 75% (w/v), and 0.05 wt% I2959 was added to initiate chain 
polymerization. 0.019 μL of the PEGDA solution was dispensed through the automated 
dispensing system onto a double-sided polished 4” silicon wafer with an epi-layer and 
BARC.  The PEGDA solutions were then imprinted with the IMPRIO 100 (Molecular 
Imprints) using an imprint force of 7 N, a UV exposure of 7 seconds, and a pre-delay of 
300 seconds. The 25%, 50% and 75% (w/v) imprints (containing 100 nm square-shaped 
particles) were placed in 3 mL dH2O and incubated at 37oC for 48 hours. The 33% (w/v) 
imprints were placed in 3 mL of 0.01 M PBS solution (pH 7.4) and incubated at 37oC for 
48 hrs. The particles were then imaged using scanning electron microscopy (SEM) (LEO 
1530 scanning electron microscope) and atomic force microscopy (AFM). SEM images 
of 33% w/v particle widths were taken before and after swelling using air-dried and 
critical point dried samples to see any critical change in dimension. AFM images of 25%, 
50%, and 75% were taken in order to see any change in particle height. AFM images 
before swelling were taken using a Digital Instruments AFM in tapping mode. AFM 
images after swelling were taken with an Asylum Research MFP-3D AFM in solution in 
contact mode using a Veeco NanoProbe with a low spring constant meant for imaging 
biological specimens.  
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5.3 RESULTS 
5.3.1 Cathepsin B Mediated Degradation of PEGDA-GFLGK-DA 
In order to demonstrate disease-responsive release, we fabricated nanoparticles 
using an equimolar mixture of PEGDA (75% w/v, MW 700) and GFLGK-DA. This 
creates a particle matrix crosslinked by the degradable peptide. We have evaluated 
enzyme-triggered degradation kinetics of imprinted PEGDA-GFLGK-DA with square 
nanoparticles using SEM at various time points following addition of Cathepsin B. As 
shown in Figure 5.1A-F, the nanoparticles begin to degrade within 30 minutes and 
between 24 and 48 hours all particles were fully degraded. Looking closely at Figure 
5.1E- F, we can see that although the particles have degraded, the remaining residual 
layer beneath the particles has not completely degraded. Meanwhile, particles that are 
exposed to dH20 without Cathepsin remain intact during this period (Figure 5.1A). 
5.3.2 Enzyme-Triggered Release of Biologics  
We have further studied how such enzyme-mediated degradation provides 
triggered release of encapsulated model drugs. Fluorescently labeled antibodies and 
plasmid DNA, encoding for beta galactosidase, were successfully incorporated during 
SFIL into PEGDA-GFLGK-DA nanoparticles. Antibody and DNA release from the 
imprinted nanoparticles, prior to and following addition of Cathepsin B, were monitored 
over time (see methods). As shown in Figure 5.2A-B, efficient enzyme-triggered release 
was achieved. A minimal amount of antibody (~ 1%) and some amount of DNA (~ 11%) 
was released prior to Cathepsin addition indicating some baseline DNA leakage from the 
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matrix. This is likely due to the highly hydrophilic nature of DNA compared to the 
antibody. However, most of the encapsulated cargo was released only after exposure to 
the enzyme. 
5.3.3 Imprinted PEGDA Swelling Morphology 
In order to characterize the change in morphology of the PEGDA-GFLGK-DA 
nanoparticles, AFM and SEM were utilized. Figure 5.3A-C demonstrates AFM images 
of 25% (w/v), 50% (w/v) and 75% (w/v) PEGDA particles in solution, respectively. The 
images show a top-down view of the particle, as well as the height profile, and a three-
dimensional view. The particle heights were on average of 175 ± 4 nm after 48 hours of 
swelling.  Non-swollen 100 nm particles (obtained using tapping mode) had a height of 
approximately 129 nm. Therefore we see a 48 nm increase in height. The three-
dimensional view in Figure 5.3A shows the large deformation in particle shape that 
occurs with the 25% (w/v) PEGDA particle due to the contact force of the AFM tip.  
Figure 5.4A-B demonstrates 33% (w/v) particles with a pre-swollen width of 97 
± 0.1 nm for both air-dried and critical point dried particles. The two different drying 
methods showed no change in dimension. Figure 5.4C demonstrates post 48 hour-
swollen particles with a width of 108 ± 0.2 nm for critical point dried particles. Thus we 




The overall goal of these experiments was to demonstrate fabrication of 
nanoparticles with precise size and shape that also incorporate environmentally-triggered 
drug release, using the SFIL technique. We fabricated nanoparticles using an equimolar 
mixture of PEGDA (MW 700) and a diacrylated, enzymatically degradable peptide 
GFLGK-DA, to create a particle matrix crosslinked by the degradable peptide. GFLG is 
known to be readily degraded by Cathepsin B, an enzyme that is sequestered 
intracellularly in lysosomes of normal cells, but is highly up-regulated, secreted and 
present in the lysosomes and extracellular tissue in certain tumors [25-30].  
An important consideration in imprinting with drugs or biological molecules is 
the orifice size of the dispense tip used to dispense the solution. Our current tip orifice for 
all experiments is 80 μm and the manufacturer suggests filtering all solutions for this tip 
with a filter of 4 nm. Therefore, depending on the size of the therapeutics to be 
encapsulated in a stimulus-responsive polymer, a dispenser tip with a larger orifice may 
be required. For studies using large therapeutics, such as DNA and IgG, a larger orifice 
would likely be required for ease of flow and to prevent clogging of the tip. Due to the 
small quantity of PEGDA-GFLGK-DA available and the large size of the DNA and 
antibody, we manually dispensed the solution to maximize the amount of solution for 
further studies and prevent clogging of the dispenser tip. Using manually dispensed 
solution, we successfully demonstrated enzyme-triggered degradation of the imprinted 
PEGDA-GFLGK-DA nanoparticles after exposure to Cathepsin B for 48 hours.  Because 
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we manually dispensed the polymer solution, the residual layer was still quite large and 
not completely degraded.  
We have also demonstrated that biological agents can be successfully 
incorporated within these imprints during the nanoimprinting process by simply mixing 
the agents with the macromer solution prior to polymerization, and we have demonstrated 
successful retention of model drug (DNA and antibody) in the absence of tumor-specific 
enzymes and an enzyme-triggered release of model drug upon the addition of Cathepsin 
B.  Although we see an initial release for DNA, most of the encapsulated cargo was 
released only after exposure to the enzyme indicating a possible means to achieve highly 
controlled, disease-responsive or intracellular release of drugs and contrast agents.  
With the successful enzymatic release of the DNA and antibody, we believe the 
PEGDA-GFLGK-DA design should allow the nanoimprinted particles to degrade in the 
presence of Cathepsin B and release the encapsulated drug preferentially inside particular 
cellular compartments (lysosomes) or inside tumor tissues. The combination of shape-
specific and stimuli-responsiveness could also provide a secondary means of targeting 
and controlled release in addition to traditional surface-ligand based targeting concepts. It 
is also easily conceivable that incorporation of different peptide sequences, specific for 
particular tissue targets or pathophysiological conditions, should allow for other disease 
or tissue-specific carrier designs. For example, Cathepsin D is highly over-expressed in 
breast cancer and has been related to its prognosis [31], and matrix metalloproteinase 
(MMP) over-expression has been correlated with tumor metastasis [32] and a host of 
inflammatory and vascular diseases [33, 34]. Incorporation of peptides specific for these 
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enzymes within the particle matrix, as described here, could provide highly specific, 
disease-triggered drug nanocarriers. Similar enzymatically degradable macroscale 
matrices have been reported for controlled release and tissue engineering applications 
[35, 36]. However, to our knowledge this is the first demonstration of nanoimprinting and 
nanocarrier synthesis using such biologically responsive macromolecules.  
It is worth noting that the system and material choices as described here 
essentially generate nano-sized hydrogels as drug carriers. The particle composition 
designed here essentially generates nano-sized hydrogels as drug carriers. The pore size 
(ξ) and molecular weight between crosslinks (Mc) of these nanoparticles would dictate 
whether a certain drug can be entrapped without significant diffusive leaching prior to an 
environmental trigger. Pore size measurements for bulk PEGDA (MW 3400) hydrogels 
of various concentrations have been previously reported by Bryant et al. [37] and we 
calculated the mesh size for bulk PEGDA (MW 700) hydrogels, Table 5.1. Thus it is 
possible to a priori model which particular therapeutic or diagnostic agents are suitable 
for stimuli-responsive, triggered release from particles of a specific composition.  
Depending on the concentration of the PEGDA (MW 700), we hypothesize that protein 
and nucleic acid-based drugs with hydrodynamic radii larger than two nanometers should 
be successfully retained and slowly released from such particles, even with a 25% (w/v) 
concentration. Thus protein, peptide and nucleic acid-based drugs, hydrophobic drug 
particles as well as nanoparticle-based contrast agents could be successfully retained 
within such imprinted nanocarriers and released primarily upon environmentally-
triggered matrix degradation.  
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An interesting aspect for future research would be to compare the change in 
swelling dimensions of the nanoparticles to the estimated swelling properties calculated 
from the swelling studies discussed in Chapter One. We have started an initial study, 
using AFM and SEM. The AFM images in this study were performed in solution in order 
to see the actual morphology of the particles in solution; however, AFM was used in 
contact mode. Even though a low spring constant tip that is meant for analyzing 
biological samples was used, the AFM tip was dragging along the surface and deforming 
the nanoparticles, as can been seen in the three-dimensional AFM views, Figure 5.3A-C. 
The 25% (w/v) particles seemed to deform more, as would be expected. In each case, the 
top of the particle was flat and we assumed a swollen height based on these 
measurements; however this height is not an accurate measurement. The most accurate 
way to measure the height, however, would be to use force-volume measurements, and 
the next method, with less accuracy, would be to use tapping mode in solution.  
The SEM images of the 33% (w/v) particles demonstrated an 11% increase in 
width; this can be corresponded to the mesh size, crosslink density and volumetric 
swelling ratios seen in Table 5.1A for the 33% (w/v) PEGDA. Although critical point 
drying was used to obtain these measurements, the critical point drying process still does 
not prevent shrinkage of the polymer structure in the vacuum chamber of the SEM. The 
most accurate way to perform all of these measurements would be to use a Field 
Emission Gun Environmental Scanning Electron Microscope (FEG-ESEM). With this 
SEM, samples can be imaged from 0 to 100% humidity. 
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In conclusion, we have shown the first demonstration to our knowledge of 
nanoimprinting and nanocarrier synthesis using biologically responsive macromolecules. 
The SFIL process has demonstrated the versatility for creating well-defined nanoparticles 
and stimuli-responsive nanoparticles, and has the potential to scale up to industrial 
production, as demonstrated in Chapter Four. Furthermore, biological agents can easily 
be incorporated into nanoparticle drug delivery systems using this method and the 
macromer concentration can be varied to encapsulate a wide variety of therapeutics and 
contrast agents. The creation of nanoscale, drug or contrast agent delivery systems with 
stimuli-responsive and environmentally-degradable features is a significant milestone in 
creating “intelligent” multi-functional nanocarriers. If the encapsulated therapeutic or 
diagnostic agent can be released only at a particular diseased tissue or cell or only inside 
a specific cellular component, it could provide significant improvement in patient 
compliance, especially for highly toxic chemotherapeutic drugs or for molecules with a 
short half-life.  The nanoimprinted drug-loaded polymer nanoparticles have the potential 
to allow for unique control of over particle transport, biodistribution and tissue or 
disease-specific release properties. 
Future studies for optimization would require in depth characterization of the 
degradation and release kinetics. For solutions that are manually dispensed and for 
thicker residual layers, the etching process required to isolate the nanoparticles etches the 
residual layer away as well as the therapeutics located within the residual layer; thus the 
overall release kinetics cannot be determined until the loading efficiency of the particles 
is determined. Our lab has already begun work on this process. In order to automatically 
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dispense drug-polymer solutions it would also be necessary to use an appropriate 
dispenser tip for the radius of the therapeutic being encapsulated. With the use of 
automated dispensing, the volume of the solution dispensed could be set such that there 
would be little residual layer and little to no etching required, and could allow for large-
















Figure 5.1  SEM Images of Imprinted Enzymatic Degradation. SFIL imprinted 
75% (w/v) PEGDA-GFLGK-DA polymer membrane with 400 nm 
square particles, showing enzymatic degradation by Cathepsin B at 
various time points: (A) at t=48 hrs after dH20 addition (scale bar = 
1μm), (B) at t=30 min. after Cathepsin addition (scale bar = 4μm), (C) 
at t=12 hrs after Cathepsin addition (scale bar = 10μm), (D) at t=12 hrs 
after Cathepsin addition (scale bar = 40μm), (E) at t=48 hrs after 
Cathepsin addition (scale bar = 600nm), (F) at t=48 hrs after Cathepsin 




Figure 5.2 Imprinted Stimuli-Responsive DNA Release: (A) DNA released from 
nanoimprinted 75% (w/v) PEGDA-GFLGK-DA and (B)  Antibody 
release from nanoimprinted 100% (w/v) PEGDA-GFLGK-DA 
hydrogel (PEGDA MW 1000), both showing enzyme-triggered release 
of DNA upon addition of Cathepsin B . The figures demonstrate the 





Figure 5.3 AFM Images of 48 Hour Swollen 100 nm PEGDA Nanoparticles. 
Imprinted with 0.019 μL, showing the top view, side profile, and 
isometric profile: (A) 25% (w/v) particles, (B) 50% (w/v) particles, and 









Figure 5.4 SEM Images of 48 Hour Swollen 100 nm PEGDA Nanoparticles. 
Squares imprinted with 33% (w/v) PEGDA using 0.019 μL of solution 
per imprint: (A) particles air dried before swelling, (B) particles dried 
using critical point drying before swelling, (C) particles dried using 


















Table 5.1  Swelling Properties of PEGDA and PEGDA-GLFGK-DA: (A) PEGDA 
(MW 700) with concentrations varying from 75% to 25% (w/v) (n=8), 
and (B) mass swelling ratio of PEGDA-GFLGK-DA (60% w/v) (n=2). 




ζ           
(Angstrom) (SD) Mc (SD) v2s (SD) Qv  (SD)
75 2.86 0.30 18.09 1.59 0.86 0.05 1.16 0.05 
60 3.15 0.48 21.47 2.69 0.84 0.07 1.19 0.07 
50 5.07 0.55 47.23 3.90 0.65 0.05 1.53 0.05 
33 8.75 1.36 106.42 11.30 0.43 0.05 2.34 0.05 
25 12.92 1.56 179.10 13.53 0.29 0.03 3.44 0.03 
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   CHAPTER SIX 




A critical aspect in fabricating nanoparticles capable of intracellular drug delivery 
is the maintenance of the stability and bioactivity of the encapsulated drug. The Step and 
Flash Imprint Lithography process has shown to be unlike any other fabrication technique 
in its ability to fabricate monodisperse, shape-specific, and stimuli-responsive 
biomaterials as small as 50 nm. Because the process utilizes low pressure, and standard 
UV illumination, and provides a gentle harvesting method for releasing the particles, we 
hypothesized that encapsulated model drugs such as proteins and nucleic acids would 
remain bioactive after undergoing the imprinting process. DeSimone and colleagues have 
demonstrated the bioactivity of PRINT imprinted PEG particles by encapsulating avidin 
within the particle matrix and subsequently exposing the particles to a solution of 
fluorescein-labeled biotin. Through the use of confocal microscopy they observed 
fluorescence only in particles with the encapsulated avidin [1]. 
This research discusses bioactivity studies performed through encapsulation of 
proteins and nucleic acids within imprinted poly(ethylene glycol) diacrylate (PEGDA) or 
stimuli-responsive, peptide-functionalized PEGDA-GFLGK-DA.  Similar crosslinking 
chemistries have been shown to be compatible with retaining the bioactivity of 
biomolecules and cells within macroscale hydrogel matrices. Various groups have 
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encapsulated cells, growth factors, ECM proteins, peptides, small molecules and nucleic 
acids within such photo polymerized hydrogels and have shown their release 
characteristics and bioactivity [2-12]. Nucleic acids are generally more susceptible to UV 
photopolymerization. The Anseth group, in addition to cell studies, has performed studies 
evaluating the effects of UV and photoinitiator on DNA stability [6, 7]. UV exposure was 
found to have no denaturing effect on the DNA; however free radicals generated by the 
photoinitiator were found to affect the DNA stability. DNA inside UV polymerized 
hydrogels retained ~ 50% integrity and this increased significantly in the presence of free 
radical scavengers, such as ascorbic acids. The hydrogel extracted DNA was shown to be 
bioactive using transfection assays. 
Through this research we demonstrate both a qualitative and quantitative measure 
of bioactivity. A streptavidin-biocytin binding study demonstrates successfully binding of 
the proteins after imprinting, indicating protein stability. Furthermore, the luciferase and 
trypsin bioactivity studies show limited quantitative bioactivity. However we hypothesize 
that this limited bioactivity is due to an inability to accurately measure the concentration 
of the proteins on a pico- and nano-molar concentration, as well as due to the very small 
pore size of the PEGDA nanogels. The DNA transfection studies themselves have proven 
unsuccessful due to a limitation in the ability to concentrate and measure the DNA. 
Although qualitative and quantitative bioactivity has been demonstrated, we suggest 
ways to further demonstrate the bioactivity of proteins and nucleic acids. 
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6.2 MATERIALS AND METHODS 
6.2.1 Polymers and Reagents 
The peptide sequence Gly-Phe-Leu-Gly-Lys (GFLGK) (MW 527) was purchased 
from Bachem and acrylated in dH20 as described in Chapter Three.  Poly(ethylene 
glycol) diacrylate (PEGDA, MW 700) was purchased from Sigma Aldrich. Phosphate 
buffered saline and phosphate buffered saline without Mg and Ca (PBS, pH 7.4) were 
purchased from Sigma Aldrich. HEPES buffer and DMSO was purchased from Sigma. 
The ultraviolet (UV) photoinitiator, 2-hydroxy-1-[4-(hydroxyethoxy) phenyl]-2-methyl-1 
propanone (I2959) was purchased from Ciba Geigy. The UV photoinitiator, dimethoxy-2-
phenyl-acetophenone (DMPA), was purchased from Sigma. The Picogreen assay and the 
NanoOrange assay were purchased from Invitrogen. Cathepsin B from bovine spleen was 
purchased from Sigma Aldrich. The Bright Glo Luciferase assay, including Luciferase 
assay reagent (containing Luciferin), Glo-Lysis buffer, and QuantiLum® Recombinant 
Luciferase, were purchased from Promega. Plasmid DNA, pgWizLuciferase (6732 bps), 
was purchased from Aldevron. Alexa Fluor 488 Bioctyin was purchased from Invitrogen. 
Streptavidin-CY5 was purchased from Southern Biotech. Trypsin from bovine pancreas 
was purchased from Sigma.   The fluorogenic proteinase substrate, Rhodamine 110, bis-
(CBZ-L-alanyl-L-arginine amide), dihydrochloride, was ordered from Invitrogen. BARC 
DUV-30J (Brewer Sciences) was supplied by NNIN and the MRC at the University of 
Texas Pickle Research Center. Tridecafluoro-1,1,2,2-Tetra-Hydrooctyl Dimethylchloro-
silane was purchased from Gelest Inc, and toluene was purchased from Sigma. Four inch 
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p-type <100>, double-sided polished, prime silicon wafers with and without an epi-layer 
of silicon on one side were purchased from Montco Silicon Technologies. Amicon Ultra 
Centrifugal Filter Unit 50K and 100K were purchased from Cole-Parmer. 
6.2.2 Streptavidin-Biotin Bioactivity Studies 
Streptavidin-CY5 (Southern Biotech) was encapsulated within nanoimprinted 
PEGDA particles. PEGDA (75% w/v, MW 700) was prepared with 0.01% (v/v) 
streptavidin-CY5 and 0.07 wt% I2959. Prior to imprinting the polymer solution, the 
template and the wafer were prepared.  A self-assembled monolayer (SAM) of 0.5% (v/v) 
(Tridecafluoro-1,1,2,2-Tetra-Hydrooctyl) Dimethylchloro-silane in toluene was applied 
to the quartz template with a fully patterned 10 x 10 mm mesa, the day prior to 
imprinting. Subsequently, a four inch silicon wafer was spin-coated with BARC (3000 
rpm, 60 s).  
0.019 μL of the macromer-protein solution was then dispensed from the IMPRIO 
100 (Molecular Imprints) and imprinted with a force of 7 N with a 300 s pre-exposure 
delay and a 10 second UV exposure. Next the nanoimprinted samples were oxygen 
plasma etched for 20 s at a power setting of 50 W, using the Plasma Therm 790 Series 
RIE to remove any residual layer. Control samples remained unetched.  Following this, 
the imprints were incubated in 100 μL of 0.427 μM Alexa Fluor 488 biocytin for 30 
minutes. Subsequently the imprints were rinsed thoroughly 5 times with dH2O and dried 
with Nitrogen. Following this the imprints were prepared on slides and imaged using a 
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using a fluorescence microscope at 160X (Zeiss Axiovert 100M) in order to determine 
whether the encapsulated streptavidin retained its biotin binding property. 
6.2.3 Luciferase and Bioactivity Studies 
6.2.3.1  Luciferase Study with PEGDA-GFLGK-DA 
To demonstrate luciferase bioactivity, luciferase was encapsulated, imprinted, 
etched, and then incubated in Cathepsin B in PBS (pH 5.5) buffer for 48 hours at 37oC 
(n=3). To prepare the luciferase encapsulated PEGDA-GFLGK solution, a 1:1 molar ratio 
of PEGDA (75% w/v, MW 700) was prepared in dH2O with 0.5 mg luciferase and 0.05 
wt% I2959. 0.4 μL of the macromer-protein solution was then manually dispensed and 
imprinted with the IMPRIO 100 (Molecular Imprints) with a force of 7 N with a 300 sec 
pre-exposure delay and a 7 sec UV exposure. Next the nanoimprinted samples were 
oxygen plasma etched for 40 sec at a power setting of 50 W, using the Plasma Therm 790 
Series RIE to remove residual layer. Control samples remained unetched. Following this, 
the imprints were incubated in 500 μL of Cathepsin B (25 U/mL) in PBS (pH 5.5) for 48 
hours at 37oC. Furthermore, to determine if temperature could play a factor in the results, 
an equivalent luciferase concentration was incubated in dH2O (at room temperature and 
37oC) in 500 μL of solution for 48 hours. For each sample 50 μL of solution was placed 
in a 96-well plate and luminescence measurements were taken with the luciferase assay 
reagent. 
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6.2.3.2 Luciferase Study with PEGDA 
Further studies were performed to find the optimum temperature, and buffer for 
luciferase. To show luciferase bioactivity using PEGDA, luciferase was encapsulated and 
imprinted, etched, and then immediately placed in Glo-Lysis buffer in a 96-well plate 
(n=25 for samples, n=6 for controls). To prepare the luciferase encapsulated PEGDA 
solution, PEGDA (25% w/v, MW 700) was prepared in dH2O with 0.5 mg trypsin and 
0.05 wt% I2959. 0.2 μL of the macromer-protein solution was then manually dispensed 
and imprinted with the IMPRIO 100 (Molecular Imprints) with a force of 7 N with a 300 
s pre-exposure delay and a 7 sec UV exposure. Next the nanoimprinted samples were 
oxygen plasma etched for 40 sec at a power setting of 50 W, using the Plasma Therm 790 
Series RIE to remove residual layer. Control samples remained unetched. Following this, 
each imprint was cut into 1/8th pieces and each piece was fit into the wells of a 96-well 
plate with 50 μL of Glo-Lysis buffer. Samples sat in the 96-well plate for 30 minutes 
during preparatory set up and the luminescence measurements were then taken with the 
luciferase assay reagent. 
6.2.4 Trypsin Bioactivity Studies 
6.2.4.1 Trypsin Study with Oxygen Etching 
To show bioactivity of trypsin, trypsin was encapsulated and imprinted, etched, 
and then released in both 10 mM HEPES buffer pH 7.55 and/or PBS (w/o Mg2+ or Ca2+) 
buffer for 24 hours. Subsequently the imprinted trypsin sample was exposed to 
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Rhodamine 110 proteinase substrate to ensure bioactivity. The experiment was performed 
in triplicate with imprinted trypsin samples before O2 etching, trypsin samples after 
oxygen etching and plain PEG imprints as controls.  
To prepare the trypsin encapsulated PEGDA solution, a stock solution of trypsin 
(50 mg/mL in 1 mM HCl) was diluted to 10 mg/mL in 10 mM HEPES and/or 0.01 M 
PBS (w/o Mg2+ or Ca2+). PEGDA (25% w/v, MW 700) was prepared in dH2O with 2.5% 
trypsin (w/w of polymer) and 0.05 wt% I2959. 0.08 μL of the macromer-protein solution 
was then dispensed from the IMPRIO 100 (Molecular Imprints) and imprinted with a 
force of 7 N with a 300 sec pre-exposure delay and a 7 sec UV exposure. Next the 
nanoimprinted samples were either oxygen plasma etched for 40 sec at a power setting of 
50 W, using the Plasma Therm 790 Series RIE to remove any residual layer. Control 
samples remained unetched. Following this, the imprints were incubated in 500 μL of 10 
mM HEPES buffer pH 7.55 and/or PBS for 24 hours at room temperature.  
To prepare the fluorescence assay Rhodamine 110 proteinase substrate was 
dissolved in DMSO to a 10 mM concentration. It was then diluted into 10 mM HEPES 
buffer, pH 7.55 to 2.5 mM concentration (5 mM is reported in literature). 25 μL of trypsin 
supernatant was mixed with 25 μL Rhodamine 110 proteinase substrate in a black 96-
well plate. The solution was then allowed to react for 5 minutes and then fluorescence 
measurements were taken with the excitation and emission wavelengths of 498 nm and 
521 nm respectively.  
In order to create a standard curve, a range of known trypsin concentrations was 
created in PBS.  25 μL of trypsin supernatant was mixed with 25 μL Rhodamine 110 
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proteinase substrate in a black 96-well plate. The solution was then allowed to react for 5 
minutes and then fluorescence measurements were taken with excitation and emission 
wavelengths of 498 nm and 521 nm respectively. Using this standard curve, a fresh 
trypsin solution with the values indicated in the standard curve was created and its 
bioactivity measured as a positive control. 
6.2.4.2 Rhodamine 110 Fluorogenic Proteinase Sensitivity Optimization 
In order to characterize the assay and provide better sensitivity, the fluorescence 
values of known trypsin concentrations (n=2) in PBS were measured at different reaction 
times with the Rhodamine 110 fluorogenic substrate. 50 μL of trypsin solution and 25 μL 
of Rhodamine 110 substrate at 4.5 mM concentration were stored at 2-8oC for the 
duration of the study. Subsequently, fluorescence measurements were taken with the 
excitation and emission wavelengths of 498 nm and 521 nm respectively.  
6.2.4.3 Optimized Trypsin Study with Oxygen Etching 
To show bioactivity of trypsin, trypsin was encapsulated and imprinted, etched, 
and then released in PBS (w/o Mg2+ or Ca2+) buffer for 24 hours. Subsequently the 
imprinted trypsin sample was exposed to Rhodamine 110 proteinase substrate to ensure 
bioactivity. The experiment was performed in triplicate with imprinted trypsin samples 
before O2 etching, trypsin samples after O2 etching and plain PEG imprints as controls.  
To prepare the trypsin encapsulated PEGDA solution, a stock solution of trypsin 
(50 mg/mL in 1 mM HCl) was diluted to 10 mg/mL in 0.01 M PBS (w/o Mg2+ or Ca2+). 
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PEGDA (25% w/v, MW 700) was prepared in dH2O with 2.5% trypsin (w/w of polymer) 
and 0.05 wt% I2959. 0.08 μL of the macromer-protein solution (theoretically 0.5 μg of 
trypsin) was then dispensed from the IMPRIO 100 (Molecular Imprints) and imprinted 
with a force of 7 N with a 300 sec pre-exposure delay and a 7 sec UV exposure. Next the 
nanoimprinted samples were either oxygen plasma etched for 40 sec at a power setting of 
50 W, using the Plasma Therm 790 Series RIE to remove any residual layer. Control 
samples remained unetched. Following this, the imprints were incubated in 500 μL of 10 
mM HEPES buffer pH 7.55 and/or PBS for 24 hours at room temperature.  
To prepare the fluorescence assay Rhodamine 110 proteinase substrate was 
dissolved in DMSO to a 10 mM concentration. It was then diluted into 10 mM HEPES 
buffer, pH 7.55 to 4.5 mM concentration (5mM is reported in literature). 50 μL of trypsin 
supernatant was mixed with 25 μL Rhodamine 110 proteinase substrate in a black 96-
well plate. The samples were then allowed to react at 2-8oC and fluorescent 
measurements were taken at 20, 30 and 90 minutes with an excitation and emission 
wavelengths of 498 nm and 521 nm respectively.   
6.2.4.4 Assays to Determine Trypsin Concentration 
In order to have a positive control to compare the bioactivity studies with, the 
concentration of the trypsin released was needed. To determine the concentration of 
trypsin being released from the nanoparticles, the NanoOrange Assay was used. Reagents 
were prepared as described in the manufacturer’s protocol. Standard samples were 
created using the manufacturer’s protocol as well as using a serial dilution. Following 
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reagent preparation, samples with volumes of 250 μL were placed into 1 mL centrifuge 
tubes and heated in a water bath at 90oC - 96oC for 10 minutes. The samples were 
allowed to cool to room temperature for 1 hour, protected from light, and then the tubes 
were centrifuged in order to make sure that any solution that had accumulated at the top 
of the tube was accounted for. Subsequently, 200 μL from each tube was placed into a 
96-well black plate and the fluorescence intensity was measured with a fluorescence plate 
reader (Beckman Coulter) at an excitation and emission of 485 nm and 595 nm 
respectively. 
6.2.5 DNA Bioactivity Studies 
6.2.5.1 Initial DNA Bioactivity Study 
A 1:1 molar ratio of PEGDA (MW 700) to GFLGK was added to dH2O to create 
a 75% (w/v) PEGDA-GFLGK solution with 0.35 mg encapsulated pLuc DNA and 0.07 
wt% I2959. 0.4 μL of macromer solution was hand dispensed and imprinted using the 
IMPRIO 100 SFIL system (Molecular Imprints). The imprints were then etched for 40 
seconds with oxygen plasma using a Plasma Therm II. After etching, samples (n=4) were 
placed in 250 μL of 25 U/mL Cathepsin B solution for 48 hours. For controls, 700 ng 
pLuc DNA was placed in 250 μL of both 25 U/mL Cathepsin B and dH20 for 48 hours. 
The etched samples were then concentrated, and the samples, along with the DNA 
control in Cathepsin B, and the DNA in dH2O were transfected using HEK293T cells, 
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with PEI being the positive control. After transfection, the samples were analyzed using 
the Luciferase Assay and the luminescence was measured.3  
6.2.5.2 DNA Bioactivity Study Optimization 
In order to determine if the temperature, Cathepsin B, or pH affected the DNA 
concentration readings, DNA was placed in varying conditions for 24 hours, then 
measured with the NanoDrop. To see if temperature had a large effect, samples were 
placed in the refrigerator, at room temperature and in the incubator at 37oC. Samples 
were also placed in 25 U/mL of Cathepsin B in the refrigerator, at room temperature and 
in the incubator at 37oC. For controls a fresh sample of DNA and a fresh sample of DNA 
in Cathepsin B at 25 U/mL were made. 
In order to create a large enough sample size for transfection, 25% w/v PEG-
GFLGK polymer with encapsulated DNA was imprinted using a sample size of n=12 for 
the following conditions: before etching, after oxygen etching, and after helium etching. 
The 12 imprints for each condition were placed in 3 mL of 16 U/mL Cathepsin B (pH 
5.5) for 48 hours in the refrigerator. Aliquots were taken from each sample, and 
subsequently the remainder of the samples was concentrated. A 40 μm cell strainer was 
used to separate out the wafers and polymer material from the solution. The strainer was 
rinsed cell strainer 3 times with PBS pH 5.5 Next, the remaining solution was 
concentrated with an Amicon Centrifugal Device (100 kDa MWCO) to filter out the 
Cathepsin and retain the DNA. The centrifugal device was rinsed 3 times with PBS pH 
 
3 Transfection performed courtesy Bilal Ghosn. 
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5.5 and brought up to a final volume of 100 μL. DNA standards were created in both TE 
buffer and PBS pH 5.5, and the Picogreen assay was performed. 
 
6.3 RESULTS 
6.3.1 Streptavidin-Biotin Bioactivity Studies 
Figure 6.1 demonstrates that the encapsulated streptavidin successfully retained 
its ability to bind to Alexa Fluor 488 biocytin after imprinting and etching. Both the 
before and after etching imprints showed a strong fluorescence with no difference in 
fluorescence intensity. The control PEGDA imprint (Figure 6.1C) with no streptavidin 
shows no background fluorescence. Although this is not a quantitative study, it 
qualitatively provides evidence of protein stability. Interestingly, Figure 6.1D shows a 
Helium etched sample in which the particles appear to be detaching from the wafer 
surface. 
6.3.2 Luciferase Bioactivity Studies 
6.3.2.1  Luciferase Study: PEGDA-GFLGK-DA 
Because luciferase is a large 60 kDa protein, it should not be able to release from 
imprinted nanocarriers. In order to release the luciferase, it was encapsulated in the 
PEGDA-GFLGK-DA stimuli-responsive nanoparticles. As seen in Figure 6.2, the 
luciferase in Cathepsin solution showed no difference from the control in Cathepsin 25 
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U/mL. The results suggest either that there is no bioactivity or that the Cathepsin in the 
sample solution may be affecting the luciferase. The graph further demonstrates that the 
control DNA has a higher bioactivity at room temperature than at 37oC, which is the 
temperature used for the experiment. Thus there are many factors in the assay affecting 
the bioactivity. Further optimization was performed to determine how Cathepsin and 
varying buffers affected the luciferase. It was determined that pH and temperature both 
cause a decrease in luciferase bioactivity, and that the optimal buffer was the Glo-Lysis 
buffer from the Luciferase assay kit. 
6.3.2.2 Luciferase Study: PEGDA 
Because pH affects the bioactivity and Cathepsin is most active at pH 5, luciferase 
was encapsulated in plain PEGDA without the use of Cathepsin. Although the pore size 
is too small to allow luciferase to diffuse out, the luciferin in the luciferase reagent is a 
318 Da molecule that can penetrate the nanoparticles. The results are illustrated in Figure 
6.3. The samples with luciferase before etching seemed to show less bioactivity than the 
samples with luciferase after etching. However, a t-test revealed that there was no 
significant difference between the two. Furthermore, there was a significant difference in 
the samples with the luciferase when compared to the PEGDA control with no luciferase. 
This suggests that the luciferase is bioactive. However, when compared to the total 
amount of luciferase encapsulated, there is a large difference in bioactivity. The results 
demonstrate bioactivity but the exact concentration of luciferin reacting with luciferase 
cannot be determined, thus there is no positive control. 
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6.3.3 Trypsin Bioactivity Studies 
Trypsin was initially encapsulated in PEGDA nanoparticles and allowed to 
release in HEPES and PBS buffer. As seen in Figure 6.3A, the PBS buffer allows for 
better sensitivity of the results than the PBS buffer. Using the PBS buffer, the before and 
after etched samples showed no significant difference in bioactivity level, as verified by a 
t-test. Furthermore, a t-test was used to compare the before etched sample to the control 
PEG sample. The results demonstrate a p-value of 0.05; thus the results cannot 
statistically be determined, but may show a slight significance. Figure 6.3B demonstrates 
a standard curve that was created for the trypsin in PBS. It demonstrates the bioactivity 
values for given trypsin concentrations. As can be seen, it shows very little sensitivity at 
lower concentration levels. 
Using known standards of trypsin, the incubation time in the Rhodamine 110 
substrate was varied in order to determine the incubation time that would yield the best 
sensitivity. As shown in Figure 6.4B the shape of the standard curves remains consistent 
from 5 minutes to 90 minutes incubation time. The graph shows that the greatest 
sensitivity occurs at longer incubation times, and that the optimal lower detection limit 
appears to be a concentration of 100 ng/mL. The 48 hour incubation time shows greater 
sensitivity to lower trypsin concentration, but the shape of the curve is not as consistent 
with the initial curves.  Using longer incubation times, the bioactivity of the trypsin 
released from the nanoparticles was measured for 20 minutes, 30 minutes and 90 
minutes. Figure 6.4A demonstrates that, for each incubation time, there was no 
significant difference between the etched and non-etched samples. Furthermore, the non-
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etched samples when compared to the control PEGDA samples with no trypsin showed a 
significant difference with p < 0.05. Thus the results suggest that the trypsin is still 
active. 
In order to verify that the standard curves at the various incubation times (20, 30 
and 90 min.) were not showing different concentration values, the standard curves were 
used to estimate the trypsin concentration for each sample. The concentration of trypsin 
in the solutions was measured for each incubation time, using the respective incubation 
standard curve. The results in Table 4.1 demonstrate that the concentrations for the 20 
and 30 minute incubation are consistent with an average value of 0.976 ng/mL. The 
concentration values for the 90 minute incubation time show a concentration of on 
average 1.138 ng/mL. Overall there is little variation in concentration reading. The 90 
minute incubation time does show a larger variation in results as can be seen by the larger 
standard deviations. 
6.3.3.1 NanoOrange Assay to Determine Trypsin Concentration 
In order to have a positive control to compare for the bioactivity studies, the 
NanoOrange assay was used for each experiment to try to determine the trypsin 
concentration. The NanoOrange assay is, in theory, able to detect concentrations as low 
as 10 ng/mL, using cuvettes and a fluorometer, and 100 ng/mL using a fluorescence plate 
reader. Despite encapsulating up to 0.5 μg of trypsin per imprint, the NanoOrange assay 
was never able to supply a usable standard curve as demonstrated in the manufacturer’s 
protocol. A new kit was ordered to verify that there was nothing wrong with the assay kit; 
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however the new kit was not able to provide accurate results. The only other kit found for 
measuring nanomolar concentration was the CBQCA assay; however, this assay requires 
a minimum of 100 ng in the aliquoted sample for measurement. Thus the trypsin 
concentration of released trypsin from the PEGDA nanoparticles was not able to be 
calculated for use as a positive control. 
6.3.4 DNA Bioactivity Studies 
The results from the initial DNA transfection and bioactivity study revealed no 
difference between the native cells, the experimental samples, and the control DNA in 
Cathepsin B (Figure 6.5). Because the DNA control in Cathepsin solution also showed 
no difference in bioactivity, this suggests that the Cathepsin may be affecting the study 
and that it is not the imprinting process. Further studies revealed that the optimal 
conditions for maintaining the DNA integrity were keeping the samples in dH2O or PBS 
at 2 - 8oC. 
Because the DNA was hand imprinted on PVA, it was necessary to separate the 
DNA from any unetched polymer remnants; this was achieved by filtering the solution.  
To concentrate the DNA, the solution was placed in concentrating centrifuges. As seen in 
Table 6.2, after the filtering and concentrating, most of the DNA was lost. At minimum, 
200 ng in 100 μL of solution is required per 96-well plate for the transfection. Thus we 




The overall goal of this research was to demonstrate that model drugs would 
remain active after undergoing the Step and Flash Imprint Lithography process. All 
process parameters for the experiments involved minimum pressure, a short exposure 7 to 
10 second exposure time, and a mild UV exposure at a wavelength of 365 nm. The 
dosimeter reading panel of the IMPRIO showed a dose of 2 mW/cm2 at the template-
substrate interface. These exposure parameters have been previously reported to be DNA 
and cell compatible [7, 8].  
We were successfully able to demonstrate that model biological drugs could be 
incorporated within the macromer and solution and imprinted using IMPRIO 100 
dispensing system, and we successfully demonstrated qualitative evidence of streptavidin 
bioactivity. The streptavidin bioactivity study demonstrated that the streptavidin binding 
sites remain active and are not damaged by the imprinting process. Both the luciferase 
and trypsin bioactivity studies showed limited quantitative bioactivity; however we were 
not able to compare to a positive control. We hypothesize that this limited bioactivity is 
due to an inability to accurately measure the concentration of the proteins on a pico and 
nanomolar concentration, as well as due to the very small pore size of the PEGDA.  
From the luciferase studies we modified an assay that was typically used with 
firefly luciferase DNA, to detect the expression of luciferase. For our studies we directly 
encapsulated the luciferase. Through the experiment, we learned that the temperature, pH 
and buffer played a large role in affecting the bioactivity. Based on the manufacturer’s 
literature, the luciferase assay is optimal at a pH of 7.8, and once the pH reaches 5.5 or 
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lower there is no longer an emission at 562 because the oxyluciferin (ie. - the reaction 
product which emits light) becomes protonated. The Cathepsin B used for our initial 
experiment has optimum activity around pH 5 to 5.5. Furthermore, the enzymes become 
degraded at temperatures above 30oC and are only stable at room temperature in Glo-
Lysis buffer for two days. The initial luciferase assay utilized a low pH and with a 48 
hour incubation at 37oC, thus the luciferase enzyme had been degraded. The second 
luciferase assay accounted for these factors and demonstrated limited quantitative 
bioactivity. Unfortunately, the luciferase was too large to leach out from the 
nanoparticles. Therefore we could not determine the quantity of the luciferase reacting 
with the luciferin inside the nanoparticles. Furthermore, because the luciferin was 
entering the particles and creating luminescence, the luminescence values may have been 
dampened by the polymer. 
Because trypsin is a smaller protein (MW 23.8 kDa, 18 Å radius of gyration), we 
hypothesized that it would successfully leach out from the PEGDA nanoparticles. After 
optimizing the assay parameters we have shown limited bioactivity of the trypsin when 
compared to the negative control of PEGDA alone. The difficulties with this study are 
with measuring the concentration of trypsin that has been released from the imprints. 
Because the molecular weight of trypsin is 23.8 kDa, the measured concentration values 
of ~ 1 ng/mL correspond to a 0.042 nM protein concentration; this is a picomolar 
concentration. Currently we have been unable to find an assay to measure such small 
concentrations.  
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Using the standard curves created with the Rhodamine-110 protease substrate 
showed fluorescence on the level of a 1 ng/mL concentration of trypsin. This is 
interesting considering that the theoretically calculated maximum amount of encapsulated 
trypsin per imprint was 0.5 μg of trypsin. This discrepancy could suggest that the trypsin 
is not easily leaching from the PEGDA nanoparticles. From Chapter Three we 
determined the pore size of a 25% (w/v) PEGDA hydrogel to be 12.92 ± 1.56 Å. Thus it 
is plausible that the trypsin is not successfully able to leave the hydrogel. This would 
account for the small measured concentration values as well as some of the inability to 
measure the concentration with standard protein assays. Another factor to consider could 
be that the protein may be adhering to the tubing of the dispense system. This could also 
affect the amount of trypsin we see in the imprints. This factor could quickly be resolved 
by coating the tubing with Sigmacoat or by purchasing low adhesion tubing.  The DNA 
transfection studies themselves have proven unsuccessful in proving bioactivity, due to 
an inability to concentrate and measure the DNA, as well Cathepsin interaction.  
In conclusion, we have demonstrated qualitative proof that the Step and Flash 
Imprint Lithography can successfully imprint encapsulated biologics that remain 
bioactive. We have also shown limited quantitative proof that the proteins trypsin and 
luciferase retain their bioactivity. The SFIL process uses low pressure and already 
established UV wavelengths and exposure energies. It should be noted that UV photo 
polymerization need not be a necessary step in generating nanoparticles using SFIL. It is 
easily conceivable that any other cross linking chemistry, such as Michael’s addition  
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nucleophilic-electrophilic crosslinks, can also be used with templates followed by 
etching. 
The limiting factor in demonstrating decisive quantitative bioactivity has been due 
to the limitations of the experiments themselves. The fact that the model biologics are too 
large to leach out from the PEGDA nanoparticles has lead to an inability to measure such 
small concentrations. For future studies we suggest encapsulating smaller molecular 
weight molecules such as fibroblast growth factor-2 (FGF-2) which is an 18 kDa 
molecule with a 14.5 Å radius of gyration [13, 14], or human growth hormone releasing 
factor (hGRF) which is a 3400 Da molecule [15]. These factors could be released and 
bioactivity could be determined using an ELISA assay. Furthermore, doxorubicin could 
be encapsulated and analyzed with HPLC, and siRNA could also easily be encapsulated 
and analyzed. For future studies with DNA transfection, separating the DNA from the 
Cathepsin is critical as well as concentrating enough for the transfection. We would 
suggest using an ion exchange column to separate the DNA and Cathepsin B, and then 
collecting the DNA fraction. This could then be concentrated in a dialysis membrane 




Figure 6.1  Fluorescence Micrographs Demonstrating Streptavidin Bioactivity. 
Encapsulated streptavidin in 400 nm imprinted features, after soaking 
in biocytin Alexa Fluor for 30 minutes using a 75% (w/v) PEGDA (MW 
700) and a 0.019 μL volume. (A) Before etching, (B), after oxygen 
etching, (C), control PEGDA imprint with 400 nm features, and (D) 









Figure 6.2  Bioactivity of Luciferase. Graphs demonstrating bioactivity levels of 








Figure 6.3  Trypsin Bioactivity Optimization. Graphs demonstrating trypsin 
bioactivity optimization using various buffers: (A) trypsin in PBS and 
HEPES buffers, and (B) standard curve using PBS buffer. 
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Figure 6.4  Trypsin Bioactivity Measured with Varying Incubation Times in 
Rhodamine 110: (A) trypsin incubated in PBS buffer with substrate 
incubation times of 20 to 90 minutes, and (B) standard curve using PBS 




Table 6.1  Concentration of Trypsin Released from PEGDA. Concentrations of 
etched and non-etched PEGDA based on the standard curves created 
for various incubation times.  
concentration (ng/mL) 
  20 min (SD) 30 min (SD) 90 min (SD) 
PEGDA before 
etch 0.980 0.007 0.979 0.031 1.142 0.008 
PEGDA   after 
etch 0.977 0.036 0.968 0.038 1.135 0.080 
 
 
Figure 6.5  Luciferase DNA Transfection. The experiment was performed with 
HEK293T cells and shows no difference between native cells, the 








Table 6.2  Average DNA Concentration Before and After Concentrating and 
Filtering.  
 






Before etch 2.62 294.74 
After O2 etch 2.68 315.16 
After He etch 3.48 372.88 
TE buffer 
Before etch 2.75 273.22 
After O2 etch 2.63 266.22 
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   CHAPTER SEVEN 
Conclusions and Future Directions 
 
7.1 SUMMARY 
In summary, we have developed a peptide-functionalized, enzyme-responsive 
poly(ethylene glycol) hydrogel capable for use with nanoimprint lithography. We have 
also developed a unique method for creating nanocarriers of precise sizes and shapes for 
drug and contrast agent delivery, utilizing Step and Flash Imprint Lithography. We have 
achieved 50 nm particle size and demonstrated efficient stimuli-responsive release of 
encapsulated drugs. The particles can be directly harvested into aqueous buffers using a 
simple, biocompatible process. In addition, the method does not require high temperature, 
high shear, organic solvents or long UV light exposure, which allows for direct 
encapsulation of biological agents. This process uses commercially available instruments 
and thus has the potential to be a translatable, high-throughput technique. A single 4 inch 
wafer could generate 1 x 1011 100 nm particles and an 8 inch wafer could generate 4 x 
1011 100 nm particles using a 10 x 10 mm mesa. Since the latest generation SFIL systems 
have the capability to imprint whole wafers at a time, imprint on top of existing 
nanofeatures, generate sub-50 nm structures and allow sub-10 nm alignment accuracy 
(manufacturer’s specifications), we envision that the process could fabricate, at a larger 
scale, smaller nanoparticles as well as multi-layered particles with varying composition 
and release mechanisms between layers.   
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The material chemistry used here is well established and also conducive to easily 
attaching specific ligands to the particle surface thus providing opportunities of cell 
targeted, disease-triggered delivery of drugs and imaging agents. The development of this 
technique for fabricating injectable nanoparticles for drug delivery, has also provided a 
path to enhance the field of study on the effects of shape and size on in-vivo properties. 
We have successfully demonstrated that model drugs can easily be incorporated into the 
imprinting system and retain biological activity. Thus, the use of SFIL along with gentle 
nanoparticle harvesting techniques can allow for the creation of multifunctional 
nanocarriers, with potential for targeting, stimuli-responsive release and the ability to 
incorporate drug and imaging agent. This ties into the long-term goal of the research to 
achieve site-specific, controlled, on-demand drug delivery leading to lower side-effects, 
increased bio-availability and improved therapeutic effectiveness and at the same time be 
able to effectively monitor the biodistribution of therapeutics using conventional imaging 
techniques. 
 
7.2 CONCLUSIONS AND FUTURE DIRECTIONS WITH PHOTO-CROSSLINKED, PEG-
PEPTIDE MATERIAL SYSTEMS FOR USE AS NANOIMPRINTED, ENZYME-RESPONSIVE 
NANOCARRIERS 
Chapter Three discussed the synthesis and characterization of photo-crosslinked, 
PEG-peptide hydrogels suitable for use as nanoimprinted, enzyme-responsive material 
systems. The overall goal of the research was to create a stimuli-responsive, peptide-
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functionalized, PEG-based system that demonstrated: (a) minimal diffusion of the drug 
through it in the absence of enzyme-triggered degradation, and (b) the ability to be 
nanoimprinted. We successfully synthesized two photo-crosslinkable configurations: 
PEG-GFGLK-PEG and PEGDA-GFLGK-DA. Both configurations create a matrix 
crosslinked with a degradable peptide spacer, GFLGK, designed for degradation by 
Cathepsin B.  
We demonstrated successful synthesis, imprintability, and enzyme-responsive 
release. Based on mesh size analysis we believe protein, peptide and nucleic acid-based 
drugs, hydrophobic drug particles as well as nanoparticle-based contrast agents could be 
successfully retained within such hydrogels and released primarily upon 
environmentally-triggered matrix degradation. The key relevance of these studies is the 
possibility that these polymer designs, as well as other similar peptide-functionalized, 
enzyme-degradable hydrogels could be nanoimprinted, and used to control drug release 
from nanoimprinted carriers. Future studies would be required in order to characterize the 
degradation and release kinetics of the two polymer configurations. 
 
7.3 CONCLUSIONS AND FUTURE DIRECTIONS WITH NANOIMPRINT LITHOGRAPHY 
TECHNIQUES FOR FABRICATION OF INJECTABLE, INTRACELLULAR DRUG 
DELIVERY NANOPARTICLES OF SPECIFIC SIZE AND SHAPE 
Chapter Four discussed nanoimprint lithography techniques for fabrication of 
injectable, intracellular drug delivery nanoparticles of specific size and shape. Thermal 
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Nanoimprint Lithography (ThNIL) and Step and Flash Imprint Lithography (SFIL) were 
evaluated, and the optimization of the SFIL process for biopolymer imprinting was 
discussed. We demonstrated the use of ThNIL and SFIL, coupled with biocompatible 
material systems to imprint and develop monodisperse injectable nanoparticles of pre-
designed sizes and geometries as small as 50 nm.  Particles of varying shape (square, 
circular, pentagonal, and triangular), size (50 - 400 nm), and composition (PMMA, 
PLGA, PEG) were fabricated using these techniques with little to no variation in 
geometry. 
We demonstrated that the SFIL technique has the potential to create well-defined 
and characterized drug delivery particles without the limitations of thermal imprint 
lithography, the PRINT process, or self-assembly formation techniques. Furthermore, we 
have demonstrated full wafer imprinting and successful isolation and release of the 
nanoparticles from the wafer using a mild harvesting method. The SFIL method, with its 
low temperature and force applications, as well as wafer-scale imprinting capability, was 
shown to be suitable for large scale fabrication of injectable drug delivery particles. 
Further optimization of the parameters will still be required to reach a true zero residual 
layer. 
This research provides a significant advance in the creation of monodisperse, 
injectable nanocarriers of specific geometry and can provide a characterized environment 
for the study of the effect of size and shape in in-vivo release properties of nanoparticles.  
With the development of such a method, we believe there is broad applicability to aid in 
further study of how nanoparticle shape and size affect delivery of drugs to tissues and 
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cells within the body. Future studies could be performed to evaluate the effect of shape 
on in-vivo drug or contrast agent release, and may allow for future tunable in-vivo release 
and targeting properties.  
 
7.4 CONCLUSIONS AND FUTURE DIRECTIONS WITH STIMULI-RESPONSIVE 
NANOIMPRINTED NANOCARRIERS: ENZYMATIC DEGRADATION AND IN-VITRO 
RELEASE STUDIES  
Chapter Five demonstrated in-vitro drug release of DNA and proteins after 
nanoimprinting the enzyme-responsive material system developed in Chapter Three, and 
demonstrated enzyme-mediated degradation. We successfully fabricated nanoparticles 
using an equimolar mixture of PEGDA (MW 700) and a diacrylated, enzymatically 
degradable peptide GFLGK-DA, to create a particle matrix crosslinked by the degradable 
peptide. We demonstrated that biological agents can be successfully incorporated within 
these imprints during the nanoimprinting process by simply mixing the agents with the 
macromer solution prior to polymerization, and we have demonstrated successful 
retention of model drug (DNA and antibody) in the absence of tumor-specific enzymes 
(with an initial leakage of DNA) and successful enzyme-triggered release of model drug 
upon the addition of Cathepsin B. To our knowledge this is the first demonstration of 
nanoimprinting and nanocarrier synthesis using biologically responsive macromolecules. 
The creation of nanoscale, drug or contrast agent delivery systems with stimuli-
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responsive and environmentally-degradable features is a significant milestone in creating 
“intelligent” multi-functional nanocarriers.  
The SFIL process has demonstrated the versatility for creating well-defined 
nanoparticles and stimuli-responsive nanoparticles. Furthermore, biological agents can 
easily be incorporated into nanoparticle drug delivery systems using this method and the 
macromer concentration can be varied to encapsulate a wide variety of therapeutics and 
contrast agent. Future studies to compare the macroscale swelling properties of the 
PEGDA and PEGDA-GFLGK-DA to the nanoscale gels would provide an interesting 
insight into the nano-gel properties, and in the understanding of what agents could be 
encapsulated. 
Future studies for optimization would require in depth characterization of the 
degradation and release kinetics. For solutions that are manually dispensed and for 
thicker residual layers, the etching process required to isolate the nanoparticles etches the 
residual layer away as well as the therapeutics located within the residual layer; thus the 
overall release kinetics cannot be determined until the loading efficiency of the particles 
is determined. In order to automatically dispense the drug - polymer solution for the 
creation of stimuli-responsive nanoparticles it would also be necessary to use an 
appropriate dispenser tip for the radius of the therapeutic being encapsulated. With the 
use of automated dispensing, the volume of the solution dispensed could be set such that 
there would be little residual layer and little to no etching required, and could allow for 
large-scale fabrication enzyme-responsive-nanocarriers.  
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7.5 CONCLUSIONS AND FUTURE DIRECTIONS WITH BIOACTIVITY OF BIOLOGICS 
ENCAPSULATED IN NANOIMPRINTED NANOCARRIERS 
Chapter Six described in-vitro bioactivity studies of DNA and proteins 
encapsulated in nanoimprinted PEGDA and peptide-functionalized PEGDA. The protein 
bioactivity assays demonstrate qualitative and quantitative evidence of bioactivity.  We 
demonstrated qualitative proof that the Step and Flash Imprint Lithography can 
successfully imprint encapsulated biologics, such as streptavidin, and allow the biologic 
to remain bioactive. We have also shown limited quantitative proof that the proteins 
trypsin and luciferase retain their bioactivity. The SFIL process uses low pressure and 
already established UV wavelengths and exposure energies.  
The limiting factor in demonstrating decisive quantitative bioactivity has been due 
to the limitations of the experiments themselves. The fact that the model biologics are too 
large to leach out from the PEGDA nanoparticles has lead to an inability to measure such 
small concentrations. For future studies we suggest encapsulating smaller molecular 
weight molecules such as fibroblast growth factor-2 (FGF-2) which is an 18 kDa 
molecule with a 14.5 Å radius of gyration, or human growth hormone releasing factor 
(hGRF) which is a 3400 Da molecule. These factors could be released and bioactivity 
could be determined using an ELISA assay. Furthermore, doxorubicin could be 
encapsulated and analyzed with HPLC, and small interfering RNA (siRNA) could be 
encapsulated and analyzed. For future studies with DNA transfection, separating the 
DNA from the Cathepsin is critical as well as concentrating enough for the transfection. 
We would suggest using an ion exchange column to separate the DNA and Cathepsin B, 
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and then collecting the DNA fraction. This could then be concentrated in a dialysis 
membrane using a concentration solution. 
Another factor leading to such small concentrations could be that the proteins are 
sticking to the tubing of the dispense system. This can be solved by coating the inside of 
the tubing with Sigmacoat, or by purchasing low adhesion tubing. It should also be noted 
that other than UV photo-crosslinking, Michael’s addition polymerization could also be 

















Glossary of Acronyms 
 
ACRL   Acrylate 
AFM  Atomic Force Microscopy 
CF4  Carbon Tetrafluoride 
CHF3  Fluoroform 
Cl2  Chlorine 
Da  Dalton 
DCM  Dicloromethane  
dH2O  Deionized Water 
DMAc  Dimethylacetamide 
D2O  Deuterium Oxide 
EBL  Electron Beam Lithography 
EPR  Enhanced permeability and retention 
FGF-2  Fibroblast growth factor-2 
GFLGK  Gly-Phe-Leu-Gly-Lys 
GFLGK-DA  acrylate-Gly-Phe-Leu-Gly-Lys-acrylate 
HBr   Hydrogen-bromide 
He  Helium 
hGRF  Human growth hormone releasing factor 
I2959  2-hydroxy-1-[4-(hydroxyethoxy) phenyl]-2-methyl-1 propanone 
IPA  Isopropyl Alcohol 
MALDI-TOF Matrix-Assisted Laser Desorption/Ionization Time of Flight 
MMP Matrix metalloproteinase 
MPS Mononuclear phagocytic system 
MW  Molecular Weight 
N  Newtons 
NHS-PEG-ACRL Acrylate-PEG-N-Hydroxy-succinamide 
NMP  N-Methyl Pyrrolidone  
 247
NMR  Nuclear Magnetic Resonance 
O2  Oxygen 
PBS  Phosphate buffered saline  
PEG  Poly(ethylene glycol)  
PEGDA  Poly(ethylene glycol) diacrylate 
PLA   Poly(lactide) 
PLGA   Poly(lactide-co-glycolide) 
PMMA  Poly(methyl methacrylate) 
PVA  Poly(vinyl alcohol)  
RES  Reticuloendothelial system 
rhBMP  Recombinant human bone morphogenetic protein 
RIE  Reactive Ion Etching 
SAM  Self-assembled Monolayer 
SEM  Scanning Electron Microscopy 
SFIL  Step and Flash Imprint Lithography 
siRNA  Small interfering RNA 
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